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Summary 
 
Infection is a major cause of morbidity and mortality in infants within the first few months of 
life. Susceptibility to infectious disease in this vulnerable population is more prevalent in 
resource-limited regions, with a higher disease burden. Due to certain deficiencies in their 
adaptive immune system, neonates rely predominantly on their innate immune system for 
protection against infection, a vital component in the early host defence against pathogens. 
Several studies have described differences in neonatal innate toll-like receptor-mediated 
responses compared to adult counterparts, though very little is known about these receptor 
responses within resource-limited settings. 
 
To address this issue, we assessed the longitudinal development of cytokine-specific 
responses of TLR4 and TLR7/8 in monocytes, myeloid dendritic cells and plasmacytoid 
dendritic cells in infants from a resource-limited setting, South Africa, within the first 12 
months of life and compared it to adults. Contrary to previously published literature, we 
observed heightened production of TH-1 cytokines: we showed increased responsiveness to 
TLR4 and TLR7/8 stimulation in infants at two and six weeks of age, which may be due to 
vaccination administered at birth. Unexpectedly, the hyper-inflammatory response persisted 
at six months in response to the LPS (TLR4) stimulus. This increased response at six months 
may be attributed to decreased passive immunity through infant weaning as well as increased 
exposure to microbial pathogens in this setting. Maturation of most cytokine responses was 
reached at twelve months for the TLR4 receptor, and at six months for the TLR7/8 receptor. 
 
The first year of life represents a critical period for maturation of the immune response. Data 
from this study point towards an elevated response within the first six months of life. This 
heightened response reflects both an ability to mount a sufficient TH-1 response in infancy, 
but more likely, the increased exposure to microbial stimuli in the environment. Thus, we 
speculate that these age-specific inflammatory responses may influence the outcome of 
immune responses to various vaccines administered, which may result in altered 
responsiveness to immunisation in infancy.  
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Opsomming 
 
Die hoof oorsaak vir morbiditeit en mortaliteit in babas binne die eerste paar maande van hul 
lewe word toegeskryf aan infeksie. In hulpbron beperkte gebiede, gekenmerk deur `n groter 
siektelas, is daar `n verhoogde vatbaarheid vir infeksie in hierdie kwesbare populasie. As 
gevolg van sekere gebreke in die verworwe immuunstelsel, maak pasgebore babas 
hoofsaaklik staat op hul aangebore immuunstelsel vir beskerming teen infeksie, ’n belangrike 
komponent vir die vroeë verdediging teen patogene. Verskeie studies het al die verskille in 
toll-tipe reseptor (TTR) bemiddelde reaksies tussen pasgebore babas en volwassenes 
vergelyk, maar nie veel is bekend oor hierdie reaksies in areas waar hulpbronne beperk is nie. 
 
Om hierdie kwessie aan te spreek is die longitudinale ontwikkeling van sitokien-spesifieke 
reaksies van die TTR4 en TTR7/8 reseptore van monosiete, miëloïede en plasmasitoïede 
dendritiese selle van babas in die hulpborn beperkte land Suid-Afrika, oor die eerste 12 
maande geëvalueer en dit vergelyk met volwassenes. In teenstelling met vorige literatuur, het 
hierdie studie ’n polarisasie tot TH-1-sitokien produksie gevind: verhoogde reaktiwiteit van 
die TTR4 en TTR7/8 is gevind in babas van twee en ses weke oud, wat gedeeltelik as gevolg 
van die inenting kan wees wat toegedien was na geboorte. Hierdie hiper-inflammatoriese 
reaksie teen die TTR4 stimulus (Lipopolisakkaried (LPS), het teen verwagting voortgeduur 
tot op ses maande en kan toegeskryf word aan die vermindering van passiewe immuniteit 
deur spening, sowel as die toenemende blootstelling aan mikrobiese patogene in die 
omgewing. Maturasie vir die meerderheid van die sitokiene reaksies, is bereik op 12 maande 
vir TTR4, en op ses maande vir TTR7/8.   
 
Die eerste lewensjaar is ‘n kritiese periode vir die ontwikkeling van die immuunstelsel. Data 
van hierdie studie dui op ‘n verhoogde reaksie binne die eerste ses maande van ‘n baba se 
lewe. Hierdie verhoogde reaksie dui op die vermoë om `n voldoende TH-1 reaksie te ontlok, 
maar meer waarskynlik, verhoogde blootstelling aan mikrobiese stimuli in die omgewing. 
Dus spekuleer ons dat hierdie ouderdom-spesifieke reaksies dalk die uitkoms van die 
immuunreaksie teen verskeie entstof toediening kan beïnvloed in babas. 
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Chapter One 
Introduction 
 
1.1. Susceptibility to infection in early life 
Neonates and young infants are at an increased risk for infectious disease compared to older 
children and adults (Bryce et al., 2005; Thaver & Zaida, 2009; WHO Health Statistics, 2010). 
Globally, the burden of infectious morbidity and mortality in newborns and young infants is 
overwhelming, with 40% of morbidity in young children (under five years) occurring within 
the first month of life (WHO Health Statistics, 2010). The highest incidence of infant 
morbidity in early life is seen in resource-limited countries, in particular African and Asian 
countries, with infection being the leading cause of morbidity and mortality (Bryce et al., 
2005; Thaver & Zaidi, 2009; WHO Health Statistics, 2011). In South Africa, the infant 
mortality rate stands at 49 per 1000 births, with HIV/AIDS, pneumonia, diarrhoea, and sepsis 
being the leading causes of infectious disease and mortality in children under the age of five 
years (WHO Health Statistics, 2011). 
 
While childhood vaccination remains the primary prevention and intervention method to 
reduce infection, neonates and young infants tend to display suboptimal immune responses to 
all vaccines, with the exception of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) 
where protective TH-1 responses were observed even when given as early as birth (Adkins et 
al., 2004; Siegrist et al., 2001; Siegrist et al., 2007). The vulnerability to infection  and lack 
of efficient vaccine responses is due to several factors, including the limited antigenic 
exposure in utero and lack of immunological memory, as well as an apparent TH-2 bias 
observed in neonates (Siegrist et al., 2001; Siegrist et al., 2007; Levy 2007).  
 
The predominant TH-2 skewing in foetal and neonatal immunity is largely derived from the 
production of TH-2-derived cytokines (e.g. IL-4) at the maternal–foetal interface (Wegmann 
et al., 1993; Morein et al., 2007). The induction of anti-inflammatory cytokine (e.g. IL-10) 
responses serves as a protective mechanism, as inflammatory responses are detrimental to 
placental integrity, resulting in preterm delivery and foetal loss (Wegmann et al., 1993; Levy 
2007; Morein et al., 2007). This TH-2 bias appears to affect the neonatal adaptive immunity, 
as TH-2 effector functions are suboptimal for several of the diseases that strike early in life 
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(Adkins et al., 2004), such as viral infections, Listeria monocytogenes and group B 
Streptococcus infections (Marodi 2006a).  
 
Considering the limited antigenic exposure and the well-established adaptive immune defects 
in early infancy, neonates and infants are largely dependent on passively acquired maternal 
antibodies (Morein et al., 2007; Belderbos et al., 2009a) and their own innate immune system 
for protection against infection (Belderbos et al., 2009a). 
 
1.2. Pathogen recognition in innate immunity 
Innate immunity represents the first line of host defence against microbial invasion. This 
branch of the immune system is critical for early host response as it functions efficiently 
without prior exposure to antigens. The innate immune system is antigen non-specific, but is 
able to differentiate between self and non-self antigens (Medzhitov & Janeway 1997; Akira et 
al., 2001; Akira et al., 2006; Mogensen 2009). It achieves this through the use of nonclonal, 
germline-encoded pattern recognition receptors (PRRs).  
 
PRRs are expressed constitutively on antigen presenting cells, such as monocytes and 
dendritic cells, and recognise microbial components known as pathogen associated molecular 
patterns (PAMPs). PAMPs are essential for survival, invariant among classes of microbes and 
not produced by mammalian cells. Different PRRs are able to detect specific PAMPs 
regardless of microbial life-cycle stage (Medzhitov & Janeway 1997; Akira et al., 2006; 
Medzhitov 2007; Medzhitov 2007; Mogensen 2009). Several classes of PRRs have been 
identified, of which the toll-like receptors (TLRs) are the most extensively studied family 
(Akira et al., 2006; Mogensen 2009). Currently, 11 TLRs are known in mammalian species, 
of which ten are present in humans. TLRs are capable of recognising distinct microbial 
stimuli and their activation by TLR-PAMP interaction activates intracellular signalling 
cascades, resulting in the production of proinflammatory mediators that modulate the innate 
immune response (Akira et al., 2001; Akira & Takeda 2004; Akira et al., 2006; Mogensen 
2009). Thus, these receptors are essential in initiating and orchestrating the early host 
response to microbes. 
 
Given the importance of the TLR system in host defence, several studies have documented 
newborn responses in comparison to adults. The inability of neonates to produce TH-1 type 
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proinflammatory cytokines severely hampers the efficacy of their cell-mediated immunity 
(De Wit et al., 2004; Levy et al., 2004; Angelone et al., 2006; Danis et al., 2008; Belderbos 
et al., 2009b; Kollmann et al., 2009). This results in an increased susceptibility of newborns 
to intracellular pathogens, such as viruses and Listeria monocytogenes. In contrast, studies 
have found a skewing of neonatal TLR-mediated responses towards TH-17 and TH-2 type 
immunity (with an increase in IL-6, IL-10 and IL-23) (Levy et al., 2004; Kollmann et al., 
2009). This TH-17 bias offers protection against certain bacterial and fungal infections 
(Kollmann et al., 2009). Therefore, rather than simply being “immature”, neonatal innate 
immune capabilities prime neonatal adaptive immunity differently to that of adults.  
 
1.3. Aims and objectives  
1.3.1. Aim 
Although several studies have described differences in neonatal TLR-mediated cytokine 
responses compared to adults, very few of these studies have evaluated the development of 
these responses over time (Corbett et al., 2010; Nguyen et al., 2010). Moreover, even less 
data is available on the ontogeny of TLR-mediated responses in resource-limited settings, 
with maturation of these responses only reported in Gambian (Burl et al., 2011) and Latin-
American infant cohorts (Teran et al., 2011). The investigation of these innate responses in a 
resource-limited setting is of considerable importance, as these infants’ responses may differ 
significantly due to the increased microbial exposure and alternative vaccine schedules 
(Thaver & Zaida 2009; WHO Health Statistics, 2011). With gram-negative organisms, such 
as Klebsiella pneumoniae and Escherichia coli (Zaidi et al., 2009), and viral pathogens, 
including  respiratory syncytial virus (RSV), (Lehmann et al., 1999) being the major cause of 
neonatal sepsis and pneumonia, especially in developing countries, it is of interest to assess 
the maturation of these TLR responses to the recognition of these specific pathogens. 
 
As part of a comparative HIV Exposed but Uninfected (HEU) infant cohort study in 
collaboration with the University of British Columbia (UBC), we aimed to document the 
ontogeny of the HIV-unexposed (UE) infants’ TLR-mediated proinflammatory cytokine 
response. We set out to assess the cytokine-specific responses to TLR4 and TLR7/8 in 
antigen-presenting cells (monocytes, myeloid dendritic cells and plasmacytoid dendritic cells) 
at 2 weeks, 6 weeks, 6 months and 12 months of age as compared to adults. This was to 
permit us to determine at which stage the infant response reaches a state of maturation, 
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thereby documenting the TLR response for normal infants with reference to the TLR4 and 
TLR7/8 responses.  
 
1.3.2. Objectives 
To achieve our aim, the objectives for the study were to:  
1. Assess the TLR-mediated production of TNF-α, IFN-α, IL-6 and IL-12p40 in monocytes, 
as well as myeloid and plasmacytoid dendritic cell subsets in infants at 2 weeks, 6 weeks, 
6 months and 12 months of life. 
2. Assess the TLR-mediated production of TNF-α, IFN-α, IL-6 and IL-12p40 in monocytes, 
as well as myeloid and plasmacytoid dendritic cell subsets in clinically healthy adults at 
one time point.  
3. To determine the time point/age at which the TLR-mediated cell-specific cytokine 
response in South African infants become comparable to the response measured in adults.  
 
1.4. Hypothesis 
For the purpose of this study, we hypothesise that the TLR-mediated cell-mediated cytokine 
responses of healthy South African infants are comparable to that of the adult responses at 
twelve months of age.  
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Chapter Two 
Literature Review 
 
2.1. Toll-like receptors 
The TLR family is the most extensively studied class of PRRs. TLRs were initially identified 
through their homology to the Drosophila melanogaster Toll protein, a receptor found to be 
critical for dorsoventral development in embryogenesis in the fruit fly (Lemaitre et al., 1996). 
Subsequent studies have proven this protein essential in the innate immune response against 
fungal infection in insects (Lemaitre et al., 1996; Medzhitov et al., 1997; Akira et al., 2006). 
These findings led to the discovery of TLRs in mammals.  
 
The mammalian TLR family currently consists of 11 members, of which ten receptors are 
present in humans. These receptors recognise specific PAMPs derived from various microbial 
pathogens, such as bacteria, viruses, fungi and protozoa (Akira et al., 2001; Akira & Takeda 
2004; Akira et al., 2006). 
 
2.1.1. Structure  
TLRs are described as type I transmembrane glycoproteins and form part of a larger 
superfamily that includes the interleukin (IL)-1 receptor (IL-1R) family. These receptors are 
characterised as homo- or heterodimeric in nature, with an extracellular domain composed of 
leucine-rich repeat (LRR) motifs and a cytoplasmic signalling domain, similar to IL-1R 
situated in the Toll-IL-1 receptor-like (TIR) domain (Means et al., 2000; Akira & Takeda 
2004; Akira et al., 2006; Mogensen 2009). 
 
The LRR domains are composed of conserved regions of 16-28 tandem motifs. Each motif is 
24-29 amino acids in length and is composed of a conserved LxxLxLxxN motif and a 
variable region. This LRR domain forms a unique horseshoe structure. The conserved leucine 
residues form the hydrophobic convex inner structure, creating parallel β-strands. LRRs, 
specifically the concave structure, are thought to be directly involved in the binding of 
specific PAMPs to the TLR structure (Akira & Takeda 2004; Akira et al., 2006; Jin & Lee 
2008). 
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Both TLRs and IL-1R have a conserved region of approximately 200 amino acids in their 
cytoplasmic tails, known as the TIR domain. The domain consists of three conserved boxes, 
and is essential in intracellular signalling cascade. The TIR domains of different TLRs vary 
in size, with approximately 20-30% of their amino acid sequence conserved among these 
receptors (Akira & Takeda 2004).  
 
Crystallography of TLR1, TLR2 and TLR10 revealed the structure of the TIR domain. The 
TIR domain consists of five parallel β-sheets surrounded by five α-helices connected by BB-
loops. The conserved boxes 1, 2, and BB-loop display most of their side chains and play a 
central role in TIR dimerisation and interaction with adaptor molecules (Akira & Takeda 
2004; Akira et al., 2006; Jin & Lee 2008). 
 
2.1.2. TLR subfamilies 
The mammalian TLR family can be separated into two distinct subfamilies based on their 
relative expression by cells of interest and recognition of specific PAMPs and/or ligands. The 
main ligands recognised by each of the 11 TLRs have been summarised in Table 1.1. The 
first subfamily consists of TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10, and is expressed 
on the cell surface. These TLRs detect lipids and lipoproteins predominantly derived from 
bacterial products. The second subfamily consists of TLR3, TLR7, TLR8 and TLR9, and is 
located intracellularly on endosomes. TLR3, TLR7, TLR8 and TLR9 recognise nucleic acids 
from several different pathogens in endosomes and lysosomes (Akira et al., 2006; Parker et 
al., 2007; Mogensen 2009). The compartmentalisation of intracellular TLRs allows for 
discrimination of self versus non-self by the localisation of foreign nucleic acid, as well as 
differentiation of the molecular structure of invaders from that of the host (Mogensen 2009).  
 
For the purpose of this dissertation, the next section will focus on TLR recognition and 
responses for TLR4 and TLR7/8 only, as these TLR responses will be the focal point of the 
thesis.  
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Table 1.1 Summary of the different PAMPs recognised by TLRs 
Receptor Ligand Origin 
TLR1 Triacyl lipopeptides Bacteria and mycobacteria 
 Soluble factors Neisseria meningitidis 
TLR2 Lipoproteins Various pathogens 
 Lipoteichoic acids Gram-positive bacteria 
 Zymosan Fungi 
 Porins Neisseria 
 β-glycan Fungi 
 Phospholipomannan Candida 
 Glycosylphosphatidylinositol-mucin Protozoa 
 Envelope glycoproteins Viruses 
 Heat shock protein 70 Host 
TLR3 Double stranded RNA Viruses 
TLR4 Lipopolysaccharide Gram-negative bacteria 
 Fusion protein Respiratory syncytial virus 
 Envelope glycoproteins Viruses 
 Glycoinositolphospholipids Protozoa 
 Mannan Fungi 
 Fibrinogen Host 
 Heat shock protein 70 Host 
TLR5 Flagellin Bacteria 
TLR6 Peptidoglycan Gram-positive bacteria 
 Diacyl lipopeptides Mycoplasma 
 Zymosan Fungi 
TLR7/8 Single stranded RNA Viruses 
 Imidazoquinoline Synthetic compound 
TLR9 CpG-containing DNA Bacteria and viruses 
TLR10 Not determined Not determined 
TLR11 Not determined Uropathogenic bacteria 
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2.1.3. TLR4 recognition of different PAMPs 
2.1.3.1. Recognition of lipopolysaccharide (LPS) and host proteins by TLR4 
LPS is a major component of Gram-negative bacterial cell walls and recognised specifically 
by TLR4. LPS, also known as an endotoxin, is the most potent immunostimulant among the 
cell wall components. The lipid portion, lipid A, is responsible for most of the pathogenicity 
associated with Gram-negative bacteria, such as the inflammatory response in endotoxic 
shock (Akira & Takeda 2001; Ezekowitz & Hoffmann 2003; Akira et al., 2006; Mogensen 
2009). 
 
TLR4 is also able to sense host-derived products secreted during inflammation and tissue 
injury. Examples of these products are heat-shock protein 60, fibronectin and plasma 
fibrinogen. The recognition of these products results in the activation of macrophages in a 
TLR4-dependent manner (Ezekowitz & Hoffmann 2003; Mogensen 2009). 
 
Although TLR4 is established as the primary receptor for the recognition of LPS, several 
accessory molecules are involved in this recognition and binding process. Free LPS 
associates with the LPS binding protein, an acute-phase protein present in the bloodstream, 
which then binds to the CD14 receptor, and is then transferred to myeloid differentiation 
protein 2 (MD-2) and associates with extracellular domain of TLR4 by oligomerisation 
(Takeda & Akira 2001; Mogensen 2009). 
 
Polymorphisms in the TLR4 gene are associated with impaired LPS responses. The missense 
mutation in humans, Asp299Gly, impairs signalling and results in decreased inflammatory 
responsiveness and increased susceptibility to gram-negative bacterial infections and sepsis 
(Cook et al., 2004; Misch & Hawn 2008). In contrast, D299G and T399I polymorphisms 
have been associated with resistance to Legionella pneumophila. Deficiencies in TLR4 have 
been associated with high susceptibility to Neisseria meningitidis, Salmonella enterica and 
Mycobacterium tuberculosis (Kopp & Medzhitov 2003). 
 
2.1.3.2. Recognition of viral glycoprotein by TLR4 
In addition to the endosomal TLRs, TLR4 is also involved in recognition of viral components 
at the cell surface. Recognition of viral PAMPs by TLR4 results in the production of 
proinflammatory cytokines, with the exception of type I IFNs. This suggests the induction of 
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an inflammatory rather than antiviral response. TLR4 recognises the fusion protein in 
respiratory syncytial virus (RSV), suggesting a crucial role in viral infection (Ezekowitz & 
Hoffmann, 2003; Mogensen, 2009). The importance of TLR4 activation in RSV was 
demonstrated by TLR4 knockout mice, where deficiencies resulted in lower levels of 
infiltrating mononuclear cells and proinflammatory cytokine production and leads to reduced 
viral clearance (Kopp & Medzhitov 2003; Koyama et al., 2008). 
 
2.1.3.3. Recognition of fungal PAMPs by TLR4 
TLR4 recognise several fungal PAMPs located in the cell wall or cell surface of fungi. TLR4 
serves as a receptor for Candida albicans-derived mannan, as well as glucuronoxylomannan, 
a component of Cryptococcus neoformans (Roeder et al., 2004; Mogensen 2009). TLR4, 
along with TLR2, is able to both recognise components of the Aspergillus species. The 
conidia of Aspergillus trigger innate immune responses through recognition by TLR4, 
whereas TLR2 is able to recognise both hyphae and conidia of the Aspergillus species 
(Roeder et al., 2004). In vivo experiments also suggest significant roles of TLR4 in fungal 
infection. TLR4-deficient mice showed increased susceptibility to disseminated Candida 
infection (Kopp & Medzhitov 2003; Netea et al., 2004; Roeder et al., 2004), whereas TLR2-
deficient mice showed increased resistance to Candida (Netea et al., 2004). 
 
2.1.3.4. Recognition of protozoan PAMPs by TLR4  
In comparison to viruses and bacteria, the TLR recognition of protozoa has been less well 
defined in literature. The primary PAMP recognised in protozoa is the 
glycosylphosphatidylinositol (GPI) anchors. GPI anchors or their fragments from protozoan 
pathogens, Leishmania major, Trypanosoma brucei, Trypanosoma cruzi, Plasmodium 
falciparum and Toxoplasma gondii, are able to activate both lymphoid and myeloid cells. GPI 
anchors are composed of a glycan core and a lipid component, and functions to secure 
proteins to the surface of eukaryotic cells. GPI anchors are able to activate TLR2 and result in 
the activation of proinflammatory signalling pathways. In addition, GPI anchors also require 
CD14 and TLR4 for the recognition of these protozoan pathogens, in example Trypanosoma 
cruzi (Gazzinelli & Denkers 2006). 
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2.1.4. TLR7 and TLR8 recognition of single stranded RNA (ssRNA)  
TLR7 and TLR8 are both structurally and phylogenetically related due to the high homology 
of TLR7 and TLR8 genes (Akira et al., 2006; Bowie 2007). TLR7/8 is essential in identifying 
ssRNA from viral genomes, such as influenza virus, vesicular stomatitis virus and human 
immunodeficiency virus (HIV). Both TLR7 and TLR8 are able to recognise uridine-rich or 
uridine/guanosine-rich ssRNA of host and viral origins. TLR7 and TLR8 are also able to 
detect synthetic antiviral imidazoquinolone derivatives, such as resiquimod (R-848) and 
guanine analogs (e.g. loxoribine) (Akira et al., 2006; Kawai & Akira 2010). TLR7 and TLR8 
induce the production of large amounts of type I IFNs after viral infection. Cytokine 
induction in response to RNA viruses is fully dependent on TLR7, which suggests that this 
receptor serves as the sensor of infection with ssRNA viruses (Kawai & Akira 2010). 
 
TLR7 and TLR8 are both located on the endosomal membrane. Many enveloped viruses 
move through the cytosol via the endosomal compartment. The degradation of viral particles 
in the cytosol results in the release of ssRNA and its recognition by TLR7/TLR8. Viral RNA 
is also released from the phagolysosome when phagocytes take up virus-infected apoptotic 
cells. The RNA from the host is degraded by extracellular RNases when released from cells 
and rarely reach the endocytic compartment, thus preventing recognition of self-antigens 
(Akira et al., 2006). 
 
Certain TLR7/8 polymorphisms are implicated in the progression of HIV-1 disease. The 
presence of the TLR7Gln11Leu polymorphism has been associated with lower baseline 
CD4+ T-lymphocyte counts and possibly increased HIV-1 susceptibility in women. This is 
suggestive of a strong effect on the initial stages of HIV infection (Oh et al., 2009). A 
previous study documented the TLR8 A1G mutation in a German cohort of HIV-positive 
patients. This polymorphism alters the start ATG of TLR8 isoform B into a GTG triplet, 
resulting in a truncated TLR8 peptide. The TLR8 A1G mutation results in a decrease in NF-
κB activation and a lower level of immune activation (Oh et al., 2008).  
 
2.1.5. TLR signalling pathway 
TLR-PAMP interactions initiate a number of signal transduction pathways. Signal 
transduction in TLR-mediated immune responses is mediated by a family of adaptor 
molecules, which include myeloid differentiation gene factor 88 (MyD88), TIR-associated 
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protein (TIRAP)/MyD88 adaptor-like (Mal) protein, TIR domain-containing adaptor protein 
inducing interferon (TRIF) and TRIF-associated adaptor molecule (Akira & Takeda 2004). 
The differential responses of specific TLRs are determined by the selective recruitment of 
adaptor molecules. MyD88 and TRIF are responsible for distinct pathways resulting in the 
production of proinflammatory cytokines and type I interferons (IFNs) respectively (Akira & 
Takeda 2004; Mogensen 2009). Figure 1.1 illustrates the TLR signalling pathway. 
 
2.1.5.1. Proinflammatory cytokine production 
The MyD88-dependent signalling pathway is activated downstream for all TLRs with the 
exception of TLR3. In TLR2, TLR4 and TLR5 stimulation, MyD88 associates with the 
cytoplasmic TIR domain and recruits IL-1 receptor kinase (IRAK) 2/1 and IRAK4 through 
homophilic interaction, that is shown to be essential in the NF-κB activation and in IL-
R1/TLR signalling in response to stimulation of these TLRs. In TLR4 activation, the 
TIRAP/Mal adaptor is also required for recruitment of MyD88 (Akira & Takeda 2004; 
Mogensen 2009; Kawai et al., 2010). 
 
The MyD88 adaptor binds to IRAK4 and IRAK2/1, resulting in the activation of IRAK1. The 
activated IRAK1 autophosphorylates its residues on the N-terminus, thereby allowing the 
binding of TRAF6. The IRAK1–TRAF6 complex then disengages from the receptor and 
interacts with the TAK1/TAB1/2/3 complex at the plasma membrane. TRAF6 complex 
activates and phosphorylates TAK1/TAB1/2/3, which then translocates together to the 
cytoplasm and phosphorylates the IKK-γ/NF-κB essential modulator (NEMO). The 
phosphorylation of IKK-β and MAP-kinases results in the modulation of NF-κB and MAP 
kinases, which translocates to the nucleus and initiates expression of proinflammatory 
cytokine genes. In addition to NF-κB, the transcription factor, interferon regulatory factor 
(IRF) 5 regulates the expression of IL-6, IL-12 and cytokine genes associated with NF-κB 
p50 (Akira et al., 2001; Akira & Takeda 2004; Mogensen 2009; Kawai et al., 2010).  
 
2.1.5.2. Type I IFN production 
Viral TLRs, such as TLR7 and TLR8, induce the production of type I IFN in addition to other 
proinflammatory cytokines. However, TLR4 is able to induce IFN-α and IFN-β production in 
a MyD88 independent manner, with the recruitment of TRIF as well as TRAM, with acts as a 
bridging adaptor in TLR4 signalling.  
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Upon stimulation, TRIF associates with receptor-interacting protein-1 (RIP-1), which is 
responsible for activation of NF-κB, or TRIF-family member-associated NF-κB activator 
(TANK) binding kinase-1 (TBK1) via TRAF3. TBK1 is comprised of a family of inducible 
IκB kinases that directly phosphorylates IRF-3 and IRF-7. IRF-3 and IRF-7 translocates to 
the nucleus and binds to the IFN-stimulated response elements, resulting in the expression 
IFN-inducible genes.  IRF-3 and IRF-7 are essential in the production of type I IFNs in the 
viral mediated responses (Akira et al., 2001; Akira & Takeda 2004; Parker et al., 2007; 
Kawai et al., 2010). 
 
TLR7 and TLR9 both induce IFN-α production in a MyD88-dependent manner. The IRF-7 
adaptor plays a vital role in the expression of type I IFN by this TLR. Upon stimulation, 
MyD88, IRAK4, IRAK1, TRAF6 and IRF-7 form a complex and are recruited to the 
receptor. IRAK1 could potentially serve as an IRF-7 kinase, as IFN responses are abolished 
in deficient cells, but all other inflammatory cytokines are produced normally (Akira et al., 
2001; Akira & Takeda 2004; Parker et al., 2007; Kawai et al., 2010). 
 
 
Figure 1.1 Schematic representation of TLRs signalling pathway (Source: Picard et al., 2010).  
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2.2. Antigen presenting cells involved in TLR-mediated responses 
The activation of innate immune cells relies on the recognition of PAMPs. The TLR family 
has emerged as primary sensors for conserved structures of bacteria, fungi and viruses. A 
number of innate immune cells differentially express TLRs, indicating specific roles for each 
cell population with regard to innate immune responses. In peripheral blood, monocytes and 
dendritic cells act as the primary antigen presenting cells (APCs), each specialising in an 
important role in pathogen recognition and specific cytokine production in response. The 
stimulation of most TLRs leads to TH-1 rather than TH-2 mediated response and cellular 
mediated adaptive immune differentiation. Thus, innate immunity is a key player in the 
inflammatory and cellular immune response against pathogens. 
 
2.2.1. Monocytes 
Monocytes are characteristically defined as non-dividing, circulating leukocytes that 
constitute approximately 10% of peripheral leukocytes in humans (Serbina et al., 2008). 
Circulating monocytes are separated into two subsets based on the expression of CD14, a 
component of the LPS receptor complex, and CD16, the FcγRIII immunoglobulin receptor. 
CD14+ monocytes contribute up to 90% of circulating monocyte population (Serbina et al., 
2008; Yona & Jung 2010). Monocytes represent immune effector cells, and express 
chemokine receptors and adhesion receptors that allow the migration from peripheral blood to 
tissues during infection. Monocytes produce inflammatory cytokines and ingest cells, debris 
and toxic molecules. They can also differentiate into inflammatory monocyte-derived 
dendritic cells or macrophages during inflammation (Geissmann et al., 2010). 
 
Monocytes are highly responsive to TLR stimulation. Several studies have shown that 
monocytes express high levels of TLR4 and TLR8 but almost undetectable levels of TLR7 
(Kadowaki et al., 2001; Zarember & Godowski 2002; Kamgang et al., 2008; Geissmann et 
al., 2010). Monocytes are able to efficiently identify and respond to bacterial, fungal and viral 
PAMPs. 
 
2.2.2. Dendritic cells 
Dendritic cells (DCs) are central to the innate immune response. DCs are responsible for the 
capture and processing of antigens, as well as for activation and differentiation of T-helper 
cells into TH-1, TH-2 and TH-17 lymphocytes and cytotoxic effector T-lymphocyte subsets in 
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lymphoid organs for the initiation of the appropriate adaptive immune response (Clark et al., 
2000; Iwasaki & Medzhitov 2004; Kadowaki 2007). DCs circulate in peripheral blood and 
tissues in an immature state and act as surveillance cells that capture and process foreign 
antigens and migrate to draining lymph nodes and present the processed antigens to the T-
lymphocytes (Clark et al., 2000; Kadowaki, 2007).  
 
DCs are identified by their surface expression of CD45 and major histocompatibility complex 
class II (MHCII) molecules and absence of other haematopoietic lineage markers, such as 
CD3, CD14, CD15 and CD16 (Clark et al., 2000). Two distinct subsets of DCs circulate 
through peripheral blood, specifically myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) 
(Clark et al., 2000; Colonna et al., 2006; Kadowaki, 2007). 
 
2.2.2.1. Myeloid dendritic cells 
The CD11c+ mDC subset has a similar marker expression to a myeloid derived cell (Lin123-, 
CD33bright, CD14dim, CD16-, CD11c+) (Clark et al., 2000; Kadowaki 2007), but has also been 
identified as ILT3+/ILT1+ (Clark et al., 2000).  MDCs in peripheral blood have been 
reported to develop macrophage morphology as well as the expression of butyrate esterase 
and CD14 in response to macrophage-colony stimulating factor (M-CSF), suggesting the 
ability to differentiate into macrophages and therefore related to monocyte-derived DCs 
(Kadowaki 2007). 
 
CD11c+ mDCs are the more dominant DC subset and express low levels of TLR4 and TLR8 
(Jarrossay et al., 2001; Kadowaki et al., 2001; Zarember & Godowski 2002). Thus, they can 
recognise bacterial, fungal and viral pathogens.  MDCs can therefore respond to bacterial and 
viral lipoproteins, as well as dsDNA and ssRNA from viruses. 
 
2.2.2.2. Plasmacytoid dendritic cells 
The Lin123-, CD11c-, ILT3+/ILT1- pDC subset share similar morphological characteristics 
with the lymphoid lineage and also express the CD123 marker on their cell surface (Clark et 
al., 2000; Barchet et al., 2005). PDCs constitute <1% of mononuclear cells in peripheral 
blood (Iwasaki & Medzhitov 2004; Barchet et al., 2005) and express high levels of TLR7 and 
TLR8 (Jarrossay et al., 2001; Kadowaki et al., 2001; Barchet et al., 2005). This subset does 
not express TLR4 and thus do not respond to LPS stimulation. Plasmacytoid DCs are 
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restricted to the recognition of DNA and RNA viruses (Kadowaki et al., 2001; Iwasaki & 
Medzhitov 2004; Barchet et al., 2005).  
 
2.3. TLR-mediated proinflammatory cytokine responses  
2.3.1. Function of proinflammatory cytokines 
Cytokines produced by macrophages/monocytes and dendritic cells drive T-cell immunity, 
which are responsible for immunity against intracellular pathogens, elimination of cancerous 
cells, stimulation of hypersensitivity reactions and autoimmune responses, as well as B cell 
stimulation.  Some of the major inflammatory cytokines produced by monocytes and DCs 
include tumour necrosis factor alpha (TNF-α), and several IL cytokines, such as IL-6, IL-12 
as well as type I IFNs. 
 
2.3.1.1.  TNF-α 
TNF-α forms part of the TNF family and is primarily secreted by activated mononuclear 
phagocytes, natural killer (NK) cells, mast cells and activated T-lymphocytes. TNF is a 
potent inflammatory mediator. TNFs induce anti-tumour immunity through cytotoxic 
function and by stimulating immune responses to cancerous cells. TNF is a potent 
chemoattractant and mediates adherence, chemotaxis and degranulation of granulocytes, such 
as neutrophils.  TNF induces vascular leakage, has negative inotropic effects and is the 
primary endogenous mediator of toxic shock and sepsis. TNF also triggers apoptosis (Borish 
& Steinke 2003). 
 
2.3.1.2.  IL-6 
IL-6 is a pleotropic cytokine secreted by various cell types, including B- and T-lymphocytes, 
mononuclear phagocytes, fibroblasts, keratinocytes, endothelial cells, mesenchymal cells and 
certain types of tumour cells. IL-6 induces the differentiation of B-lymphocytes into plasma 
cells; mediates activation, growth and differentiation of T-lymphocytes and IL-2 production 
by this cell type. It also stimulates the differentiation of macrophages and megakaryocytes. 
IL-6 is the most important inducer of hepatocyte synthesis of acute phase proteins and 
pyrexia (Borish & Steinke 2003; Blanco et al., 2008). Along with transforming growth factor 
beta (TGF-β), IL-6 also participates in the differentiation of TH-17 subset (Blanco et al., 
2008). 
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2.3.1.3.  IL-12 
IL-12 is a heterodimeric cytokine derived from monocytes, macrophages, B-lymphocytes, 
DCs, neutrophils and mast cells, but it is primarily produced by activated mDCs (Borish & 
Steinke 2003; Blanco et al., 2008).  The biologically active form, IL-12p70, is a heterodimer 
composed of p40 and p35 units. The IL-12p40 subunit is able to bind to the IL-23α chain, 
which is homologous to the IL-12p35 subunit (Borish & Steinke 2003). IL-12 plays an 
essential role in the differentiation and expansion of TH-1 cells. This cytokine has multiple 
effects on T-lymphocytes and NK cells. It activates and stimulates the proliferation, 
cytotoxicity and cytokine production in NK cells and stimulates the proliferation of T-helper 
and cytotoxic lymphocytes. IL-12 also induces the production of TNF-α and IFN-γ by NK 
cells, as well as IFN-γ and TNF-β by T-lymphocytes (Brunda 1994). IL-23 is secreted by 
activated dendritic cells and, along with IL-6, is responsible for the differentiation of TH-17-
mediated lymphocyte differentiation (Hunter et al., 2005). 
 
2.3.1.4.  Type I IFNs 
The type I IFN family is composed of IFN-α, IFN-β, IFN-δ, IFN-ω and IFN-τ, subtypes of 
which IFN-α and IFN-β have been described in humans. IFN-α and -β are produced by 
various cells types, such as fibroblasts, NK cells, T-lymphocytes, DCs in response to viruses 
and intracellular pathogens, but it has been found that pDCs are the largest producers of type 
I IFNs (Bogdan 2000). 
 
The secretion of type I IFNs enhances cytotoxicity of NK cells and CD8+ T cells, and 
protects DCs and uninfected cells from the cytopathic effect of viruses, thus assisting their 
antigen presentation function (Bogdan 2000; Barchet et al., 2005). Also, type I IFNs are 
secreted synergistically with other cytokines, regulating immune responses. Through 
secretion of IL-6 and type I IFNs, pDCs promote differentiation of memory B cells into 
antibody secreting plasma cells, facilitating the production of anti-viral antibodies (Barchet et 
al., 2005). Type I IFN induces the production of IL-12 and IL-18 production in macrophages 
and works synergistically with IL-12 to activate NK cells to produce IFN-γ (Bogdan 2000). 
IFN-α has other important biological actions, including upregulation of MHC class I 
molecules and mediation of antitumor activity (Borish & Steinke 2003). 
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2.3.2. Cytokine response in monocytes 
Monocytes are the most potent inducers of TNF-α in comparison to other APCs. In response 
to TLR2 and TLR4 stimulation, monocytes induce the production of large amounts of TNF-α, 
IL-6 (Kadowaki et al., 2001) and IL-12 (Zarember & Godowski 2002). Also, stimulation of 
TLR2 and TLR4 induces the release of IL-1β, a potent pyrogen. Monocytes secrete IL-12 and 
TNF-α in response to TLR8 stimulation (Gorden et al., 2005). 
 
2.3.3. Cytokine response in myeloid DCs 
The mDC subset is the major IL-12 producer. Myeloid DCs produce large amounts of TNF-α 
and lesser amounts of IL-6 and IL-12 in response to PG (TLR2/6) (Kadowaki et al., 2001; 
Zarember & Godowski 2002). This subset of DCs also produces TNF-α, IL-12 and IL-6 in 
response to LPS (TLR4) (Jarrossay et al., 2001). Myeloid DC also respond to TLR8, by 
production of IL-12 and TNF-α (Gorden et al., 2005). 
 
2.3.4. Cytokine response in plasmacytoid DCs 
Plasmacytoid DCs are the primary type I IFN-producing cells during viral infection in 
response to TLR7 stimulation. Plasmacytoid DCs are able to prime viral-specific primary and 
secondary CD4+ and CD8+ T-lymphocyte immune responses in vitro and in vivo (Kadowaki 
et al., 2001; Barchet et al., 2005) . In addition to IFNs, TLR-activated pDCs produce high 
levels of IL-6 (Kadowaki et al., 2001; Barchet et al., 2005; Cao & Liu 2007; Koyama et al., 
2008) and stimulation with TLR7 and TLR9 agonists induced TNF-α production in pDCs 
(Gorden et al., 2005). 
 
2.4. Neonatal TLR-mediated innate immunity 
2.4.1. Infectious morbidity in neonates and young infants 
Infections are the major cause of neonatal and infants morbidity and mortality. Presently, 
99% of the 4 million neonatal and young infant morbidity and mortality cases occur in 
developing countries. Although the exact cause of neonatal deaths in developing countries is 
rarely known, estimates suggest that pneumonia and diarrhoea are the most common causes 
of neonatal and infant morbidity (Bryce 2005; WHO Health Statistics 2010). In developing 
countries, neonates and infants are particularly susceptible to infectious agents, such as 
Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae and 
Streptococcus pyogenes (WHO Young infant group 1999), as well as group B streptococci, 
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Escherichia coli, HSV, CMV, RSV, varicella-zoster virus (VZV), Candida species (Marodi, 
2006), as well as Mycobacterium tuberculosis and Plasmodium species (Gold et al., 2007). 
 
2.4.2. TH-2 bias in neonates 
The foetal immune system is heavily biased against TH-1 cytokine production and toward 
immunosuppression by the production of anti-inflammatory cytokines. This skewing plays a 
key role in the dampening of maternal proinflammatory TH-1-type alloimmune responses. 
Excessive proinflammatory cytokine production, including IFN-γ and TNF, at the maternal–
foetal interface is detrimental to the placental integrity and is the major cause of preterm 
delivery and foetal loss (Wegmann et al., 1993; Marodi 2006b; Levy 2007; Philbin & Levy 
2010). Thus, the maternal-foetal interface secretes TH-2 cytokines, such as IL-4, IL-5, IL-6 
and IL-10, to divert the maternal immune response away from damaging TH-l-mediated 
cellular immune responses (Wegmann et al., 1993; Marodi 2006b; Levy 2007).  
 
A strong bias towards TH-2 polarisation in newborns is largely derived from the placental 
tissue by the production of TGF-β, prostaglandin E2 and progesterone, as well as the 
endogenous TH-2 derived cytokines (Morein et al., 2007). This skewing has been associated 
with the increased susceptibility to infections in neonates. Cytotoxic T-lymphocyte responses 
are not primed in the neonate; furthermore, the T-lymphocyte responses to intracellular 
pathogens (with the exception of BCG) and T-lymphocyte-based vaccines responses are 
impaired in neonates (Siegrist et al., 2001). However, antibody production in infancy as well 
as passive immunity acquired from the mother provides a measure of protective immunity for 
the neonate in the first few months of life (M’Rabet et al., 2008). 
 
2.4.3. TLR-mediated cytokine responses in early life. 
Innate immunity plays an important role in the induction of inflammatory response, clearance 
of infection and priming of adaptive immune responses. Innate immune cells are critical for 
early host defence and for the establishment of adaptive immunity. TLRs play a crucial role 
in innate immunity as they are essential for the recognition of microbial pathogens and trigger 
responses important to both inflammation and the instruction of adaptive immunity (Marodi 
2006; Levy 2007b).  Given the importance of the TLR system in host defence, several studies 
have documented newborn responses in comparison to adults. 
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2.4.3.1. TLR responses to bacterial ligand stimulation 
In response to TLR2/1 and TLR2/6 stimulation, several studies observed a significantly lower 
production of TNF-α and IL-12p70 (Levy et al., 2004; Levy et al., 2006a) in neonatal 
monocytes and mDCs in comparison to adults.  In response to TLR4 stimulation, neonates 
show a similar trend of cytokine impairment. LPS-mediated (TLR4) TNF-α and IL-12p70 
production (Levy et al., 2004; Belderbos et al., 2009b) in neonates remain impaired at least 
up to one month of age (Belderbos et al., 2009b).  Soluble factors have been associated with 
the impairment of the TLR-mediated cytokine responses seen in neonates. Adenosine, a 
plasma factor present in high amounts in neonatal plasma, has been shown to increase 
intracellular levels of cyclic adenosine monophosphate (cAMP), thereby inhibiting TLR-
mediated TNF-α production, and thereby inhibiting inflammatory response (Levy et al., 
2006a). 
 
In contrast, neonates produce large amounts of IL-6 and IL-10 in response to TLR2 and 
TLR4. This high IL-6/TNF-α ratio and increased IL-10 production reflects a distinct 
polarisation of the TLR-mediated response, illustrating the TH-2-skewing in neonates (Levy 
et al., 2004; Angelone et al., 2006). Along with increased IL-6 production, neonates produce 
higher levels of IL-23 than adults. The robust production of IL-6 and IL-23 induces the 
production of IL-17, which initiates the differentiation of naïve TH-0 T-lymphocytes to the 
TH-17 lineage. The TH-17 subset is responsible for elimination of bacterial and fungal 
infections such as Candida albicans, Mycobacterium tuberculosis, Klebsiella pneumoniae 
and Salmonella typhimurium (Gold et al., 2007; Levy 2007). The induction of this pathway 
suggests the innate immune response to TLR stimulation in neonates favours the TH17 rather 
than TH1 CD4 T-lymphocyte development. 
 
2.4.3.2. TLR responses to viral ligand stimulation 
Neonatal cord blood produces equal amounts of TNF-α in response to TLR7/8 (Levy et al., 
2004) and decreased amounts of IL-12p40 and IL-12p70 in response to TLR3 stimulation 
when compared to adults (De Wit et al., 2003; Belderbos et al., 2009b). This deficiency in 
IL-12p70 has been attributed to the defective production of the IL-12p35and IL-12p40 
subunits, induced by the increased IL-10 and IL-6 production (Belderbos et al., 2009b; 
Renneson et al., 2009).  In addition, as mDCs are the most effective IL-12 producers, the 
defective IL-12p70 production might be due to the immaturity of this cell type (Renneson et 
Stellenbosch University  http://scholar.sun.ac.za
20 
 
al., 2009). However, neonatal mononuclear cells show comparable production of TNF-α 
(Levy et al., 2004 and Levy et al., 2006b) and IL-12 in response to TLR7/8 stimulation to 
adults (Levy et al., 2006b). The mechanisms and implications for the robust response to 
TLR7/8 in the perinatal period are currently not understood.  
 
The production of type I IFNs is a key feature of the host defence against invading 
intracellular and viral pathogens.  Defective type I IFN production by neonatal pDCs is a 
significant feature seen in response to TLR stimulation. In response to human CMV and HSV 
infection, neonatal mDCs and pDCs produce lower amounts of type I IFNs in comparison to 
adults (Renneson et al., 2009).  Of note, cord blood pDCs have a decreased production of 
type I IFNs in response to stimulation with TLR7/8 (Danis et al., 2008) and TLR9 (De Wit et 
al., 2004).  These type I IFN responses in neonatal have been shown to mature rapidly in the 
first month of life to adult levels (Belderbos et al., 2009b). 
 
The inability of neonates to produce TH-1 type cytokines IL-12p70 or IFN-α to TLR 
stimulation severely hampers the efficacy of cell-mediated immunity to HCMV, HSV and 
Mycobacterium tuberculosis. The decreased type I IFN production in pDCs is most likely due 
to deficient IRF-7 translocation to the nucleus, diminishing their ability to elicit antiviral 
responses (Danis et al., 2008). Notably, the induced production of IL-6 and IL-10 in response 
to both agonists and infection favours the TH-17 polarisation and immunosuppression and is 
essential in the induction of B-lymphocyte and anti-inflammatory responses in neonates 
(Angelone et al., 2006; Kollmann et al., 2009). 
 
Thus, neonates’ innate immune capabilities are functionally different when compared to adult 
responses. Neonatal TLR-mediated inflammatory responses are specifically skewed towards 
TH-17 and TH-2 type immunity, thus resulting in an increased of risk of severe viral and 
intracellular pathogen infections, while offering protection against certain bacterial 
infections. 
 
2.5. Methods of cytokine detection 
Several methods have been developed for the detection of cytokine expression in response to 
stimulation of the innate immune cells. The enzyme-linked immunosorbent assay (ELISA) is 
employed for the analysis of secreted cytokine in fluids and cell supernatants, whereas 
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reverse transcriptase polymerase chain reaction (RT-PCR) is utilised for the semi-quantitative 
measurement of inducible mRNA production (Pala et al., 2000). While both these methods 
are suited for high-throughput analysis, it does not allow analysis of cell-specific cytokine 
production. 
 
Enzyme-linked immunospot (ELISPOT) assays, intracellular cytokine staining (ICS) 
methods and limiting dilution analysis (LDA) are frequently utilised for the analysis of cell-
specific cytokine production (Pala et al., 2000). However, these methods only allow the 
detection of one analyte at a time and are therefore not suitable for high- throughput analysis. 
The recent introduction of multiparameter analysis in flow cytometry allows for the 
measurement of multiple parameters in a single sample, thus providing a more 
comprehensive description of cellular responses. 
 
2.5.1. Multiparameter flow cytometry 
Fluorescence-activated flow cytometry is one of the leading technologies routinely used in 
immunology. Flow cytometry was first introduced for the phenotypic measurement of cells. 
This has been expanded to measure the functionality of cells through cytokine production and 
cytotoxicity or apoptosis on a cellular level (De Rosa et al., 2003). In fact, recent technical 
advances allows for the simultaneous measurement of a multitude of parameters on 
individual cells (Chattopadhyay et al., 2008). This technique is known as multiparameter 
flow cytometry. 
 
Multiparameter flow cytometry is defined as the use of five or more fluorescent markers to 
identify multiple characteristics of cells in a single sample (Perfetto et al., 2006; Nomura et 
al., 2008). This allows for a more comprehensive description of responsive cell subsets. This 
method has been applied to several applications, such as the identification of cellular subsets, 
characterisation of rare subsets and the functional characterisation of cell types (De Rosa et 
al., 2003; Nomura et al., 2008). 
 
Multiparameter flow cytometry has several distinct advantages. The use of more colours can 
improve the accuracy of measurements in rare cell types and exclude debris and unwanted 
cell populations from analysis by the use of a “dump channel”. In addition, this technique 
allows for improved detection of low-frequency cell populations and shared markers between 
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the cells of interest (De Rosa et al., 2003; Perfetto et al., 2004). More importantly, the 
technology can identify cells with complex phenotypes, such as in haematological 
malignancies, or cells responding to vaccines or cells from diseased states (Chattopadhyay et 
al., 2008). 
 
The most noteworthy disadvantage of multiparameter flow cytometry is that it requires 
extensive preparation and setup. The selection of markers for reagent panels for 
immunophenotyping needs to remain unaltered under three conditions:  in vitro stimulation, 
viral infection and cryopreservation. The most suitable fluorochrome-labelled antibodies for 
detection need to be selected based on the background staining of and spectral overlap 
between the chosen fluorescent dyes, which if minimal, can be eliminated by compensation 
(Perfetto et al., 2006; Nomura et al., 2008; Chattopadhyay et al., 2008). 
 
Furthermore, accurate cytometer setup and data collection, as well as accurate data analysis 
of multiple combinations of positive and negative markers are essential components in 
multiparameter flow cytometry to obtain reliable data (Nomura et al., 2008; Perfetto et al., 
2006; Chattopadhyay et al., 2008).  Once optimised, this technology allows high throughput 
analysis of specific cell markers and responses. One of the most important applications for 
multiparameter flow cytometry is the detection of multiple parameters using intracellular 
cytokine staining (Chattopadhyay et al., 2008). 
 
2.5.2. Intracellular cytokine staining (ICS) 
ICS is a technique initially introduced for immuno-staining of tissue sections, but was 
adapted for detection of cytokines and markers in permeabilised and fixed cells in suspension 
(Arora et al., 2002). Flow cytometric analysis of the intracellular cytokine (ICC) stained cells 
allows characterisation of a large number of cells, thus displaying the heterogeneity of the 
various cell populations. The advantage of ICS over existing techniques, such as ELISA and 
ELISPOT, is that multicolour staining in ICC analysis allows for characterisation of various 
cell subsets and sub-populations based on their cytokine profile, as well as their expression of 
cell surface markers (Maino et al., 1998; Arora et al., 2002; Nomura et al., 2008). 
 
Detection of cytokine positive cells is achieved by the inhibition of cytokine secretion by 
Golgi blockers, fixation and permeabilisation of cells of interest. These cells are then stained 
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for direct detection of intracellular cytokine expression with fluorochrome-conjugated 
antibodies and analysed using multiparameter flow cytometry (Arora et al., 2002; Lamoreaux 
et al., 2006). 
 
2.5.2.1. Application of intracellular cytokine staining 
The use of ICS in multiparameter flow cytometry was first described in HIV-1 infection, 
where progressive disease was correlated with decreased IL-2 or IL-2 + IFN-γ CD4+ 
expressing T-lymphocytes. These studies employed a nine-plus colour panel, which showed 
that increased cytokine polyfunctionality in cells strongly correlated with reduced disease 
burden. These studies also revealed that polyfunctional cells express higher levels of IFN-γ 
per cell than cells that produce only one cytokine (Chattopadhyay et al., 2008). Several other 
studies have also investigated the polyfunctional cytokine response to CMV in HIV infected 
patients (Maino et al., 1998). 
 
2.5.2.2. Applications for ICS in TLR stimulation 
In innate TLR-mediated immune analysis, previously assays were limited in either the 
analysing the percentage of innate cells by flow cytometry (Jarrossay et al., 2001) or cytokine 
production in response to TLR stimulation subsets (Deering and Orange, 2006). Ida et al 
(2006) demonstrated a method of intracellular detection of TNF-α and IFN-α production in 
response to TLR-mediated DC stimulation. Although this assay was able to detect TLR-
mediated response in using 4-colour flow cytometry, its disadvantage was that only a limited 
response can be detected at one time. 
 
Recently, Jansen et al (2008) described a new method for detection of intracellular cytokine 
production in innate immune cells in response to TLR stimulation. This method of cytokine 
stimulation and detection was employed in this study. This intracellular cytokine stimulation 
method has numerous advantages: it has been optimised for use of peripheral blood 
mononuclear cells as well as whole blood allowing the comparison of responses in the 
presence and absence of soluble factors. This assay is suitable for cryopreservation and 
shipment on dry ice after freezing, eliminating the need for immediate analysis. 
 
This multiparameter flow cytometric approach allows identification of the pattern of the 
cytokine response to TLR stimulation at the single cell level (monocytes, myeloid dendritic 
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cells, plasmacytoid dendritic cells). More importantly, this assay was employed in this study, 
as it requires minimal blood volumes, such as those obtainable in a young infant cohort. It is 
also easily adaptable to include coupling to other multiplexed assays, such as cytokine bead 
arrays, without increasing the necessary sample volume. Thus, this multiparameter flow 
cytometric approach is ideal for robust screening of various TLR responses and perfectly 
suited for use in larger multicentre infant cohorts. 
 
Stellenbosch University  http://scholar.sun.ac.za
25 
 
Chapter Three 
Materials and Methods 
3.1. Ethical approval 
Ethical approval was obtained from the Stellenbosch Committee for Human Research for 
longitudinal follow-up of an infant cohort and analysis of an adult control group (Addendum 
A). Project number N08/10/289 was assigned to the study. The study was conducted 
according to the Declarations of Helsinki, as well as the guidelines stated by the Medical 
Research Council (MRC) and Institute of Child Health (ICH).  
 
3.2. Study design 
This study is described as a prospective comparative longitudinal study. It forms part of a 
multidisciplinary, international, collaborative pilot study aimed at investigating the innate 
immune responses in HIV-Exposed Uninfected (HEU) and HIV unexposed (UE) neonates.  
The working hypothesis of the larger pilot study is that transient innate immune abnormalties 
are present in the HEU infants. This research project is a sub-study of the larger pilot study 
aimed at describing the ontogeny of these innate immune responses in the UE infant 
population only in order to establish a baseline for normal responses in South African infants. 
 
3.3. Participant recruitment  
Infants born to HIV-negative mothers were recruited postnatally at the Tygerberg Academic 
Hospital, Western Cape from March 2009 to June 2009. A total of 29 UE infants were 
enrolled into the study after signed informed consent from the mother, of which one infant 
was subsequently excluded from the study and the infant-mother pair was withdrawn from 
the study. A list of maternal exclusion criteria and infant inclusion criteria was employed for 
the recruitment of mother-infant pairs that were eligible for enrolment and participation in the 
study.  
 
Maternal exclusion criteria: 
 Active tuberculosis (TB) infection or currently on TB treatment 
 Pre-eclampsia 
 Hypertension with protein urinary loss of more than 300mg/dL 
 Perinatal pyrexia of more than 38°C or prolonged rupture of membranes 
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 Maternal haemoglobin of less than 8g/dL at time of delivery 
 Syphilis with treatment completion of less than 4 weeks 
 
Infant inclusion criteria 
 Birth weight greater than 2kgs 
 Gestational age (GA) greater than 37 weeks 
 No congenital abnormalities 
 
The study objectives, procedures and information on the consent forms were carefully 
explained to each mother in her preferred language by the study coordinator or trained 
counsellors at the Children’s Clinical Research Unit (KIDCRU), Tygerberg Hospital (copy 
presented in Addendum B). The consent forms were signed by the mothers before enrolment 
of their infants into the study. Mothers were informed of their right to withdraw their consent 
and exclude their infants at any point in the study. All information regarding the participants 
was handled in a confidential manner. To ensure anonymity of participants, each patient was 
assigned a subject study number during recruitment and all data were linked to the assigned 
subject number. 
 
In addition, ten clinically healthy adult controls were recruited, with informed consent, as a 
separate group for comparative analysis at the KIDCRU facilities and Division of Medical 
Virology, Tygerberg Hospital, from October to November 2009. A subject number was 
assigned to each adult control to ensure anonymity and all the data was linked to the assigned 
subject number. The cross-sectional group of healthy adults served as a standard of 
comparison for the maturation of the TLR-mediated innate cytokine response in the infants at 
the different time points. This allowed for the determination of the age at which the infant’s 
response is similar to the adult group. The decision not to include the infant mothers as a 
comparative group was based on their hormonal changes post-partum, which would not be at 
a stable baseline level. As no published data exists on the TLR-mediated innate immune 
responses of mothers around birth, we speculated that the hormonal responses could be a 
confounding factor in the analysis of the in vitro TLR-mediated cytokine responses, thus 
making the mothers an unsuitable group of controls.   
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3.4. Clinical evaluation and follow-up of infant cohort 
Mothers of enrolled babies were referred to KIDCRU when the infants were 2 weeks, 6 
weeks, 12 weeks, 6 months and 12 months of age for clinical assessment. Medical 
practitioners experienced in Paediatric Medicine examined the infants at each visit. During 
each visit, all infections, socio-economic factors and nutritional information was recorded by 
the medical practitioner or recruitment nurse. In addition, demographic information, 
vaccination history, medical history, growth parameters, feeding methods, episodes of illness 
and medication used was recorded for the all the infant participants (Addendum C, D and E). 
 
3.5. Sample collection  
3.5.1. Preparation of sodium heparin syringes  
The sodium heparin syringes were prepared under sterile conditions using a Class II 
Biosafety Cabinet in a Biosafety Level 3 (BSL3) facility at the Division of Medical Virology, 
NHLS, Tygerberg Hospital. A sterile 23 gage needle (BD Biosciences, USA) was utilised to 
prime sterile 5ml syringes (Neomedic, UK) with 10 000 USP units/ml sodium heparin 
(Pharmaceutical Partners of Canada, Canada). Approximately 250μl sodium heparin was 
transferred from the sodium heparin vial to the 5ml syringe. The syringes were then sealed 
with a syringe cap (BD Biosciences, USA), taken to the KIDCRU facilities, and kept at room 
temperature until blood collection. Prepared syringes older than 24 hours were not utilised for 
blood collection.   
 
3.5.2. Blood collection 
A total of 5ml blood was obtained from the infants at each visit. After the application of 
EMLA anaesthetic cream, a study nurse performed venepuncture via peripheral vein in the 
cubital fossa or the external jugular vein in the neck. For routine analysis of full blood count 
and differential blood count, CD4/CD8 analysis and HIV testing, 500μl of whole blood was 
collected into an EDTA paediatric tube (BD Biosciences, USA).  For the immune analysis, 
4.5ml of whole blood was collected into the sodium heparin-primed syringe. The blood was 
stored at room temperature until analysis or in vitro stimulation. If the blood specimens were 
clotted, the patient was recalled for a follow-up visit to obtain another blood sample. 
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3.6. Methodology for routine analysis  
3.6.1. Full blood count and differential blood count analysis 
At each visit, full and differential blood count analysis was performed to avoid blood draw 
from severely anaemic infants. For analysis, the remaining 350μl EDTA blood was analysed 
on the ADVIA 2120 Haematology System® (Siemens Healthcare Diagnostics, USA) by a 
qualified technologist at the Division of Haematology, NHLS, Tygerberg Hospital.  
 
Medical practitioners employed a grade toxicity table (Division of AIDS Toxicity Grading 
Table for Severity of Paediatric Adverse Events, September 1993) to assess whether a 
subsequent blood draw could be performed on the infant. If the infant’s haemoglobin level 
was Grade 1 category on the toxicity scale, a maximum of 2.5ml blood was collected from 
the infant. If the patient’s haemoglobin level was in the Grade 2 category, no blood draw was 
performed at the visit and iron supplementation was administered to the infant. The patient 
was then rescheduled for a later date. 
 
3.6.2. HIV-1 dried blood spot (DBS) PCR  
A DBS HIV-1 PCR was performed on the EDTA blood sample at 2, 6 and 12 weeks of age to 
ensure the HIV-negative status of the recruited infants. The AMPLICOR HIV-1 DNA Test 
kit version 1.5 (Roche Diagnostics, USA) was employed for HIV testing at the 2 and six 
week follow-up visits and the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 
was employed at the 12 week follow-up visit. The assays have four major processes: (1) 
sample preparation, (2) PCR amplification of target DNA using HIV-1 specific 
complimentary primers, (3) hybridisation of the amplified product to oligonucleotide probes 
specific to the target DNA and (4) the detection of probe-bound amplified products by 
colorimetric determination.  
 
The DBS was prepared in a Class II biosafety cabinet in the BSL3 facility at the Division of 
Medical Virology, NHLS, Tygerberg Hospital within 6 hours after blood collection. DBS 
were prepared by placing two blood spots of 75μl EDTA blood onto a specimen collection 
card (Munktell Filter AB, Sweden), and dried overnight in the biosafety cabinet. The 
qualitative DBS HIV-1 PCR was performed by a qualified molecular technologist. The 
amplification process and temperature is depicted in Table 3.1. Results were read on the 
Anthos Plate Reader (Biochrom Ltd, UK) at 450nm, and reported as positive or negative. For 
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inconclusive or positive results, the sample was repeated to avoid reporting of false positive 
results. 
 
Table 3.1 Amplification process for HIV-1 detection 
Process Temperature  Time  
5 cycles   
Denaturation of DNA 95°C 10 seconds 
Annealing of target primers 52°C 10 seconds 
Extension of PCR product 72°C 10 seconds 
35 cycles   
Denaturation of DNA 90°C 10 seconds 
Annealing of target primers 52°C 10 seconds 
Extension of PCR product 72°C 10 seconds 
Hold 72°C 15 minutes 
   
3.6.3. HIV-1 mini-pool ELISA for adult controls 
To confirm the HIV-negative status of the 10 adult controls, an HIV-1 mini-pool ELISA was 
performed on stored plasma samples of blood collected for the innate immune analysis. The 
AxSYM system and AxSYM HIV Ag/Ab Combo reagent kit (Abbot, Germany) was 
employed for the mini-pool ELISA assay. This assay is a microparticle enzyme immunoassay 
for the simultaneous qualitative detection of antibodies to HIV-1and HIV-2 transmembrane 
protein and HIV p24 antigen in human serum or plasma. The presence or absence of 
antibodies or p24 antigen in the sample is determined by comparing the rate of formation of 
fluorescent product to the cut-off rate, previously calculated by the AxSYM HIV Ag/Ab 
Combo Index Calibrator. If the rate of formation is greater than or equal to the cut-off rate, 
the sample is considered reactive. 
 
The AxSYM HIV Ag/Ab ELISA was performed by a qualified medical technologist. For the 
adult control samples, a 1:10 dilution was prepared by mixing 50µl plasma of each adult 
participant sample into a 2ml tube. The samples were then placed into the AxSYM system for 
HIV testing. Results were reported as positive or negative.  
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3.7. Methodology for innate immune stimulation 
3.7.1. TLR ligand stimulation 
For this study, the TLR stimulation was performed by the investigator at the Division of 
Medical Virology, NHLS, Tygerberg Hospital. Endotoxin-free reagents and materials were 
utilised for blood sampling, processing and stimulation. Endotoxin (LPS) is a potent immune 
modulator and contamination can result in overstimulation of the cells of interest. All the 
preparation and in vitro stimulation was performed under sterile conditions using a Class II 
Biosafety Cabinet in a BSL3 laboratory.   
 
3.7.1.1. Preparation of TLR ligands  
The TLR ligands employed were specific for the appropriate TLR stimulated and lacked 
activity for all the other TLRs. LPS was used for the stimulation of TLR4 (Invivogen, USA) 
and R-848 was employed for the stimulation of TLR7/8 (Invivogen, USA). The 
concentrations and volumes for each TLR ligand used in the preparation of the TLR 
stimulation plates are described in Table 3.2. 
 
Table 3.2 TLR ligand panel for in vitro stimulation of innate immune cells. 
TLR Ligand Stock 
Concentration 
Concentration per 
well 
Volume 
per well 
TLR4 LPS 200ng/ml 10ng/ml 10µl 
TLR7/8 R848 200µM 10µM 10µl 
 
Before dilution, the LPS ligand was sonicated for 10 minutes in a Branson B200 sonicator 
(Branson Untrasonic Corporation, USA) in order to disrupt lipids aggregated on the wall of 
tubes and distribute them evenly within the solution.  Both ligands were vortexed at high 
speed for 30 seconds and diluted from the stock concentration with sterile endotoxin-free 
RPMI 1640 media (Lonza, Biowhittaker, USA) into sterile endotoxin-free 1.8ml cryovials 
(Corning, USA). Endotoxin-free filter tips (Axygen, USA) were employed for this procedure.  
 
3.7.1.2. Preparation of 6-hour ICC TLR stimulation plates 
Sterile endotoxin-free 96-well round bottom polystyrene plates (Corning, USA) were used for 
the preparation of TLR stimulation plates. A final concentration of 2mg/ml Brefeldin A 
(BFA) (Sigma-Aldrich, Germany) was prepared from stock concentration of 10mg/ml using 
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endotoxin-free, RNase- and DNase-free ethanol. BFA acts as a Golgi-secretion inhibitor. For 
whole blood stimulation, 20mM EDTA (Fisher-Scientific, USA) was prepared with deionised 
water (Lonza, Biowhittaker, USA) in order to stop cell stimulation. A 1:10 dilution of BD 
FACSLysing Solution (BD Biosciences, USA) was also prepared with deionised water 
(Lonza, Biowhittaker, USA) in order to lyse red blood cells. The FACSLysing solution also 
acts as a fixative to aid in cryopreservation of cells.  
 
The TLR stimulation plates were prepared as previously described by Jansen et al (2008) and 
Kollmann et al (2009). The LPS ligand was sonicated for 10 minutes and both LPS and R-
848 ligands were vortexed at high speed for 30 seconds before aliquoting into the 96-well 
stimulation plate. Ten microlitres of RPMI 1640 media was aliquoted into the first well as a 
control and a measure of basal stimulation. Ten microlitres of LPS and R-848 ligands was 
then aliquoted into the relevant demarcated wells. One microlitre of BFA was also added into 
each of the wells.  The stimulation plates were sealed with aluminium plate sealers (Nunc, 
Denmark) and enclosed in Parafilm (Pechiney Plastic Packaging Company, USA). The plates 
were stored at -80oC until whole blood in vitro stimulation.  
 
3.7.2. In vitro stimulation 
Innate immune analysis was performed at the 2-week, 6-week, 6-month and 12-month time 
points. Blood processing and in vitro stimulation were performed under sterile conditions in a 
BSL3 facility at the Division of Medical Virology, NHLS, Tygerberg Hospital. As described 
earlier, whole blood was collected directly into a sodium heparin-primed syringe and stored 
at room temperature. The blood was processed within 2 hours of venepuncture. The pre-
prepared TLR stimulation plates were thawed for 20-30 minutes in an incubator at 37˚C in 
5% CO2 to warm up the plates to prior to use. A sterile 15ml conical tube (BD Biosciences, 
USA) was labelled with the patient study number and 1ml RPMI 1640 media was pipetted 
into the tube. The tube was incubated at 37˚C in 5% CO2 for 20-30 minutes to warm up the 
media prior to use.  
 
A second sterile 15ml conical tube was labelled with the patient study number. The 4.5ml 
heparinised blood was transferred from the syringe to the 15ml conical tube and the blood 
was examined for clots by carefully pipetting the blood up and down using a 1000μl pipette. 
For in vitro stimulation, 400μl heated RPMI media was transferred to a third 15ml conical 
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tube labelled with a patient study number and 400μl heparinised whole blood was added to 
the media in a 1:1 ratio and mixed thoroughly. Two hundred microlitres of the blood-RPMI 
mixture was aliquoted into the stimulation wells in the 96-well plates and mixed thoroughly. 
The stimulation plate was then incubated at 37°C in 5% CO2.  
 
After 6 hours of incubation, 25ul of 20mM EDTA was added to each well at a final 
concentration of 2mM per well and the plate was incubated for a further 10 minutes at 37°C 
in 5% CO2. Four sterile 2ml screw-cap microtubes (Quality Scientific Plastics, USA) were 
labelled with the corresponding stimulation well numbers and 1400µl of 1:10 BD 
FACSLysing solution was added to each tube. After incubation, the stimulated whole blood 
mixture in each well was transferred into each corresponding labelled tube and resuspended 
in the FACSLysing solution. The tubes were incubated for 10 minutes at room temperature 
and stored at -80oC  until the samples were shipped to the Child & Family Research Institute, 
University of British Columbia, Vancouver, Canada for sample processing and analysis.  
 
3.8. Methodology for flow cytometric analysis 
The flow cytometric training and subsequent analysis of the TLR-stimulated samples was 
performed by the investigatior at the Child and Family Research Institute, UBC, as part of the 
international collaborative study. All samples were permeabilised, stained with antibodies 
from the established 8-colour flow cytometric panel (Jansen et al., 2008; Blimkie et al., 2011) 
and samples were run on  the  BD FACSAria II flow cytometer (BD Biosciences).  
 
3.8.1. Description of instrumentation 
The BD FACSAria II flow cytometer (BD Biosciences, USA) was employed for the analysis 
of samples. This instrument is a high-speed fixed-alignment benchtop cell sorter that can be 
operated at varied pressures to acquire up to 70,000 events per second. It enables multicolour 
analysis of up to 13 fluorescent markers and two scatter parameters, forward scatter (FSC) 
and side scatter (SSC) at a time. It is equipped with blue (488-nm), red (633-nm) and violet 
(405-nm) solid state lasers for excitation of fluorochrome-conjugated antibodies. It is also 
equipped with two types of signal detectors; photomultiplier tubes (PMTs) and a photodiode 
detector. PMTs detect signals generated by SSC and all fluorescence channels whereas the 
photodiode signal generated by FSC.  
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The BD FACSAria II possesses both octagon and trigon detector arrays. The octagon detector 
array contains six PMTs that detect SSC and up to seven fluorescence signals excited by the 
blue laser. The trigon arrays detect fluorescence signals excited by the red and violet lasers, 
respectively. Each trigon contains two PMTs that detect up to three fluorescence channels. 
The PMTs within each array convert light into electrical pulses that can be processed by the 
electronics system and converted into data. Acquisition and data analysis, as well as most BD 
FACSAria II cytometer functions, are performed and controlled by BD FACSDiva software 
(BD FACSAria II User Guide). 
 
For the purpose of our study, Table 3.3 illustrates the light path, filters, detectors and voltage 
settings for the BD FACSAria II employed in our study. The detectors and filters are listed in 
the order that the emitted light hits them, with the exception of FSC, as it is measured from 
light that passes through the cell. All other detectors detect light scattered 90º.  
 
Table 3.3 BD FACSAria II set up for the flow cytometric analysis 
Laser  Detector  Filter 1 
(LP)  
Filter 2 
(BP)  
Parameter 
detected  
Detector 
voltage  
Amplification 
Type 
Blue Laser  
(488 nm)  
SSC (PD)  na  488/10 
BP  
SSC-A  440 LINEAR 
488 A (PMT)  735 LP  780/60 
BP  
PE-Cy7-A  605 LOG 
488 B (PMT)  655 LP  695/40 
BP  
PerCP-Cy5.5-A  585 LOG 
488 C (PMT)  595 LP  610/20 
BP  
PE-TexRed  na   
488 D (PMT)  556 LP  575/26 
BP  
PE 498 LOG 
488 E (PMT)  502 LP  530/30 
BP  
FITC 480 LOG 
Violet Laser 
 (407 nm)  
407 A (PMT)  502 LP  530/30 
BP  
Alexa-430-A  na  
 407 B (PMT)  blank  450/40 
BP  
Pacific Blue-A  530 LOG 
Red Laser  
(633 nm)  
633 A (PMT)  755 LP  780/60 
BP  
APC-Cy7-A  605 LOG 
633 B (PMT)  685 LP  720/40 
BP  
Alexa700-A  515 LOG  
633 C (PMT)  blank  660/20 
BP   
APC-A  492 LOG  
 
3.8.2. Optimisation of eight-colour flow cytometric panel 
The development of 8-colour panel was previously described in Jansen et al (2008). The 
antibody conjugates, their clones as well as their respective titrations used in this study are 
illustrated in Table 3.4.  
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Table 3.4 Antibody staining panel for ICC 
Fluorochrome Marker 
measured 
Clone Supplier Dilution  Volume 
per well 
PerCP Cy5.5 HLA-DR  TU36 BD #custom 1:100 1µl 
PE-Cy7 CD14 M5E2 eBioscience #25-0149 1:100 1µl 
APC CD11c 5HCL3 BD #340714 1:50 2µl 
PE CD123 6H6 eBioscience #12-1239 1:200 0.5µl 
FITC IFN-α A11 Antigenix #MC100133 1:100 1µl 
APC-Cy7 IL-6 AS12 BD #custom 1:100 1µl 
eFluor450 IL-12p40/70 C8.6 eBioscience # 48-7139 1:400 0.25µl 
AlexaFluor700 TNF-α Mab11 BD #557996 1:100 1µl 
 
Fluorescence spillover was analysed by use of fluorescence minus one (FMO) controls for 
each monoclonal antibody conjugate included in the 8–colour staining panel (Table 3.4). 
FMO controls were performed in order to assess the delineation of the true positive and 
populations for the regent of interest. This distinguishes the fluorescent cells expressing the 
marker of interest from cells that do not express the marker but detected as positive within 
that channel.  
 
The FMO control was performed using R-848 stimulated and RPMI-stimulated 
(unstimulated) cell controls. The frozen control tubes were thawed in a water bath at 37˚C for 
5-10 minutes and spun in a microcentrifuge at 600xg for 5 minutes at room temperature. 
After centrifugation, the supernatant was aspirated from each tube and the remaining pellets 
were resuspended in 200µl of 1:10 FACSPermeabilising Solution (BD Biosciences). The 
samples were incubated in the dark for 10 minutes at room temperature. After incubation, the 
cells were resuspended in 100µl PBSAN and centrifuged at 600xg for 5 minutes at room 
temperature to stop the permeabilisation process. The supernatant was discarded and the 
pellets were washed in 200µl PBSAN and centrifuged at 600xg for 5minutes. This process 
was repeated and the pellets were resuspended in 75µl PBSAN after centrifugation.  
 
For the FMO staining of the cell control for each tested antibody, each tested antibody FMO 
was prepared by aliquoting the volumes of the antibodies as described in Table 3.4, with the 
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exception of the tested antibody and a total of 17.25µl PBSAN per well was added to the 
tube. The mastermix was then vortexed for 10-15 seconds and 25µl of the mixture was 
pipetted into each cell control well to make up a final well volume of 100µl per well. 
 
The cell controls were then acquired on the BD FACSAria II and analysed for the percentage 
of spillover for each tested antibody. The compensation matrix was then adjusted to account 
for the spillover, when detected, and these adjusted settings were then employed for the 
analysis of the samples. 
 
Table 3.5 Representative compensation matrix for the analysis of samples 
 FITC PE PerCP-Cy5-5 PE-Cy7 APC APC-Cy7 Pacific Blue Alex 700 
FITC  29.11 1.847 0.2719 0 -0.1527 0.6106 -0.4128 
PE 0.6607  6.615 1.07 -0.249 -0.3758 0.3544 -0.6247 
PerCP-Cy5-5 0.1683 0.2436  33.73 2.026 11.66 1.175 30.06 
PE-Cy7 0.1653 1.982 0.3268  0 15.32 0.1029 0.5033 
APC-A 0.1415 0.1788 1.576 0.4223  20.5 0.9705 65.71 
APC-Cy7 0.08945 0.119 0.3078 2.183 12.56  0.3553 13.26 
Pacific Blue 0.1281 0.1833 0 0 0.05744 -0.172  -0.2704 
Alex 700 0.1859 0.208 1.44 0.9827 0.2883 29.7 0.662  
 
3.8.3. Permeabilisation and cell staining 
All the reagents were prepared prior to use. For permeabilisation of samples, a 1:10 dilution 
of BD FACSPermeabilisation Solution (BD Biosciences, USA) was prepared with deionised 
water. The PBSAN washing and staining solution was prepared with 50ml of 5% bovine 
serum albumin (Invitrogen, USA) (5g/100ml in deionised water), 5ml of 10% sodium azide 
(10g/100ml in deionised water), and 50ml of 10X Dulbecco’s phosphate-buffered saline 
(DPBS) (Gibco, USA) in 395ml deionised water. The solution was stored at 4ºC until use. 
The paraformaldehyde solution (BD Biosciences, USA) used as a fixative, was prepared as a 
1:10 dilution with DPBS.  The following antibodies were employed for the staining process: 
HLA-DR PerCp-Cy5.5 (BD Biosciences, USA); 
CD14 PE-Cy7 (BD Biosciences, USA); 
CD11c APC (BD Biosciences, USA); 
CD123 PE (eBiosciences, USA); 
IFN-α FITC (Antigenix, USA); 
IL-6 APC-Cy7 (BD Biosciences, USA); 
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IL-12p40/70 eFluor450 (eBiosciences, USA)   
TNF-α AlexaFluor700 (BD Biosciences, USA) 
 
For the compensation, Anti-Mouse Ig CompBeads were employed (BD Biosciences, USA).  
The dilutions were for each antibody is illustrated in Table 3.3. For the innate immune 
analysis, no live/dead discriminator was employed as the stimulated cells were fixed and 
frozen prior to flow cytometric analysis. At the time of the study no product for live/dead cell 
discrimination was available that would endure the fix-freeze-thaw process and if this marker 
was included during the staining process, all the cells would have been identified as dead 
cells.  
 
For each set of experiments, an RPMI-stimulated negative control and an R848- stimulated 
positive control were prepared with the patient samples. For the preparation of the controls, 
whole blood was obtained from a clinically healthy adult donor. The in vitro stimulation for 
controls was similar to that of the patient samples. Ten patient samples along with one R-848 
positive cell control and one unstimulated negative control were prepared for each run.  
 
The frozen sample tubes were placed in a water bath at 37˚C for 5-10 minutes until thawed. 
When thawed, the samples were spun in a microcentrifuge at 600xg for 5 minutes at room 
temperature. A 96-well round bottom plate was labelled with the patient study numbers 
(rows) and the different TLR ligands (columns). After centrifugation, the supernatant was 
aspirated from each tube. The remaining pellets in each stimulation tube were resuspended in 
200µl of the 1:10 FACSPermeabilising Solution and the patient samples was transferred into 
their respective rows in the 96-well round bottom plate. The plate was incubated in the dark 
for 10 minutes at room temperature. After incubation, the pellets in the wells were 
resuspended in 100µl PBSAN and centrifuged at 600xg for 5 minutes at room temperature to 
stop the permeabilisation process. The supernatant was discarded and the pellets were washed 
in 200µl PBSAN and centrifuged at 600xg for 5minutes. This process was repeated and the 
pellets were resuspended in 75µl PBSAN after centrifugation.  
For the antibody staining process, a mastermix of the antibodies was prepared in the dark as 
the fluorochromes are light-sensitive. The volumes of each antibody were added to the 
mastermix as described in Table 3.3. A total of 17.25µl PBSAN per well was added to the 
mastermix. The mastermix was then vortexed for 10-15 seconds and 25µl of the antibody 
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mastermix was pipetted into each well to make up a final well volume of 100µl per well. The 
wells were mixed thoroughly by pipetting and the plate was incubated in the dark at room 
temperature for 45 minutes. After incubation, 100µl PBSAN was added to the wells and the 
plate was centrifuged at 600xg for 5 minutes at room temperature. The supernatant was 
discarded and the pellets were washed in 200µl PBSAN and centrifuged at 600xg for 5 
minutes. This process was repeated and the pellets were resuspended in 100µl of 1:10 
dilution paraformaldehyde. The samples were stored overnight at 4˚C. The samples were 
protected from light.  
 
For compensation controls, single-stained bead controls were prepared for each antibody in 
the staining panel. A 96-well round bottom plate was labelled with the antibodies included in 
the staining panel and 92µl PBSAN was added to each well. The positive and negative anti-
Mouse Ig CompBeads were vortexed at high speed for a minimum of 15 seconds. Three 
microlitres of the positive and negative anti-Mouse Ig CompBeads was added to each well. 
Two microlitres of each antibody was added to the demarcated wells and mixed thoroughly. 
The bead mix was incubated in the dark for a minimum of 20 minutes at room temperature. 
After incubation, 100µl PBSAN was added to the wells and the plate was centrifuged at 
600xg for 5 minutes at room temperature and the supernatant was discarded. After 
centrifugation, the beads were washed in 200µl PBSAN and centrifuged at 600xg for 5 
minutes. This process was repeated and the beads were resuspended in 100µl of 1:10 dilution 
paraformaldehyde. The single-stained bead controls were stored overnight at 4˚C and 
protected from light. The stained beads were protected from light. 
 
3.8.4. Acquisition 
Before acquisition, the sample tubes and beads were vortexed for 5 seconds to ensure that the 
cells and beads were well suspended. All samples were analysed on the BD FACSAria II 
flow cytometer, which employed BD FACSDiva™ software for data acquisition and 
analysis. The FSC and SSC gain was set up in dot plot using the unstained control. The 
positive R-848 control was employed to set the gain for each fluorescent channel. This 
enabled positioning of the high positive cells between the 3rd and 4th decade on the plot. The 
unstimulated negative cell control was used to position the negative cells within the 1st 
decade. After setup, the experimental samples, negative unstimulated and positive R-848 
stimulated cell controls were acquired on the BD FACSAria II.  For sample acquision, a 
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maximum of 500 000 and a minimum of 250 0000 gated events were collected for each 
sample tube. Thereafter, the single-stained bead control tubes were acquired. A maximum of 
5000 bead events were acquired for each bead control.  
 
3.8.5. FlowJo analysis 
The FCS files for the samples were analysed using FlowJo (Tree Star, OR, USA).  Before 
analysis, the compensation for each experiment was set using the single stained CompBeads 
sample FCS files. In each single-stained bead control histogram, the positive and negative 
gate was defined for that specific fluorescent channel and these were used to define the 
compensation matrix.  The sample FCS files were compensated with the matrix. Further 
subset gating was applied to enable identification of the specific cellular subsets of interest 
and the production of intracellular cytokines for each specific cell population.  
 
3.8.5.1. Identification of cell subsets 
Figure 3.1 demonstrates the dot plots employed for the identification of monocytes, mDCs 
and pDCs. Back gating was performed on each population of interest to verify their position 
in relation to the FSC versus SSC axis (Figure 3.2 to 3.4). The unstimulated samples for each 
participant was used to apply the gating strategy, therefore each gating strategy was 
specifically applicable to each participant. The primary gating strategy (FSC versus SSC) was 
used to yield a live gate to include all cells and exclude debris and dead cells. Secondary 
gating was applied to identify monocytes and dendritic cells. Monocytes were identified 
based on their expression of MHCII+ and CD14+ surface markers. Dendritic cells were 
identified based on MHCII+ CD14- expression. Further gating was applied to dendritic cell 
gate to identify the mDC (CD11c+) and surface pDC (CD123+) subpopulations. Bulk gating 
was used to apply these gate coordinates to the rest of the samples for that specific 
participant. After bulk gating, the gates were checked and adjusted manually for each 
participant sample.  
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Figure 3.2 Example of backgating strategy for the monocyte population using FlowJo. Dot plot A represents the 
monocyte population in the secondary gate used to identify monocytes and DCs (CD14 vs MHCII). Dot plot B 
indicates the gated monocyte population relative to the monocyte versus DC gate. Dot plot C indicates the gated 
monocyte population in the live gate (FSC vs SSC).   
 
 
  
Figure 3.3 Example of backgating strategy for the mDC population using FlowJo. Dot plot A represents the 
mDC population in the tertiary gate used to identify mDCs and pDCs (CD11c vs CD123). Dot plot B indicates the 
gated mDC population relative to the monocyte versus DC gate. Dot plot C indicates the gated mDC population in 
the live gate (FSC vs SSC).   
Figure 3.1 Example of identification of monocytes, mDCs and pDCs by flow cytometry. Dot plot A indicates the 
live gate, which included all cells. Dot plot B indicates the differentiation of monocytes (MHCII+CD14+) and DCs 
(MHCII+CD14-). Dot plot C indicates the CD11c and CD123 expression by DCs. Myeloid DCs were differentiated by 
expression of CD11c marker and pDCs were differentiated by expression of CD123 marker 
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A B 
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3.8.5.2. Evaluation of intracellular cytokine production 
Monocytes, mDCs and pDCs were analysed for the intracellular production of TNF-α, IL-6, 
IL-12p40, and IFN-α in response to each TLR ligand. Figure 3 demonstrates the gating 
strategy for the identification of intracellular cytokine response profile in an unstimulated and 
R848 (TLR7/8) stimulated sample in monocytes, mDCs and pDCs.  
 
Dot plots were set up for each of the cell types (monocytes, mDCs and pDCs), as described in 
section 3.8.5.1. The unstimulated sample for each participant was used to determine the 
negative break points for each cytokine combination for each cell population (e.g. TNF-α 
versus IL-6). The negative response was defined as where the unstimulated cell populations 
lie within the unstimulated sample gate. The coordinates of these break points for each of the 
cytokine combinations in each cell break points were applied to each cell type. A histogram 
plot was then chosen and the break points determined for the positive and negative dot plot 
populations were applied to the histogram for each of the cytokines for each cell type.  
 
Boolean gating was employed in order to identify the single-, double-, triple-, and quadruple 
cytokine-expressing populations. Using the histograms created to depict the positive and 
negative cytokine populations, the positive cytokine-expressing cells of interest were grouped 
together (e.g. TNF-α and IL-6) and the AND function selected. This allows for the 
determination of the double positive TNF-α+IL-6+ population within that cell type. Bulk 
gating was then used to apply these gates to the stimulated samples for that cell population 
for that specific participant. This process was followed for each participant at each time point. 
Figure 3.4 Example of backgating strategy for the pDC population using FlowJo. Dot plot A represents the pDC 
population in the tertiary gate used to identify mDCs and pDCs (CD11c vs CD123). Dot plot B indicates the gated 
pDC population relative to the monocyte versus DC gate. Dot plot C indicates the gated pDC population in the live 
gate (FSC vs SSC).  
 
 
 
A B C 
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3.9. Data collection and statistical analysis 
The whole blood samples were evaluated for cytokine production in response to TLR 
stimulation at the 2 weeks, 6 weeks, 6 months and 12 months of age. The analysed data from 
each participant at each time point was transferred to a Microsoft Excel spreadsheet 
(Microsoft, USA). For the determination of total cytokine responses in monocytes, mDCs and 
pDCs, the following calculations were performed in Microsoft Excel; for the total TNF-α 
production, the sum of TNF-α+, TNF-α+IL-6+, TNF-α+IL-12+ and TNF-α+IL-6+IL-12+ 
populations were determined. For the total IL-6 production, the sum of IL-6+, TNF-α+IL-6+, 
IL-6+IL-12+ and TNF-α+IL-6+IL-12+ populations were determined. For the total IL-12+ 
production, the sum of IL-12+, IL-6+IL-12+, TNF-α+IL-12+ and TNF-α+IL-6+IL-12+ 
populations were determined. For the total IFN-α production, the sum of IFN-α+, IFN-α+IL-
6+, TNF-α+IFN-α+ and IFN-α+TNF-α+IL-6+ populations were determined. These values 
were analysed using statistical software.  
 
For the determination of polyfunctional responses in monocytes, mDCs and pDCs, the 
following populations were analysed: the TNF-α+, IL-6+, IL-12+ and IFN-α+ single positive 
Figure 3.5 Example of intracellular cytokine production in monocytes, mDCs and pDCs of infants and 
adults. Monocytes, mDCs and pDCs were analysed for the intracellular production of IL-6, IL-12, TNF-α and 
IFN-α. 
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populations were analysed for single-positive cytokine responses. The TNF-α+IL-6+, TNF-
α+IL-12+, IL-6+IL-12+, IFN-α+IL-6+ and TNF-α+IFN-α+ double-positive populations were 
analysed for double-positive cytokine responses. The TNF-α+IL-6+IL-12+ and IFN-α+TNF-
α+IL-6+ triple-positive populations were analysed for triple-positive cytokine responses. 
 
For statistical analysis of the participant flow cytometric data, GraphPad Prism 5 (GraphPad 
Software Incorporated, USA) and Statistica 10 (StatSoft, USA) statistical software was 
employed.  To analyse the statistical differences between the pairwise comparison of means 
between infant responses (at 2 weeks, 6 weeks, 6 months and 12 months) and adult responses, 
an analysis of variance (ANOVA) estimation method was employed, with type III sum of 
squares to account and compensate for unequal n. The same method, ANOVA with type III 
sum of squares, was employed to determine the statistical significance of the pairwise 
comparison of means in infant responses between each time point. This was performed with 
the Variance Estimation and Precision method in Statistica 10. Confidence intervals were set 
at 95%. The mean values with standard deviations as well as p-values were reported.  Results 
were displayed graphically as follows; for the total cytokine responses, bar graphs were used, 
depicting the mean and standard deviation and for the poyfunctional responses, line graphs 
were used, depicting the mean and 95% confidence intervals. P-values of <0.05 were 
regarded as significant and p-values of <0.01 were regarded as highly significant. 
 
  
Stellenbosch University  http://scholar.sun.ac.za
43 
 
Chapter Four 
Results 
4.1. Participant characteristics 
4.1.1. Demographics  
From the period of March 2009 to June 2009, 28 UE infants were included for innate immune 
analysis. Most of the participants lived in the residential areas surrounding Tygerberg 
Hospital, Cape Town. Ten clinically healthy adult controls were recruited as a separate group 
for comparative analysis during October and November 2009. The infants recruited into the 
study were predominantly of coloured or mixed ethnicity with a mean gestational age of 
36±7.5 weeks (Table 4.1). The majority of the adults recruited into the control group were of 
coloured or mixed ethnicity and between the age of 23 and 54 years with a mean age of 
37±10 years. All infants received their vaccinations at the scheduled timelines outlined in the 
extended programme of immunisation (EPI) implemented by the Department of Health, 
South Africa. 
 
4.1.2. Feeding practices 
In our study, all the infants were exclusively breastfed from birth up to a minimum of 12 
weeks of life (Table 4.1). At the six months visit, we recorded that the infants were on a 
mixed diet consisting of either breast milk or formula and solids. The reason for this was that 
many of the mothers recruited on the study had already returned to employment around this 
time point. At 12 months, all the infants were on mixed feeding that consisted of formula and 
solids (data not shown). 
 
4.1.3. Rate of attrition  
The rate of attrition was documented throughout the duration of the study (Table 4.1). A 
substantial loss to follow-up of infants was noted during the course of study. At the two-week 
time point, one infant did not attend the visit, but re-entered the study at the 6-week visit. At 
the 6-week time point, two infants were lost to follow-up. The highest attrition rate was 
observed at the six-month follow up visits, as four infants were lost to follow-up. At the 12-
month time point, a further two infants did not arrive for the follow-up visit. 
 
Data was collected to ascertain the causes for the loss to follow-up in the infant group. The 
key reasons for the high attrition rate were: (1) refusal of further participation in the study for 
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unknown reasons (n=4) and (2) mothers resuming work responsibilities (n=3). One infant 
died during the course of the study due to adenovirus infection. No loss to follow-up was 
observed in the adult group, as no follow-up visits were required. 
 
Table 4.1 General characteristics of participants. This table describes the  
distribution and number of participants recruited in each group. 
 
  
Number of infant participants (%) 28 (100) 
Gestational age in weeks (mean ± SD) 36 ± 7.5 
Gender  
      Male 15 (54) 
      Female 13 (46) 
Ethnicity   
      Black   8 (29) 
      Coloured/Mixed race 19 (68) 
      Caucasian   1   (3) 
Feeding practices  
      Breastfed at birth 28 (100) 
      Duration of exclusive breastfeeding ± 12 weeks 
      Introduction of solids/mixed feeding ±  6 months 
Follow-up visits  
      Two week time point 28 (100) 
      Six week time point 28 (100) 
      Six month time point 23   (82) 
      Twelve month time point 20   (71) 
Number of adult participants (%) 10 (100) 
Age in years (mean ± SD) 37.4 ± 10 
Gender  
     Male 2 (20) 
     Female 8 (80) 
Ethnicity  
     Black 2 (20) 
     Coloured/Mixed race 6 (60) 
     Caucasian 2 (20) 
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4.2. Comparison of cytokine responses in infants versus adults 
Using the multiparameter flow cytometric approach, we assessed the total production of 
TNF-α, IL-6, IL-12/23p40, and IFN-α2 at the single-cell level at basal level (unstimulated 
control), as well as in response to LPS (TLR4) and R-848 (TLR7/8) stimulation in 
monocytes, mDCs and R-848 (TLR7/8) stimulation in pDCs. At each time point (2 weeks, 6 
weeks, 6 months and 12 months); the infant responses were compared to the adult group for 
each cell type.  
 
The monocytes and mDCs responded to TLR4 and TLR7/8 stimulation, whereas the pDC 
population responded to TLR7/8 stimulation. No response was observed to TLR4 stimulation 
in pDCs. We observed TNF-α, IL-6, and IL-12/23p40 production by monocytes and mDCs, 
but not IFN-α2 (data not shown). In pDCs, we observed the production of TNF-α and IFN-
α2, but not IL-6 or IL-12/23p40 (data not shown). Thus, only the analysis for each of these 
cytokines will be discussed for each respective cell type. Data comparisons were defined as 
significant if p<0.05 and highly significant if p<0.01. 
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4.2.1. Monocytes  
4.2.1.1.  Total TNF-α response  
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Figure 4.1 Percentage of TNF-α-producing monocytes at basal level. Bar graphs represent mean and 
standard deviation. The grey bar depicts the adult group. P-values depicted in black denote comparisons 
between infant groups and the adult group. P-values depicted in red denote comparison between infant time 
points. 
 
At basal level, no significant differences were observed in the percentage of TNF-α-
producing monocytes between the adult group and infants groups when measured at two 
weeks, six weeks, six months and 12 months of age. The highest percentage of TNF-α-
producing monocytes was observed at the 12 month time point and was comparable to the 
adult group. 
  
In the comparison of responses over time, no significant differences in the percentage of 
TNF-α-producing monocytes were observed between any of the time points, with the 
exception of two weeks and 12 months. A significantly higher percentage of TNF-α-
producing monocytes was observed at 12 months compared to the two-week time point 
(p<0.05).  
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Figure 4.2 Percentage of TNF-α-producing monocytes in response to LPS stimulation. Bar graphs represent 
mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points.  
 
In response to TLR4 stimulation, no significant difference was observed in the percentage of 
TNF-α-producing monocytes between the adults and infants at 2 and 6 weeks of age, though 
a slightly higher percentage of TNF-α-producing cells at 2 weeks and slightly lower 
percentage of TNF-α-producing cells at 6 weeks was seen compared to adults. At 6 months, 
however, the percentage of TNF-α-producing monocytes was significantly higher in infants 
compared to the adult group (p<0.01). At the 12 month time point, no significant differences 
were observed, though the percentage of TNF-α-producing monocytes remained higher in 
infants. 
  
When comparing each time point in the infant population, several changes over time were 
also observed. Although no significant difference was observed in the percentage of TNF-α-
producing monocytes between the two and six weeks, the six month time point revealed 
significantly higher responses to TLR4 stimulation compared to the 2 weeks, 6 weeks and 12 
month time points (p<0.01). No significant differences were observed 12 months and the two 
and six week time points. 
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Figure 4.3 Percentage of TNF-α-producing monocytes in response to R848 stimulation. Bar graphs 
represent mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points.  
 
In response to TLR7/8 stimulation, the percentage of TNF-α-producing monocytes in infants 
were significantly higher compared to the adult monocyte responses at 2 weeks (p<0.01), six 
weeks (p<0.01) and six months (p<0.01) of age. At 12 months, though infants showed a 
lower percentage of TNF-α-producing monocytes, no significant difference was observed 
when compared to adults. 
  
The comparison in infant responses over time showed no significant difference in the 
percentage of TNF-α-producing monocytes between two week and six weeks, as well as the 
between the six week and six month time points. The 12 month time point showed 
significantly lower percentage of TNF-α-producing monocytes when compared to 2 weeks, 6 
weeks and 6 months time points (p<0.01).  
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4.2.1.2. Total IL-6 response 
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Figure 4.4 Percentage of IL-6-producing monocytes at basal level. Bar graphs represent mean and standard 
deviation. The grey bar depicts the adult group. P-values depicted in black denote comparisons between infant 
groups and the adult group. P-values depicted in red denote comparison between infant time points. 
 
At basal level, no significant differences were observed in the percentage of IL-6-producing 
monocytes between the adult group and infants groups when compared at two weeks, six 
weeks, six months and 12 months of age. The highest percentage of IL-6-producing 
monocytes was observed at the 6 month time point and was comparable to the adult group, 
with a significant decline at the 12 month time point in comparison to the adult group. 
  
In the comparison of responses over time, no significant differences were observed in the 
percentage of IL-6-producing monocytes between any of the time points.   
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Figure 4.5  Percentage of IL-6-producing monocytes in response to LPS stimulation. Bar graphs represent 
mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points. 
 
In both the infant and adult groups, a low percentage of IL-6-producing monocytes were 
observed in both the infant and adult groups in response to TLR4 stimulation. At two and six 
weeks of age, no significant difference in the percentage of IL-6-producing monocytes was 
observed, though infants produced a higher percentage of IL-6-producing monocytes in 
comparison to the adult monocytes. At six months and 12 months, the percentage of IL-6-
producing monocytes in the infant group were significantly higher at both time points 
compared to the adult monocytes, with p-value of less than 0.01 and 0.05 respectively. 
 
Comparison of the infant’s responses at two weeks and six weeks revealed no significant 
differences between the time points. At six months, the percentage of IL-6-producing 
monocytes was significantly higher compared to the two-week and six-week time points 
(p<0.01). At 12 months of age, the percentage of IL-6-producing monocytes was only 
significantly higher compared to the 6-week time point (p<0.05).  
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Figure 4.6  Percentage of IL-6-producing monocytes in response to R-848 stimulation. Bar graphs represent 
mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points. 
 
In response to TLR7/8 stimulation, significantly higher percentages of IL-6-producing 
monocytes were observed in infants at 2 weeks, 6 weeks, 6 months and 12 months of age 
when compared to the adult responses (p<0.01).  
 
In comparison of infant responses over time, no significant difference was observed in infants 
between two weeks and six weeks, two weeks and six months as well as six weeks and six 
months of age.  At 12months of age, infants showed a significantly lower percentage of IL-6-
producing monocytes compared to six weeks (p<0.05), but no significant differences were 
observed between two  week and twelve months, and  six months and twelve months of age.  
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4.2.1.3. Total IL-12/23p40 response  
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Figure 4.7 Percentage of IL-12/23p40-producing monocytes at basal level. Bar graphs represent mean and 
standard deviation. The grey bar depicts the adult group. P-values depicted in black denote comparisons 
between infant groups and the adult group. P-values depicted in red denote comparison between infant time 
points. 
 
At basal level, no significant differences were observed in the percentage of IL-12/23p40-
producing monocytes between the adult group and infants groups when compared at two 
weeks, six weeks, six months and 12 months of age. The highest percentage of IL-12/23p40-
producing monocytes was observed at the 2 weeks time point, with the high standard 
deviation indicating that certain infants showed much higher cytokine responses at this time 
point. At 12 months the percentage of was comparable to the adult group. 
  
In the comparison of responses over time, infants at 2 weeks showed significantly higher 
percentages of  IL-12/23p40-producing monocytes compared to six weeks (p<0.01), six 
months (p<0.05) and 12 months (p<0.05) of age. No significant differences were observed 
between the other time points.  
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Figure 4.8 Percentage of IL-12/23p40-producing monocytes in response to LPS stimulation. Bar graphs 
represent mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points. 
 
In response to TLR4 stimulation, no significant difference in the IL-12/23p40-producing 
monocytes was observed between the adult group and infants at two and six weeks of age, 
though infants had lower percentages of IL-12/23p40-producing monocytes compared to the 
adults. At six months of age, the percentage of IL-12/23p40-producing monocytes was 
significantly higher in infants at six months compared to the adult (p<0.05).  At twelve 
months of age, no significant difference was observed between infants and adults at this time 
point, and was comparable to adults.  
 
The comparison of infant responses over time showed no significant difference in the 
percentage of IL-12/23p40-producing monocytes between the 2-week and 6-week time 
points. At six months, significantly higher percentages of IL-12/23p40-producing monocytes 
was observed compared to two weeks and six weeks (p<0.01). At 12 months, no significant 
difference was observed compared to the other time points, with the exception of  six months, 
where a significantly lower percentage of IL-12/23p40-producing monocytes was observed at 
twelve months compared to 6-month time point (p<0.01). 
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Figure 4.9 Percentage of IL-12/23p40-producing monocytes in response to R-848 stimulation. Bar graphs 
represent mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points. 
  
In response to TLR7/8 stimulation, the percentage of IL-12/23p40-producing monocytes was 
lower in infants at two weeks, six weeks-, six months- and twelve months of age when 
compared to the adults. This was only found to be significant at 2 weeks and 12 months of 
age (p<0.01)  
 
In the comparison of infants’ responses over time, no significant differences in the percentage 
of IL-12/23p40-producing monocytes were observed between the two-week and six-week 
and six week and six month time points. Significantly higher responses were observed at 6 
months compared to the two week and 12 month time points. Furthermore, significantly 
lower responses were observed at 12 months compared to the six-week time point.  
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4.2.2. Myeloid DCs 
4.2.2.1. Total TNF-α response 
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Figure 4.10 Percentage of TNF-α-producing mDCs at basal level. Bar graphs represent mean and standard 
deviation. The grey bar depicts the adult group. P-values depicted in black denote comparisons between infant 
groups and the adult group. P-values depicted in red denote comparison between infant time points. 
 
At basal level, the percentage of TNF-α-producing mDCs in infants at two weeks, six weeks, 
six months and 12 months were significantly lower in comparision to the adult group 
(p<0.01).  
  
In the comparison of responses over time, no significant difference was observed in the 
percentage of TNF-α-producing mDCs between infant groups at 2 weeks and six weeks of 
age. At six months, infants had significantly higher percentages of TNF-α-producing mDCs 
compared to two weeks (p<0.01) and six weeks (p<0.01). At 12 months, a decline in the 
percentage of TNF-α-producing mDCs was observed in comparison to six months, but this 
was not found to be significant.  
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Figure 4.11 Percentage of TNF-α-producing mDCs in response to LPS stimulation. Bar graphs represent 
mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points. 
 
In response to TLR4 stimulation, no significant difference was observed in the percentages of 
TNF-α-producing mDCs between infants at two- and six week time points and adults, 
although it was higher compared to adults. At six months, a significantly higher percentage of 
TNF-α-producing mDCs was observed in infants compared to adults (p<0.01). At 12 months, 
higher percentages of TNF-α-producing mDCs was observed in infant mDCs compared to the 
adults, but was not statistically significant.  
 
The comparison of infant responses over time revealed no significant differences in the 
percentage of TNF-α-producing mDCs in infants between 2 weeks and 6 weeks of age. At six 
months, a significantly higher percentage of TNF-α-producing mDCs was observed in infants 
when compared to the two weeks (p<0.05) and six weeks (p<0.01) time points. At 12 months, 
a significant decline in the percentage of TNF-α-producing mDCs was observed compared to 
the 6 month time point (p<0.05). 
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Figure 4.12 Percentage of TNF-α-producing mDCs in response to R-848 stimulation. Bar graphs represent 
mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points. 
 
In response to TLR7/8 stimulation, infants at two weeks and six weeks of age showed 
significantly higher percentages of TNF-α-producing mDCs when compared to the adults 
(p<0.05). At 6 months and 12 months of age, infants showed lower percentages of TNF-α-
producing mDCs compared to the adult group. This was only significant at 12 months 
(p<0.01). 
 
The comparison over time showed a trend towards decreasing percentages of TNF-α-
producing mDCs in infants over time. The six-week time point showed a somewhat lower 
response compared to the infants at 2 weeks, though this was not significant. At six months, 
infants showed higher showed significantly lower percentages of TNF-α-producing mDCs 
compared to two weeks (p<0.01) and 6 weeks (p<0.01). The most substantial decrease was 
observed at 12 months, which was significantly lower compared to the two-week, six-week 
and six-month time points (p<0.01). 
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4.2.2.2. Total IL-6 response  
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Figure 4.13 Percentage of IL-6-producing mDCs at basal level. Bar graphs represent mean and standard 
deviation. The grey bar depicts the adult group. P-values depicted in black denote comparisons between infant 
groups and the adult group. P-values depicted in red denote comparison between infant time points. 
 
At basal level, no significant differences were observed in the percentage of IL-6-producing 
mDCs in infants at two weeks, six weeks, six months and 12 months in comparision to the 
adult group. At six months of age, the percentage of IL-6-producing mDCs were comparable 
to the adult. A decline in this response was observed at 12 months. 
  
In the comparison of responses over time, no significant difference was observed in the 
percentage of TNF-α-producing mDCs between infant groups at any of the progressive time 
points.  
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Figure 4.14 Percentage of IL-6-producing mDCs in response to LPS stimulation. Bar graphs represent 
mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points. 
 
In response to TLR4 stimulation, infants demonstrated higher percentages of IL-6-producing 
mDCs at all four time points in comparison to the adults. This was found to be significant at 
the 6 months and 12 month time points, with p<0.01 and p<0.05 respectively. 
 
In comparison of infant responses over time, no significant difference in the percentages of 
IL-6-producing mDCs was observed between two weeks and six weeks of age. At 6 months, 
infants showed significantly higher percentages of IL-6-producing mDCs compared to the 
two-week (p<0.05) and six-week time point (p<0.01). At 12 months, though a decline in the 
percentage of IL-6-producing mDCs was observed compared to six months, this was not 
significant. 
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Figure 4.15 Percentage of IL-6-producing mDCs in response to R-848 stimulation. Bar graphs represent 
mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values with brackets depicted in red denote 
comparison between infant time points. 
 
In response to TLR7/8 stimulation, infants showed significantly higher percentages of IL-6-
producing mDCs at 2 weeks, 6 weeks, 6 months and 12 months compared to the adult 
responses (p<0.01). 
 
In the comparison of infants responses over time, no significant difference was observed in 
the percentage of IL-6-producing mDCs between two weeks showed and six weeks of age. At 
6 months, infants showed significantly lower percentages of IL-6-producing mDCs compared 
the 6 week time point (p=0.01). At 12 months, no significant differences were observed in 
infants’ responses compared to the other time points, with the exception of the six-week time 
point where significantly lower IL-6 responses were observed (p<0.05).  
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4.2.2.3. Total IL-12/23p40 response in mDCs 
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Figure 4.16 Percentage of IL-12/23p40-producing mDCs at basal level. Bar graphs represent mean and 
standard deviation. The grey bar depicts the adult group. P-values depicted in black denote comparisons 
between infant groups and the adult group. P-values depicted in red denote comparison between infant time 
points 
 
At basal level, no significant differences were observed in the percentage of IL-12/23p40-
producing mDCs between the adult group and infants groups at two weeks, six weeks, six 
months and 12 months of age. The highest percentage of IL-12/23p40-producing monocytes 
was observed at the 2 weeks time point, with the high standard deviation indicating that 
certain infants showed much higher spontaneous cytokine responses at this time point. At 12 
months the percentage of was comparable to the adult group. 
  
In the comparison of responses over time, no significant differences were observed when 
comparing the infant groups with time point comparison, with the exception of the two week-
six month time point comparison. Infants at 2 weeks showed significantly higher percentages 
of IL-12/23p40-producing mDCs compared the six month time point (p<0.05).  
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Figure 4.17 Percentage of IL-12/23p40-producing mDCs in response to LPS stimulation. Bar graphs 
represent mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points. 
 
In response to TLR4 stimulation, no significant differences were observed in the percentages 
of IL-12/23p40-producing mDCs in infants at two weeks and six weeks of age compared to 
the adults. At the 6 months, a significantly highly percentage of IL-12/23p40-producing 
mDCs was observed in infants compared to the adults (p<0.01). At 12 months of age, no 
significant difference was observed in the percentage of IL-12/23p40-producing mDCs in 
infants compared to the adults. 
 
The comparison over time revealed no significant difference between the two week and six 
week time points. In addition, significantly higher percentages of IL-12/23p40-producing 
mDCs was observed in infants at six months when compared to the two-week and six-week 
time points (p<0.01).  At 12 months, a significant decline in the percentage of IL-12/23p40+ 
mDCs was observed compared to the 6 month time point (p<0.01). 
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Figure 4.18 Percentage of IL-12/23p40-producing mDCs in response to R-848 stimulation. Bar graphs 
represent mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points. 
 
In response to TLR7/8 stimulation, no significant differences in the percentage of IL-
12/23p40-producing mDCs were observed between infants and adult groups at two weeks, 
six weeks and six months of age. At 12 months, infants had significantly lower percentages 
of IL-12/23p40-producing mDCs compared to the adults (p<0.01).  
 
In the comparison of infant responses over time, no differences were observed in the 
percentage of IL-12/23p40-producing mDCs between the two-week and six-week, two-week 
and six months as well as six-week and six-month time points. At 12 months, a significant 
decline in the percentage of IL-12/23p40-producing mDCs was observed compared to two 
weeks, six weeks and six months of age (p<0.01). 
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4.2.3. Plasmacytoid DCs 
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Figure 4.19 Percentage of TNF-α-producing pDCs at basal level. Bar graphs represent mean and standard 
deviation. The grey bar depicts the adult group. P-values depicted in black denote comparisons between infant 
groups and the adult group. P-values depicted in red denote comparison between infant time points. 
 
At basal level, no significant difference in the percentage of TNF-α-producing pDCs was 
observed between infants and adult groups at two weeks and six weeks of age. At 6 months, 
infants showed significantly higher percentages of TNF-α-producing pDCs compared to the 
adults (p<0.01). At the 12-month time point, no significant difference was observed in the 
percentage of TNF-α-producing pDCs between infants and adults. 
 
In the comparison of infant responses over time, no differences were observed in the 
percentage of TNF-α-producing pDCs between the two-week and six-week time points. At 6 
months, a significant higher percentage of TNF-α-producing pDCs was observed compared 
to six weeks and six weeks of age (p<0.01). Furthermore, infants at 12 months showed a 
significantly decline in the percentage of TNF-α-producing pDCs (p<0.01). 
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Figure 4.20 Percentage of TNF-α-producing pDCs in response to R-848 stimulation. Bar graphs represent 
mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points. 
 
In response to TLR7/8 stimulation, no significant difference was observed in the percentage 
of TNF-α-producing pDCs between adults and infants at 2 weeks and 6 weeks of age. The 
same trend was observed at 6 months, with comparable percentages of TNF-α-producing 
pDCs between the infant and adult group at this time point. At 12 months, however, a 
significant decline in TNF-α-producing pDCs was observed in infants compared to the adults 
(p<0.05). 
 
In the evaluation of the response over time, a trend towards increased TNF-α response was 
observed in the first six months, although no significant differences was observed between 
these time points.  At 12 months of age, lower percentages of TNF-α-producing pDCs were 
observed in infants when compared to the two-week, six-week and six-month time points. 
This was only found to be significant at the six-week and 12 month (p<0.05) and six-month 
and 12 months time point comparisons (p<0.01).  
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4.2.3.2. Total IFN-α response 
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Figure 4.21 Percentage of IFN-α-producing pDCs at basal level. Bar graphs represent mean and standard 
deviation. The grey bar depicts the adult group. P-values depicted in black denote comparisons between infant 
groups and the adult group. P-values depicted in red denote comparison between infant time points. 
 
At basal level, no significant difference in the percentage of IFN-α-producing pDCs was 
observed between adult and infants groups at two weeks, six weeks, six months and 12 
months of age. At the 2-week and 6-month time point, infant pDC responses were 
comparable to the adult group.  
 
In the comparison of infant responses over time, no differences were observed in the 
percentage of TNF-α-producing pDCs between tehifnat groups at any of the time points.    
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Figure 4.22 Percentage of IFN-α-producing pDCs in response to R-848 stimulation. Bar graphs represent 
mean and standard deviation. The grey bar depicts the adult group. P-values depicted in black denote 
comparisons between infant groups and the adult group. P-values depicted in red denote comparison between 
infant time points. 
 
In response to TLR7/8 stimulation, no significant difference in the percentage of IFN-α-
producing pDCs was observed between infant and adults at any of the time points. Infants 
produced slightly lower percentages of IFN-α-producing pDCs compared to the adults at 2 
weeks and slightly higher percentages of IFN-α-producing pDCs at 6 months. At the 6 week 
and 12 month time points, infants showed percentages of IFN-α-producing pDCs that were 
comparable to the adults. 
 
The comparison of infants’ responses over time showed no significant difference when 
comparing all the progressive time points, with the exception of two-week and six-month 
time point where a significantly higher percentage of IFN-α-producing pDCs was observed at 
six months compared to two weeks of age (p<0.01). Furthermore, a trend towards increased 
percentages of IFN-α-producing pDCs was observed in the first three time points. A decline 
in this trend was observed at the 12-month time point.   
 
 
p<0.01 
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Table 4.2 Flow cytometric comparison of percentage of cells expressing cytokines for longitudinal infant and adult responses to LPS and R-848 stimulation. Analysis of the mean 
percentage of monocytes, mDC, or pDC expressing a particular cytokine. Statistically significant differences between age groups are indicated in bold.   
   LPS (TLR4)  R-848 (TLR7/8)  
 Cytokine  Mean ± SD p-value  Mean ± SD p-value  
Monocytes                
 Total TNF-α 2 wk  7.30 ± 6.10     2 wk  93.12 ± 5.42     2 wk 
 % positive 6 wk  5.52 ± 4.13    6 wk 0.5351  92.92 ± 4.18    6 wk 0.9348 
  6 mo  18.67 ± 16.05   6 mo 0.0000 0.0002  92.37 ± 4.16   6 mo 0.8481 0.7964 
  12 mo 10.02 ±13.21  12 mo 0.0068 0.1427 0.3790  77.63 ± 20.87  12 mo 0.0000 0.0000 0.0000 
  Adult 5.95 ± 2.55 Adult 0.3070 0.0014 0.9107 0.7239  83.16 ± 3.83 Adult 0.2453 0.0084 0.0048 0.0043 
 Total IL-6 2 wk  2.38 ± 2.32     2 wk  59.49 ± 13.75     2 wk 
 % positive 6 wk  1.73 ± 1.11    6 wk 0.6370  66.83 ±10.32    6 wk 0.0959 
  6 mo  6.88 ± 7.77   6 mo 0.0004 0.0021  64.49 ± 14.97   6 mo 0.6006 0.2701 
  12 mo 5.11 ± 6.93  12 mo 0.2434 0.0230 0.0677  56.91 ± 22.65  12 mo 0.1154 0.0349 0.5830 
  Adult 0.59 ± 0.26 Adult 0.0197 0.0011 0.5361 0.3335  26.79 ± 15.49 Adult 0.0000 0.0000 0.0000 0.0000 
 Total IL-12/23p40 2 wk  1.71 ± 2.50     2 wk  57.03 ± 22.06     2 wk 
 % positive 6 wk  1.54 ± 1.40    6 wk 0.9051  63.14± 18.19    6 wk 0.2420 
  6 mo  8.59 ± 8.28   6 mo 0.0000 0.0000  69.62 ± 13.66   6 mo 0.2245 0.0206 
  12 mo 4.05 ± 5.19  12 mo 0.0025 0.0828 0.1071  49.07 ± 22.39  12 mo 0.0004 0.0122 0.1551 
  Adult 4.45 ± 2.56 Adult 0.8298 0.0264 0.1072 0.1299  75.84 ± 6.54 Adult 0.0003 0.3779 0.0685 0.0079 
mDCs                
 Total TNF-α 2 wk  14.57 ± 12.49     2 wk  85.81 ± 7.83     2 wk 
 % positive 6 wk  12.53 ± 11.33    6 wk 0.6138  82.78 ± 8.96    6 wk 0.4191 
  6 mo  24.52 ± 18.74   6 mo 0.0043 0.0181  71.07 ± 11.68   6 mo 0.0027 0.0002 
  12 mo 13.39 ± 17.15  12 mo 0.0126 0.8421 0.7841  56.88 ± 24.06  12 mo 0.0007 0.0000 0.0000 
  Adult 6.80 ± 2.74 Adult 0.2379 0.0015 0.2844 0.1504  73.00 ± 2.12 Adult 0.0023 0.7019 0.050 0.0116 
 Total IL-6 2 wk  3.98 ± 4.17     2 wk  39.17 ± 10.55     2 wk 
 % positive 6 wk  3.45 ± 3.46    6 wk 0.7628  43.98 ± 12.11    6 wk 0.2029 
  6 mo  8.55 ± 7.91   6 mo 0.0054 0.0131  33.95 ± 13.84   6 mo 0.0103 0.1812 
  12 mo 6.89 ± 9.70  12 mo 0.3873 0.0677 0.1246  35.12 ± 18.41  12 mo 0.7756 0.0286 0.3172 
  Adult 1.04 ± 0.35 Adult 0.0176 0.0020 0.3033 0.2122  19.99 ± 9.53 Adult 0.0044 0.0072 0.0000 0.0002 
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 Total IL-12/23p40 2 wk  2.82 ± 3.35     2 wk  63.77 ± 16.15     2 wk 
 % positive 6 wk  2.98 ± 3.12    6 wk 0.9061  64.53 ± 13.06    6 wk 0.8544 
  6 mo  8.98 ± 8.01   6 mo 0.0000 0.0000  58.43 ± 13.05   6 mo 0.1527 0.2145 
  12 mo 2.65 ± 4.08  12 mo 0.0000 0.8164 0.9044  39.67 ± 19.63  12 mo 0.0000 0.0000 0.0000 
  Adult 1.48 ± 0.81 Adult 0.5276 0.0000 0.3997 0.4534  57.95 ± 3.06 Adult 0.0019 0.9319 0.2347 0.2957 
pDCs                
 Total TNF-α 2 wk  Undetectable        67.62 ± 20.35     2 wk 
 % positive 6 wk  Undetectable       69.45 ± 11.53    6 wk 0.6788 
  6 mo  Undetectable       72.63 ± 11.89   6 mo 0.4815 0.2728 
  12 mo Undetectable       59.76 ± 20.51  12 mo 0.0086 0.0406 0.0983 
  Adult Undetectable       73.94 ± 2.94 Adult 0.0218 0.8271 0.4452 0.2854 
 Total IFN-α 2 wk  Undetectable       59.95 ± 25.44     2 wk 
 % positive 6 wk  Undetectable       69.26 ± 13.64    6 wk 0.0649 
  6 mo  Undetectable       77.03 ± 11.46   6 mo 0.1305 0.0013 
  12 mo Undetectable       68.59 ± 20.70  12 mo 0.1244 0.9004 0.1087 
  Adult Undetectable       68.01 ± 3.89 Adult 0.9321 0.1895 0.8504 0.2294 
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   Basal Stimulation  
 Cytokine  Mean ± SD p-value 
Monocytes         
 Total TNF-α 2 wk  0.42 ± 0.56     2 wk 
 % positive 6 wk  0.56 ± 0.35    6 wk 0.5661 
  6 mo  0.89 ± 0.81   6 mo 0.2265 0.0816 
  12 mo 0.99 ± 1.77  12 mo 0.7127 0.1235 0.0408 
  Adult 1.09 ± 0.28 Adult 0.7918 0.5708 0.1329 0.0562 
 Total IL-6 2 wk  0.27 ± 0.29     2 wk 
 % positive 6 wk  0.40 ± 0.41    6 wk 0.2766 
  6 mo  0.45 ± 0.51   6 mo 0.6587 0.1280 
  12 mo 0.21 ± 0.63  12 mo 0.0709 0.1458 0.6585 
  Adult 0.45 ± 0.17 Adult 0.1619 0.9738 0.7602 0.2687 
 Total IL-12/23p40 2 wk  6.60 ± 16.22     2 wk 
 % positive 6 wk  0.47 ± 0.64    6 wk 0.0070 
  6 mo  0.75 ± 0.61   6 mo 0.9051 0.0132 
  12 mo 1.12 ± 1.3  12 mo 0.8815 0.7879 0.0249 
  Adult 2.15 ± 1.1 Adult 0.7421 0.6479 0.5766 0.1432 
mDCs         
 Total TNF-α 2 wk  0.35 ± 0.22     2 wk 
 % positive 6 wk  0.63 ± 0.38    6 wk 0.2582 
  6 mo  1.19 ± 1.5   6 mo 0.0222 0.0009 
  12 mo 0.71 ± 0.93  12 mo 0.0666 0.7549 0.1766 
  Adult 1.85 ± 0.68 Adult 0.0009 0.0484 0.0003 0.0000 
 Total IL-6 2 wk  0.37 ± 0.26     2 wk 
 % positive 6 wk  0.49 ± 0.41    6 wk 0.5412 
  6 mo  0.68 ± 1.20   6 mo 0.2963 0.1064 
  12 mo 0.30 ± 0.44  12 mo 0.6466 0.3565 0.7252 
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  Adult 0.68 ± 0.67 Adult 0.1537 0.9697 0.4456 0.2274 
 Total IL-12/23p40 2 wk  4.32 ± 10.30     2 wk 
 % positive 6 wk  0.77 ± 0.76    6 wk 0.0154 
  6 mo  0.85 ± 1.24   6 mo 0.9564 0.0229 
  12 mo 1.40 ± 2.02  12 mo 0.7300 0.6871 0.0646 
  Adult 1.98 ± 0.81 Adult 0.7790 0.5719 0.5352 0.2328 
pDCs         
 Total TNF-α 2 wk  0.23 ± 00.43     2 wk 
 % positive 6 wk  0.48 ± 0.66    6 wk 0.5687 
  6 mo  1.71 ± 3.32   6 mo 0.0077 0.0018 
  12 mo 0.17 ± 0.35  12 mo 0.0022 0.5083 0.9020 
  Adult 0.00 ± 0.00 Adult 0.7881 0.0059 0.4194 0.7064 
 Total IFN-α 2 wk  2.06 ± 5.32     2 wk 
 % positive 6 wk  1.36 ± 2.17    6 wk 0.4295 
  6 mo  2.51 ± 2.66   6 mo 0.2053 0.6279 
  12 mo 1.38 ± 1.92  12 mo 0.2493 0.9880 0.4776 
  Adult 2.04 ± 1.03 Adult 0.5927 0.6998 0.5658 0.9872 
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4.3. Comparison of polyfunctional cytokine responses 
We assessed the percentage of single, double and triple cytokine-producing cells in 
monocyte, mDC and pDC populations at basal (unstimulated) level as well as in response to 
LPS and R-848 stimulation. At each time point (2 weeks, 6 weeks, 6 months and 12 months); 
the infant responses were compared to the adult group as well as between time points for each 
respective cell type.  
 
The basal level cytokine response was assessed in both monocytes and mDC populations. 
These cell populations responded to TLR4 and TLR7/8 stimulation, whereas the pDC 
population responded only to TLR7/8 stimulation. No response was observed to TLR4 
stimulation in pDCs.  For the monocytes and mDCs, we assessed the polyfunctional 
responses of TNF-α+, IL-6+, IL-12+ single-cytokine producing cells, TNF-α+IL6+, TNF-
α+IL-12+ double-cytokine producing cells and TNF-α+IL-6+IL-12+ triple-cytokine 
producing cells.  
 
The basal level cytokine response was assessed in the pDC population. However, for TLR 
stimulation, pDCs only responsed to TLR7/8 stimulation, the production was IL-12/23p40 
and IL-6 was not observed, with the exception of the TNF-α+IFN-α+IL-6+ triple-cytokine 
producers (Addendum F). Therefore, in the pDC population we assessed the polyfunctional 
production of TNF-α and IFN-α+ single-cytokine producing cells, the TNF-α+ IFN-α+ 
double-cytokine producing cells as well as the  TNF-α+IFN-α+IL-6+ triple-cytokine 
producing cells as observed in both infant and adult pDCs in response to TLR7/8 stimulation.  
 
Line graphs were employed to illustrate the variation over time, with the exception of the 
basal stimulation data, which is depicted in tabular format. Data comparisons were defined as 
significant if p<0.05 and highly significant if p<0.01. 
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4.3.1. Monocytes 
4.3.1.1. Single cytokine expression 
Table 4.3 Percentage of single cytokine producers in monocytes at basal level. Table illustrates mean and 
SD of TNF-α+, IL-6+ and IL-12+ single producers in infants and adults as well as the p-values for the infant-
adult comparison. Significant values are denoted in bold. 
Monocytes  Mean ± SD 
Infant vs Adult 
(p-value) 
 2 wk  0.32 ± 0.40 0.2254 
TNF-α+ 6 wk  0.47 ± 0.32 0.5515 
% positive 6 mo  0.59 ± 0.55 0.9317 
 12 mo 0.74 ± 1.22 0.6233 
 Adult 0.61 ± 0.17  
 2 wk  0.21 ± 0.20 0.7588 
IL-6+ 6 wk  0.34 ± 0.41 0.1107 
% positive 6 mo  0.25 ± 0.25 0.4784 
 12 mo 0.11 ± 0.30 0.5869 
 Adult 0.17 ± 0.07  
 2 wk   6.53 ± 16.22 0.1166 
IL-12/23p40+ 6 wk  0.40 ± 0.62 0.6525 
% positive 6 mo  0.52 ± 0.51 0.6885 
 12 mo 0.92 ± 1.22 0.7904 
 Adult 1.76 ± 1.03  
 
At basal level, no robust expression of TNF-α+ IL-6+ and IL-12/23p40+ was observed in 
both infant and adult monocytes. In TNF-α+ response, no significant differences were 
observed in the the percentage of TNF-α+ monocytes in infants at 2 weeks, 6 weeks, 6 
months and 12 months of age in comparison to the adults.  
 
A similar trend was observed for the IL-6+ monocytes. No significant differences were 
observed in the percentages of IL-6+ monocytes between the infants and the adults at each 
time point. 
 
The percentage of IL-12/23p40+ monocytes in infants at 2 weeks, 6 weeks, 6 months and 12 
months showed no significant differences when compared to the adult group. Though, infants 
at 2 weeks showed a higher percentage of IL-12/23p40+ monocytes, which may be due to 
spontaneous cytokine responses produced by some infants at that time point.  
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Figure 4.23 Percentage of single cytokine producers in monocytes in response to LPS. Figure illustrates 
TNF-α+, IL-6+ and IL-12+ single producers in infants versus adults. Vertical bars denote 95% confidence 
intervals. 
 
In response to TLR4 stimulation, monocytes demonstrated the robust production of TNF-α 
and very low production of IL-6+ and IL-12+. In comparison to the adults, no significant 
difference was observed in the percentage of TNF-α+ monocytes in infants at two and six 
weeks of age. At six months, infants demonstrated a significantly higher percentage of TNF-
α+ monocytes compared to adults (p<0.01). At 12 months, no significant difference was 
observed in the percentage of TNF-α+ monocytes between infants and adults. 
 
The percentage of IL-6+ monocytes was significantly higher in infants at two weeks in 
comparison to the adults (p<0.05), with no significant differences observed at in infants 6 
weeks and 6 months of age when compared to adults. At 12 months, a significantly higher 
percentage of IL-6+ monocytes was observed infants compared to adults (p<0.01).  
  
The percentage of IL-12/23p40+ monocytes was significantly higher in infants at the 2 week 
time point when compared to the adults (p<0.05). No significant differences were observed at 
the other subsequent time points in comparison to the adult group.  
 
p<0.01 
p<0.05 p<0.01 
p<0.05 
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Figure 4.24 Percentage of single cytokine producers in monocytes in response to R-848. Figure illustrates 
TNF-α+, IL-6+ and IL-12+ single producers in infants versus adults. Vertical bars denote 95% confidence 
intervals. 
 
In response to TLR7/8 stimulation, monocytes showed the highest production of TNF-α+.and 
lowest production of IL-6+. In comparison to the adult group, no significant differences were 
observed in the percentage of TNF-α+ monocytes at 2 weeks, 6 weeks, 6 months and 12 
months time points. 
 
No significant difference was observed in the percentage of IL-6+ monocytes in infants at the 
2 weeks, 6 weeks and 6 months time points in comparison to the adult group. At the 12 
month time point, infants had significantly higher percentage of IL-6+ monocytes compared 
to the adult group (p<0.05).  
 
The percentage of IL-12/23p40+ monocytes was significantly lower in the infant group at the 
2 week (p<0.01), 6 week (p<0.05), 6 month (p<0.05) and 12 month (p<0.05) time points 
when compared to the adults.  
  
p<0.05 
p<0.01 
p<0.05 p<0.05 
p<0.05 
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4.3.1.2. Double cytokine expression 
Table 4.4 Percentage of double cytokine producers in monocytes at basal level. Table illustrates mean and 
SD of TNF-α+IL-6+, TNF-α+IL-6+and IL-6+IL-12+ double producers in infants and adults as well as the p-
values for the infant-adult comparison. Significant values are denoted in bold. 
Monocytes  Mean ± SD 
Infant vs Adult 
(p-value) 
 2 wk  0.04 ± 0.09 0.0460 
TNF-α+IL-6+ 6 wk  0.03 ± 0.02 0.0387 
% positive 6 mo  0.11 ± 0.17 0.6386 
 12 mo 0.07 ± 0.22 0.1732 
 Adult 0.14 ± 0.07  
 2 wk  0.05 ± 0.07 0.0008 
TNF-α+IL-12+ 6 wk  0.05 ± 0.07 0.0006 
% positive 6 mo  0.13 ± 0.10 0.0439 
 12 mo 0.17 ± 0.32 0.1458 
 Adult 0.26 ± 0.07  
 2 wk  0.02 ± 0.02 0.0003 
IL-6+IL-12+ 6 wk  0.01 ± 0.01 0.0003 
% positive 6 mo  0.05 ± 0.06 0.2027 
 12 mo 0.02 ± 0.05 0.0006 
 Adult 0.07 ± 0.02  
 
At basal level, low expression of TNF-α+IL-6+, TNF-α+ IL-12/12p40+ and IL-6+IL-
12/23p40+ was observed in both infant and adult monocytes. For the TNF-α+IL-6+ response, 
infants produced significantly lower percentage of TNF-α+IL-6+ monocytes at the two weeks 
and six week time points in comparison to the adults (p<0.05). At the six months and twelve 
months time points, no significant differences were observed in the percentage of TNF-α+IL-
6+ monocytes in infants compared to the adults.  
 
The percentage of TNF-α+IL-12/23p40+ monocytes in infants was significantly lower in 
infants at two weeks, six weeks and six months when compared to the adult group (p<0.01). 
At 12 months, no significant differences were observed in the percentages of TNF-α+IL-
12/23p40+ monocytes between the infants and the adults at each time point. 
 
The percentage of IL-6+IL-12/23p40+ monocytes was found to be significantly lower in 
infants at the 2 week and 6 week time points compared to adults (p<0.01). At 6 months, the 
percentage of IL-6+IL-12/23p40+ monocytes between infants and adults were found to be 
comparable. At 12 months, the percentage of IL-6+IL-12/23p40+ monocytes showed a 
significant decline in infants when compared to the adult group (p<0.01). 
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Figure 4.25 Percentage of double cytokine producers in monocytes in response to LPS. Figure illustrates 
TNF-α+IL-6+, TNF-α+IL-12+ and IL-6+IL-12+ double producers in infants versus adults. Vertical bars denote 
95% confidence intervals. 
 
In response to TLR4 stimulation, monocytes demonstrated high expression of TNF-α+IL-6+ 
and TNF-α+IL-12/23p40+. At two and six weeks of age, no significant difference in the 
percentage of TNF-α+IL-6+ monocytes was observed in infants when compared to adults. At 
6 and 12 months of age, infants showed significantly higher percentages of TNF-α+IL-6+ 
monocytes compared to the adults, with p-value of less than 0.01 and 0.05 respectively.  
 
With respect to the TNF-α+IL-12/23p40+ monocytes, infants showed significantly lower 
percentages at 2 weeks and six weeks of age in comparison to the adults (p<0.01). No 
significant differences in the percentage of TNF-α+IL-12/23p40+ monocytes were observed 
between infants and adults at the 6 month and 12 month time points.  
 
No significant differences in the percentages of IL-6+IL-12/23p40+ monocytes were 
observed in infants in comparison to the adults at the 2 week, 6 week and 6 month time 
points. At 12 months, infants showed a significantly higher percentage of IL-6+IL-12/23p40+ 
monocytes when compared to the adult group (p<0.01). 
p<0.01 
p<0.05 
p<0.01 
p<0.05 
p<0.05 
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Figure 4.26 Percentage of double cytokine producers in monocytes in response to R-848. Figure illustrates 
TNF-α+IL-6+, TNF-α+IL-12+ and IL-6+IL-12+ double producers in infants versus adults. Vertical bars denote 
95% confidence intervals. 
 
In response to TLR7/8 stimulation, monocytes demonstrated high expression of TNF-α+ IL-
6+ and TNF-α+IL-12/23p40+ and low expression of IL-6+IL-12/23p40+. In comparison to 
the adult group, infants showed significantly higher percentages of TNF-α+IL-6+ monocytes 
at the 2 week, 6 week, 6 month and 12 month time points (p<0.01).  
 
The opposite trend was observed for the TNF-α+IL-12/23p40+ response. The percentages of 
TNF-α+IL-12/23p40+ monocytes were significantly lower in infants at the 2 week, 6 week, 6 
month and 12 month in comparison to the adult group (p<0.01). 
 
The percentage of IL-6+IL-12/23p40+ monocytes were comparable to the adult group at the 
2 week, 6 week and 6 month time points, as no significant differences were observed. At 12 
months, infants showed significantly higher percentages of IL-6+IL-12/23p40+ monocytes 
than the adult group (p<0.01). 
 
 
 
 
 
 
p<0.01 
p<0.01 
p<0.01 
p<0.01 p<0.01 
p<0.01 
p<0.01 
p<0.01 
p<0.01 
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4.3.1.3. Triple cytokine expression 
Table 4.5 Percentage of triple cytokine producers in monocytes at basal level. Table illustrates mean and 
SD of TNF-α+IL-6+IL-12+ triple producers in infants and adults as well as the p-values for the infant-adult 
comparison. Significant values are denoted in bold. 
Monocytes 
 Mean ± SD 
Infant vs Adult 
(p-value) 
 2 wk  0.01 ± 0.02 0.0000 
TNF-α+IL-6+IL-12+ 6 wk  0.01 ± 0.01 0.0000 
% positive 6 mo  0.04 ± 0.06 0.0398 
 12 mo 0.02 ± 0.05 0.0003 
 Adult 0.07 ± 0.02  
 
At basal level, low expression of TNF-α+IL-6+IL-12/12p40+ was observed in both infant 
and adult monocytes. At each time point, infants showed significantly lower percentages of 
TNF-α+IL-6+IL-12/23p40 monocytes at two weeks (p<0.01), six weeks (p<0.01), six months 
(p<0.05) and 12 months (p<0.01) in comparison to the adults.  
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Figure 4.27 Percentage of triple cytokine producers in monocytes in response to LPS. Figure illustrates the 
expression of TNF-α+IL-6+IL-12+ monocytes in infants versus adults. Vertical bars denote 95% confidence 
intervals. 
 
In response to TLR4 stimulation, low production of TNF-α+IL-6+IL-12/23p40+ was 
observed in infant and adult monocytes. No significant difference was observed in the 
percentages of TNF-α+IL-6+IL-12+ monocytes in infants at the 2 week and six week time 
points when compared to the adult group. At six months of age, infants produced 
significantly higher percentages of TNF-α+IL-6+IL-12/23p40+ monocytes in comparison to 
the adult group (p<0.01). At 12 months of age, no significant differences were observed in 
the percentage of TNF-α+IL-6+IL-12/23p40+ monocytes between infants and adults. 
 
  
p<0.01 
Stellenbosch University  http://scholar.sun.ac.za
81 
 
 
Figure 4.28 Percentage of triple cytokine producers in monocytes in response to R-848. Figure illustrates 
the expression of TNF-α+IL-6+IL-12+ monocytes in infants versus adults. Vertical bars denote 95% confidence 
intervals. 
 
In response to TLR7/8 stimulation, robust production of TNF-α+IL-6+IL-12/23p40+ was 
observed in infant and adult monocytes. The percentages of TNF-α+IL-6+IL-12/23p40+ 
monocytes was significantly higher in infants at the two week, six week and six month time 
points in comparison to the adults (p<0.01). At 12 months, no significant difference in the 
percentage of TNF-α+IL-6+IL-12/23p40+ monocytes was observed between the infant and 
adult group. 
  
p<0.01 
p<0.01 
p<0.01 
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4.3.2. Myeloid dendritic cells 
4.3.2.1. Single cytokine expression 
Table 4.6 Percentage of single cytokine producers in mDCs at basal level. Table illustrates mean and SD of 
TNF-α+, IL-6+ and IL-12+ single producers in infants and adults as well as the p-values for the infant-adult 
comparison. Significant values are denoted in bold. 
mDCs  Mean ± SD 
Infant vs Adult 
(p-value) 
 2 wk  0.28 ± 0.15 0.0000 
TNF-α+ 6 wk  0.49 ± 0.33 0.0000 
% positive 6 mo  0.79 ± 0.77 0.0031 
 12 mo 0.54 ± 0.67 0.0000 
 Adult 1.38 ± 0.41  
 2 wk  0.30 ± 0.22 0.2274 
IL-6+ 6 wk  0.38 ± 0.41 0.4456 
% positive 6 mo  0.35 ± 0.45 0.9697 
 12 mo 0.21 ± 0.22 0.1537 
 Adult 0.38 ± 0.35  
 2 wk  4.25 ± 10.29 0.1754 
IL-12/23p40+ 6 wk  0.65 ± 0.67 0.6262 
% positive 6 mo  0.50 ± 0.55 0.5796 
 12 mo 1.30 ± 1.98 0.8815 
 Adult 1.60 ± 0.80  
 
At basal level, low expression of TNF-α+ IL-6+ and IL-12/23p40+ was observed in both 
infant and adult mDCs. In comparison to the adults, infants produced significantly lower 
percentages of TNF-α+ mDCs at the two week, six week, six month and twelve month time 
points in comparison to the adult group (p<0.01).  
 
The percentage of IL-6+ mDCs was comparable between the infant and the adult groups at all 
the progressive time points, as no significant differences was observed in the percentages of 
IL-6+ mDCs between the infants and the adults at each subsequent time point. 
 
A similar trend was observed in the percentage of IL-12/23p40+ mDCs. The percentages of 
IL-12/23p40 mDCs in infants at two weeks, six weeks, six months and twelve months 
showed no significant differences when compared to the adult group. Though, infants at 2 
weeks showed a higher percentage of IL-12/23p40+ mDCs, which may be due to 
spontaneous cytokine responses produced by a few infants at that time point.  
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Figure 4.29 Percentage of single cytokine producers in mDCs in response to LPS. Figure illustrates TNF-
α+, IL-6+ and IL-12+ single producers in infants versus adults. Vertical bars denote 95% confidence intervals. 
 
In response to TLR4 stimulation, mDCs demonstrated high production of TNF-α+ and low 
production of IL-6+ and IL-12/23p40+. Although higher percentages of TNF-α+ mDCs were 
observed at 2 weeks and 6 weeks, no significant differences were observed at these time 
points when compared to the adult group. At six months, infants showed a significantly 
higher percentage of TNF-α+ mDCs when compared to the adult mDCs (p<0.01). No 
significant difference was observed in the percentage of TNF-α+ mDCs between infants at 12 
months of age and the adult group. 
 
The percentage of IL-6+ mDCs between the infants and adults showed no significant 
difference at the two week, six week and six month time points. At 12 months, infants 
showed a significantly higher percentage of IL-6+ mDCs when compared to the adult group 
(p<0.05). 
 
No significant differences were observed in the percentage of IL-12/23p40+ mDCs in infants 
at two weeks, six weeks, six months and twelve months of age compared to the adult group.  
  
p<0.01 
p<0.01 
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Figure 4.30 Percentage of single cytokine producers in mDCs in response to R-848. Figure illustrates TNF-
α+, IL-6+ and IL-12+ single producers in infants versus adults. Vertical bars denote 95% confidence intervals. 
 
In response to TLR7/8 stimulation, mDCs demonstrated high production of TNF-α+ and low 
production of IL-6+ and IL-12/23p40+. Infants showed significantly lower percentages of 
TNF-α+ mDCs at 2 weeks (p<0.05), 6 weeks (p<0.01), 6 months (p<0.01) and 12 months 
(p<0.01) of age when compared to the adult group. 
 
The percentage of IL-6+ mDCs showed no significant difference between the adult group and 
the infant groups at the two week, six week and six month time points. At 12 months of age, 
the infants showed a significantly higher percentage of IL-6+ mDCs when compared to the 
adult group (p<0.01). 
 
The percentages of IL-12/23p40+ mDCs were significantly lower in infants at 2 weeks and 6 
weeks of age compared to the adults (p<0.01). At 6 months, the percentage of IL-12/23p40+ 
mDCs was comparable to adults as no significant difference was observed between the two 
groups. At 12 months, the percentage of IL-12/23p40+ mDCs showed a significant decline 
compared to the (p<0.05).  
 
  
p<0.05 
p<0.01 
p<0.01 p<0.01 
p<0.01 
p<0.01 
p<0.01 
p<0.05 
Stellenbosch University  http://scholar.sun.ac.za
85 
 
4.3.2.2. Double cytokine expression 
Table 4.7 Percentage of double cytokine producers in mDCs at basal level. Table illustrates mean and SD of 
TNF-α+IL-6+, TNF-α+IL-12+ and IL-6+IL-12+ double producers in infants and adults as well as the p-values 
for the infant-adult comparison. Significant values are denoted in bold. 
mDCs  Mean ± SD 
Infant vs Adult 
(p-value) 
 2 wk  0.03 ± 0.04 0.0539 
TNF-α+IL-6+ 6 wk  0.06 ± 0.05 0.1122 
% positive 6 mo  0.16 ± 0.33 0.8620 
 12 mo 0.07 ± 0.18 0.1795 
 Adult 0.17 ± 0.20  
 2 wk  0.03 ± 0.04 0.0007 
TNF-α+IL-12+ 6 wk  0.06 ± 0.05 0.0024 
% positive 6 mo  0.16 ± 0.29 0.2099 
 12 mo 0.08 ± 0.15 0.0127 
 Adult 0.24± 0.09  
 2 wk  0.02 ± 0.03 0.3190 
IL-6+IL-12+ 6 wk  0.03 ± 0.04 0.3514 
% positive 6 mo  0.09 ± 0.23 0.5498 
 12 mo 0.01 ± 0.03 0.2019 
 Adult 0.07 ± 0.07  
 
At basal level, low expression of TNF-α+IL-6+, TNF-α+ IL-12/12p40+ and IL-6+IL-
12/23p40+ was observed in infant and adult mDCs. No significant differences were observed 
in the percentages of TNF-α+IL-6+ mDCs between infant and adult mDCs at any of the 
progressive time points.  
 
The percentage of TNF-α+IL-12/23p40+ mDCs in infants was significantly lower in infants 
at the two week and six week time points compared to the adult group (p<0.01). At the 6 
month time point, the percentage of TNF-α+IL-12/23p40+ mDCs in infants was comparable 
to the adult group. At 12 months, infants showed a significant decline in the percentage of 
TNF-α+IL-12/23p40+ mDCs when compared to the adult group (p<0.05).  
 
The comparison of the percentage of IL-6+IL-12/23p40+ mDCs between the infants and the 
adults were not found to be significant at any of the progressive time points.  
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Figure 4.31 Percentage of double cytokine producers in mDCs in response to LPS. Figure illustrates TNF-
α+IL-6+, TNF-α+IL-12+ and IL-6+IL-12+ double producers in infants versus adults. Vertical bars denote 95% 
confidence intervals. 
 
In response to TLR4 stimulation, mDCs demonstrated high expression of TNF-α+IL-6+ and 
TNF-α+IL-12+ in infants and adults, but not IL-6+IL-12/23p40. At the two week and six 
week time points, no significant differences were observed in the percentages of TNF-α+IL-
6+ mDCs between the infant and adult groups. Infants showed significantly higher 
percentages of TNF-α+IL-6+ mDCs compared to the adults at the six month (p<0.05) and 
twelve month time points (p<0.01).  
 
No significant difference in the percentage of TNF-α+IL-12/23p40+ mDCs was observed 
between the infants and adults at the two and six weeks time points. At six months, infants 
showed a significantly higher percentage of TNF-α+IL-12/23p40+ mDCs when compared to 
the adult group (p<0.01). At 12 months, no significant difference was observed in the 
percentage of TNF-α+IL-12/23p40+ mDCs between infant and adult groups. 
 
The percentage of IL-6+IL-12/23p40+ mDCs in infants at the two week time point was 
significantly lower than the adult group (p<0.05). No significant differences were observed 
for any other the subsequent time points when compared to the adult group. 
 
  
p<0.05 
p<0.01 
p<0.01 
p<0.01 
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Figure 4.32 Percentage of double cytokine producers in mDCs in response to R-848. Figure illustrates 
TNF-α+IL-6+, TNF-α+IL-12+ and IL-6+IL-12+ double producers in infants versus adults. Vertical bars denote 
95% confidence intervals. 
 
In response to TLR7/8 stimulation, mDCs demonstrated high expression of TNF-α+IL-6+ 
and TNF-α+IL-12/23p40+ and low expression of IL-6+IL-12/23p40+ in both infant and adult 
groups. The percentages of TNF-α+IL-6+ mDCs were significantly higher in infants at two 
week (p<0.05) and 6 week (p<0.01) time points compared to the adult group. At six months, 
no significant differences wer observed in the percentage of TNF-α+IL-6+ mDCs between 
infants and adults. At 12 month a significant increase in the percentage of TNF-α+IL-6+ 
mDCs was observed in infants when compared to the adults (p<0.01). 
 
The percentage of TNF-α+IL-12/23p40+ mDCs in infants at the two-week and six week time 
points showed no statistical significance when compared to the adult group. At 6 months of 
age, infants showed significantly lower percentages of TNF-α+IL-12/23p40+ mDCs in 
comparison to the adults, with a p-value of less than 0.01. This significant decline was also 
observed at 12 months of age when compared to the adult group with a p-value of less than 
0.01. 
 
The percentage of IL-6+IL-12/23p40+ mDCs between infants and adults showed no 
significant difference in infants at 2 weeks, 6 weeks and 6 months. At 12 months, infants 
showed a significantly higher percentage of IL-6+IL-12/23p40+ mDCs compared to the 
adults (p<0.01). 
 
p<0.05 
p<0.01 
p<0.01 
p<0.01 
p<0.01 
p<0.01 
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4.3.2.3. Triple cytokine expression 
Table 4.8 Percentage of triple cytokine producers in mDCs at basal level. Table illustrates mean and SD of 
TNF-α+IL-6+IL-12+ triple producers in infants and adults as well as the p-values for the infant-adult 
comparison. Significant values are denoted in bold. 
mDCs 
 Mean ± SD 
Infant vs Adult 
(p-value) 
 2 wk  0.01 ± 0.02 0.1632 
TNF-α+IL-6+IL-12+ 6 wk  0.02 ± 0.04 0.2686 
% positive 6 mo  0.08 ± 0.21 0.6075 
 12 mo 0.01 ± 0.02 0.1621 
 Adult 0.07± 0.07  
 
At basal level, low level expression of TNF-α+IL-6+IL-12/12p40+ was observed in both 
infant and adult mDCs. At each time point, no significant difference was observed in the 
infants at two weeks, six weeks, six months and twelve months in comparison to the adult 
group.  
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Figure 4.33 Percentage of triple cytokine producers in mDCs in response to LPS. Figure illustrates the 
expression of TNF-α+IL-6+IL-12+ mDCs in infants versus adults. Vertical bars denote 95% confidence 
intervals. 
 
In response to TLR4 stimulation, low production of TNF-α+IL-6+IL-12/23p40+ was 
observed in infant and adult mDCs. No significant differences were observed in the 
percentage of TNF-α+IL-6+IL-12/23p40+ mDCs in infants at the two week and six week 
time points in comparison to the adult group. At six months, a significant increase in the 
percentage of TNF-α+IL-6+IL-12/23p40+ mDCs were observed compared to adult group 
(p<0.01). At 12 months, no significant difference was observed in the percentage of TNF-
α+IL-6+IL-12/23p40+ mDCs between the infants and adults.  
 
  
p<0.01 
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Figure 4.34 Percentage of triple cytokine producers in mDCs in response to R-848. Figure illustrates the 
expression of TNF-α+IL-6+IL-12+ producers in infants versus adults. Vertical bars denote 95% confidence 
intervals. 
 
In response to TLR7/8 stimulation, robust production of TNF-α+IL-6+IL-12/23p40+ was 
observed in infant and adult mDCs. Significantly higher percentages of TNF-α+IL-6+IL-
12/23p40+ mDCs was observed in infants at two weeks, six weeks and six  months when 
compared to the adults (p<0.01). At 12 months of age, no significant difference in the 
percentage of TNF-α+IL-6+IL-12/23p40+ mDCs was observed between infants and adults.    
  
p<0.01 
p<0.01 
p<0.01 
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4.3.3. Plasmacytoid dendritic cells 
4.3.3.1. Single cytokine expression 
Table 4.9 Percentage of single cytokine producers in pDCs at basal level. Table illustrates mean and SD of 
TNF-α+ and IFN-α single producers in infants and adults as well as the p-values for the infant-adult comparison. 
Significant values are denoted in bold. 
pDCs  Mean ± SD 
Infant vs Adult 
(p-value) 
 2 wk  0.22 ± 0.44 0.4238 
TNF-α+ 6 wk  0.40 ± 0.59 0. 1453 
% positive 6 mo  0.78 ± 1.33 0.0060 
 12 mo 0.17 ± 0.35 0.5605 
 Adult 0.00 ± 0.00  
 2 wk  2.05 ± 5.32 0.9688 
IFN-α+ 6 wk  1.25 ± 2.01 0.5036 
% positive 6 mo  1.87 ± 1.60 0.9062 
 12 mo 1.38 ± 1.92 0.5930 
 Adult 2.00 ± 0.90  
 
At basal level, low level expression of TNF-α+ and IFN-α+ was observed in infant and adult 
pDCs. The percentage of TNF-α+ pDCs showed no significant difference in infants at the two 
week and six week time points in comparison to the adult group. The six-month time point 
revealed a significantly higher percentage of TNF-α+ pDCs in infants compared to the adult 
group (p<0.01). At 12 months of age, no significant difference was observed in the 
percentage of TNF-α+ pDCs in infants compared to the adults. 
 
The percentage of IFN-α+ pDCs showed no significant differences in infants at two weeks, 
six weeks, six months  and twelve months in comparison to the adult group.  
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Figure 4.35 Percentage of single cytokine producers in pDCs in response to R-848. Figure illustrates the 
expression of TNF-α+ and IFN-α+ pDCs in infants versus adults. Vertical bars denote 95% confidence intervals. 
 
In response to TLR7/8 stimulation, low expression of TNF-α+ and IFN-α+ was observed in 
infant and adult pDCs. The percentage of TNF-α+ pDCs showed no significant difference in 
infants at two weeks, six weeks, six months and twelve months of age in comparison to the 
adult group. 
 
The percentage of IFN-α+ pDCs showed no significant differences in infants at two weeks, 
six weeks and six months in comparison to the adult group. At 12 months, infants showed a 
significantly higher percentage of IFN-α+ pDCs was observed in infants compared to the 
adult group (p<0.05). 
 
  
p<0.01 
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4.3.3.2. Double cytokine expression 
Table 4.10 Percentage of double cytokine producers in pDCs at basal level. Table illustrates mean and SD 
of TNF-α+IFN-α double producers in infants and adults as well as the p-values for the infant-adult comparison. 
Significant values are denoted in bold. 
pDCs  Mean ± SD 
Infant vs Adult 
(p-value) 
 2 wk  0.00 ± 0.01 0.9899 
TNF-α+ IFN-α+ 6 wk  0.04 ± 0.09 0.8285 
% positive 6 mo  0.45 ± 0.99 0.0116 
 12 mo 0.00 ± 0.00 1.0000 
 Adult 0.00 ± 0.00  
 
At basal level, low expression of TNF-α+IFN-α+ was observed in infant and adult pDCs. No 
significant differences were observed in the percentage of TNF-α+IFN-α+ pDCs in infants at 
the two-week and six-week time points in comparison to the adults. At the six-month time 
point, a significantly higher percentage  of TNF-α+IFN-α+ pDCs was observed in infants in 
comparison to the adult group (p<0.05). At the 12-month time point, no significant difference 
was observed in infant group in comparison to the adult group.  
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Figure 4.36 Percentage of double cytokine producers in pDCs in response to R-848. Figure illustrates the 
expression of TNF-α+IFN-α+ pDCs in infants versus adults. Vertical bars denote 95% confidence intervals. 
 
In response to TLR7/8 stimulation, robust expression of TNF-α+IFN-α+ was observed in 
infant and adult pDCs. No significant differences were observed in the percentage of TNF-
α+IFN-α+ pDCs in infants at two weeks, six weeks, six months and twelve months compared 
to the adults. The highest expression in infants was observed at the six-month time point and 
the lowest expression was observed at the two-week time point. 
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4.3.3.3. Triple cytokine expression 
Table 4.11 Percentage of triple cytokine producers in pDCs at basal level. Table illustrates mean and SD of 
TNF-α+IFN-α+IL-6+ triple producers in infants and adults as well as the p-values for the infant-adult 
comparison. Significant values are denoted in bold 
pDCs  Mean ± SD 
Infant vs Adult 
(p-value) 
 2 wk  2.06 ± 5.32 0.9894 
TNF-α+IFN-α+IL-6+ 6 wk  1.36 ± 2.17 0.8532 
% positive 6 mo  2.51 ± 2.66 0.0197 
 12 mo 1.38 ± 1.92 1.0000 
 Adult 2.04 ± 1.03  
 
At basal level, low level expression of TNF-α+IFN-α+IL-6+ was observed in infant and adult 
pDCs. No significant differences were observed in the percentage of TNF-α+IFN-α+IL-6+ 
pDCs in infants at the two-week and six-week time points in comparison to the adults. At the 
six month time point, a significantly higher percentage of TNF-α+IFN-α+IL-6+ pDCs was 
observed in infants in comparison to the adult group (p<0.05). At the 12-month time point, no 
significant difference was observed between the infant and adult groups.  
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Figure 4.37 Percentage of triple cytokine producers in pDCs in response to R-848. Figure illustrates the 
expression of TNF-α+IFN-α+IL-6+ pDCs in infants versus adults. Vertical bars denote 95% confidence 
intervals 
 
In response to TLR7/8 stimulation, low expression of TNF-α+IFN-α+IL-6+ was observed in 
infant and adult pDCs. No significant differences were observed in the percentages of TNF-
α+IFN-α+IL-6+ pDCs in infants at the two week, six week, six month and twelve month time 
points when compared to the adults. The highest expression in infants was observed at the 2-
week time pointand the lowest expression was observed at the 12 month time point. 
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Chapter Five 
Discussion 
5.1. Introduction 
Neonates and young infants rely predominantly on their innate immune system for host 
defence against microbial invasion. Given the importance of the TLR system in innate 
immunity, several have described postnatal TLR-mediated innate immune function in 
neonatal cord blood versus adults (De Wit et al., 2003; Levy et al., 2004; Levy et al., 2006a; 
Levy et al., 2006b; Angelone et al., 2006; Belderbos et al., 2009b; Renneson et al., 2009). 
However, only a limited number of studies have investigated the longitudinal development of 
postnatal TLR-mediated responses in early childhood (Upham et al., 2002; Nguyen et al., 
2010; Corbett et al., 2010). Moreover, very few studies have documented TLR-mediated 
cytokine responses in resource-limited or low-income countries (Burl et al., 2011; Teran et 
al., 2011); hence, very little information exists on these responses in a more pathogen-
exposed, less resourced and therefore much more vulnerable infant population.  
 
In South Africa, 16% of all deaths are caused by the environmental burden of disease, with 
diarrhoeal and respiratory infections being the major contributors to mortality (South African 
Environmental Burden of Disease, 2009). Intestinal infections and influenza/pneumonia 
infections, were found to be the leading causes of childhood deaths in South Africa, with a 
mortality rate of  17.4% and 11.7% within the first year, respectively (Statistics South Africa, 
2009). Bacterial contamination of water sources has been found to be a major cause of enteric 
infections in South African rural communities (Momba et al., 2010). A study performed in 
the Eerste River/Kuils River demonstrated unacceptably high levels of faecal coliforms, of 
which 85% were E.Coli (Fourie, 2005), resulting in increased susceptibility to diarrhoeal 
disease. Another South African study observed, among others, increased incidence of 
diarrhoeal disease that was linked to densification of low-cost housing settlements, with 
higher incidences found in people living in main houses and in children less than 10 years of 
age (Govender et al., 2011). With the high burden of environmental and infectious disease, it 
is imperative to address the issue of maturation of specific TLR responses of the infants in 
this setting with a high disease burden. 
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 In our study, we aimed to describe the ontogeny of TLR4- and TLR7/8-mediated in vitro 
cytokine response in South African infants to determine the development and stage at which 
infant’s responses reach maturity in a country with a higher infectious disease burden. To our 
knowledge, this is the first study to document the longitudinal development of the cell-
specific (monocytes, mDCs and pDCs) TLR-mediated cytokine responses in within the first 
year of life in a resource-limited setting. The longitudinal follow-up of our infant cohort 
during first year of life coincides with EPI schedule implemented in South Africa, depicted in 
Figure 5.1. (Department of Health, 2009) and the age at which infants have an increased 
susceptibility to infectious disease (Thaver & Zaida 2009). This is advantageous as it allows 
for the evaluation of TLR-mediated innate responses in relation to vaccination and against a 
background of increased microbial exposure, which is a common characteristic in developing 
countries. 
 
 
Figure 5.1 EPI vaccine schedule for study infants from birth to 18 months as well as blood draw time 
points. The Rotavirus vaccine and pneumococcal vaccine adminstration were not yet implemented at the time of 
the study, so all infants missed these two vaccinations.  
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5.2. Maturation of cytokine response in monocytes and mDCs 
5.2.1. Cytokine-specific responses at basal level 
Monocytes and mDCs populations are known to have a similar cytokine profile and will 
therefore be discussed together under this heading. Overall, monocyte and mDC populations 
produced low TNF-α, IL-6 and IL-12/23p40cytokine responses at basal level, in comparison 
to the responses to TLR4 and TLR7/8 stimulants.  
 
Infant monocytes showed slightly lower, but not significant, TNF-α response at two and six 
weeks compared to the adult response, whereas in contrast to this mDCs showed significantly 
higher cytokine production when compared to the adult mDCs. This finding was in line with 
the data observed in the Gambian infant cohort, which found a significantly lower induction 
of TNF-α production at basal level (unstimulated control) in comparison to all the other TLR 
ligands, including TLR4 and TLR7/8 (Burl et al., 2011). Similar findings to our study were 
seen in a Belgian infant cohort study published by Nguyen et al (2010). No robust production 
of TNF-α production was observed in cord blood stimulated at basal level (unstimulated 
control) compared to the adults. The IL-6 responses in monocytes and mDCs were similar in 
both infant and adult groups. Similar to the adults, low percentages of IL-6-producing were 
observed in infants at each time point, which indicates no robust IL-6 response at basal level. 
This finding in infants at two- and six weeks of age was in line with the Gambian cohort, 
which observed significantly low induction of IL-6 at basal level, in comparision to all the 
TLR stimulants, including TLR4 and TLR7/8 (Burl et al., 2011). 
 
No robust IL-12/23p40 response was observed in infant or adult monocytes. The IL-12/23p40 
responses in infant monocytes and mDCs were noticeably higher in infants at two weeks of 
age, though not statistically significant. Although, to our knowledge, no data has been 
published in response to the IL-12/23p40 cytokine response at basal level, we speculate that 
the probable cause of this response is due to spontaneous cytokine responses in some infants 
at this time point. Furthermore, Vanden Eijnden et al (2006) observed no significant 
difference in the IL-12/23p40 mRNA in neonatal and adult dendritic cells at basal level, 
suggesting no difference in IL-12/23p40 production between the two age groups. This is in 
contrast to our data at 2 weeks of age. The increase in IL-12/23p40 could suggest an increase 
in the production of IL-23 and consequently IL-17, indicating a response to BCG vaccination 
administered at birth.  A previous study has observed an increase IL-12/23p40 production in 
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mice dendritic cells post-BCG exposure (Rothfuchs et al., 2009), which together with IL-
23p19 subunit, results in the production of IL-23, an important component of the 
differentiation of TH-0 naïve cells to the TH-17 pathway (Kollmann et al., 2009). This 
spontaneous increase could provide evidence of early protective TH-17 responses to BCG 
vaccination. 
 
At six months of age, infant monocytes showed no significant increase in the TNF-α response 
in comparison to the adults, whereas infant mDCs showed a significantly lower and higher 
TNF-α response respectively. At 12 months of age, the monocyte population showed no 
significant difference in the percentage of TNF-α-producing cells compared to the adults, 
though the response in mDCs remained significantly lower in the infants at 12 months of age 
compared to adults. In comparison to the Belgian infant cohort, the findings at six and twelve 
months of age were in line their data (Nguyen et al., 2010). No robust TNF-α production was 
observed in their infant groups at 6-9 months and 12 months of age, though no statistical 
significance was determined between their infant and adult groups at any of the time points 
 
With respect to the Belgian infant study, our study findings were also comparable to their 
stimulation at basal level, as no robust IL-6 production was seen in their infants at birth, 3 
months, 6-9 months and 12 months of age, in comparision to the adults (Nguyen et al., 2010). 
The same trend was observed for the IL-12/23p40 response in infant monocytes and mDCs at 
6 weeks, 6 months and 12 months of age were similar to the adults. Unfortunately, no 
literature was found to compare our findings.  
 
5.2.2. Age–dependant differences in infants and adult responses to LPS (TLR4) 
The cytokine responses in monocytes and mDCs were overall similar in both cell types for 
infants as well as adults in response to LPS. We thus discuss them together here. We found 
an amplified capacity to produce TNF-α and IL-6 in neonatal monocytes and mDCs at two 
and six weeks of age in response to stimulation. In response to LPS, the IL-12/23p40 
response was decreased in monocytes and similar in mDCs when compared to the adult group 
at both two and six weeks of age.  
 
Various studies have observed diminished proinflammatory cytokine responses in cord blood, 
which were in contrast when compared to our findings in neonates at two weeks of age. 
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Decreased TNF-α responses was observed in cord blood monocytes and mDCs in Canadian 
infants (Kollmann et al., 2009; Corbett et al., 2010), although a previous Australian infant 
study reported similar TNF-α production (Yerkovich et al., 2007). Previous studies have also 
reported high IL-6 responses in cord blood monocytes (Yerkovich et al., 2007; Kollmann et 
al., 2009; Corbett et al., 2010) and mDCs (Kollmann et al., 2009; Corbett at al., 2010). 
Increased IL-12/23p40 cytokine responses was reported in cord blood monocytes (Yerkovich 
et al., 2007; Kollmann et al., 2009) as well as diminished IL-12/23p40 cytokine responses 
was observed in cord blood mDCs (Kollmann et al., 2009). Unexpectedly, our IL-12/23p40 
responses were in agreement with previous Corbett et al, which reported higher percentages 
of IL-12/23p40-producing monocytes (Corbett et al., 2010) and mDCs (Vanden Eijnden et 
al., 2006) in cord blood. In a Gambian infant cohort, neonates showed a decreased production 
of inflammatory cytokines at birth (cord blood) (Burl et al., 2011). Decreased TNF-α 
production was observed in response to TLR4 in cord blood, which was in contrast to the 
responses we observed at two weeks of age. However, Gambian infants showed a trend 
towards increased production of proinflammatory cytokines within the first month of life. At 
one month of age, these infants showed an increased TNF-α and production from birth (cord 
blood) (Burl et al., 2011). This was contradictory to our findings, as we observed similar 
TNF-α responses between two and six weeks of age, but an increased capacity to produce 
TNF-α at six weeks of age when compared to the adult group after TLR4 stimulation. 
 
In our study, we observed an increased ability in expression of single cytokines in both 
monocytes and mDCs at two and six weeks of life compared to the adult group, namely with 
the TNF-α+ single-producing cells. There is a trend towards decreased expression of double 
and triple cytokine producing cells, TNF-α+IL-6+, TNF-α+IL-12+ and TNF-α+IL-6+IL-12+ 
by infant monocytes and mDCs. This finding was in line with the results published by Corbet 
et al, who found similar expression of single cytokine and polyfunctional cytokine producing 
monocytes and mDCs in cord blood as compared to the adults (Corbett et al., 2010).   
 
At two and six weeks, we observed increased percentages of TNF-α-producing cells and 
percentages of IL-6-producing cells, with the percentage of monocytes and mDCs producing 
IL-6 was substantially lower compared to TNF-α. This was contradictory to previous studies 
performed on cord blood, where a high IL-6/TNF-α ratio was observed in resource-rich 
settings (Angelone et al., 2006; Nguyen et al., 2010) and was also reported in neonates from 
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Western Australia and Papua New Guinea (van den Biggelaar et al., 2009). This high IL-
6/TNF-α ratio persisted within the first seven days of life, irrespective of exposure to 
infection in utero (Angelone et al., 2006). However, a Gambian infant study observed high 
IL-6/TNF-α ratios at birth, which at one month of age was in accordance with our study, with 
lower IL-6/TNF-α ratio observed due to the robust IL-6 production and increasing TNF-α 
production at one month of age (Burl et al., 2011).  
 
The diminished cytokine responses to bacterial lipoproteins described in previous literature 
are due to inhibitory factors present in neonatal plasma. Neonatal plasma contains a 3-fold 
higher concentration of adenosine than adult plasma, which elevates intracellular cAMP 
levels. The elevated adenosine levels present in neonatal plasma and sensitivity of neonatal 
mononuclear cells to adenosine-induced cAMP accumulation consequently inhibits TNF-α 
production in response to bacterial lipoprotein stimulation (Levy et al., 2006ba). Adenosine 
receptor ligation has also been shown to suppress the LPS-induced TNF-α and IL-12 
production upstream in the intracellular pathway, resulting in diminished cytokine production 
(Hasko et al., 2000).  
 
The observed hyperresponsiveness in our infant cohort at two and six weeks of age is may be 
due to the Mycobacterium bovis BCG vaccination administered after birth. Stimulation with 
BCG is known to elicit inflammatory responses through TLR2, TLR4 (Uehori et al., 2003) 
and TLR9 (Bafica et al., 2005) activation. Neonates have been shown to elicit an innate 
immune response to BCG stimulation. Exposure of cord blood to BCG antigens evokes an 
IFN-γ production from NK cells (Watkins et al., 2008; van den Biggelaar et al., 2009) and 
IL-12 production from CD14+ cells (Watkins et al., 2008). The expression of IL-12 by APCs 
activates NK cells, resulting in proliferation, cytotoxicity and cytokine production, such as 
IFN-γ (Borish et al., 2003; Watkins et al., 2008), as well as facilitating the differentiation of 
naïve CD4+ T lymphocytes into mature TH-1 effector lymphocytes (Borish et al., 2003; 
Watkins et al., 2008). Additionally, neonatal DCs preferentially produce IL-12/23p40 and IL-
23p19 in response to LPS stimulation (Vanden Eijnden et al., 2006), which together form the 
IL-23 heterodimer. Apart from IL-23, neonates also demonstrate an increased capacity to 
produce IL-6 and IL-1β, which are all key cytokines in the differentiation of naïve T-
lymphocytes to the TH-17 lineage (Kollmann et al., 2009). TH-17 lymphocytes produce 
cytokines, such as IL-17 and IL-21, which trigger the release of antimicrobial peptides, 
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cytokines and chemokines that would result protection against extracellular bacteria and 
fungi by the production (Curtis & Way 2009). Immunisation against Mycobacterium 
tuberculosis has been demonstrated to confer protection via IL-17 cytokine production, which 
is critical for the regulation of the chemokines, CXCL9, CXCL10, and CXCL11. The IL-17 
chemokine response initiates neutrophil and macrophage infiltration and recruitment of 
CD4+ T-lymphocytes producing IFN-γ, which subsequently restricts mycobacterial growth 
and controls infection (Khader et al., 2007; Curtis & Way 2009). Vaccination with BCG at 
birth could in turn favour the development of TH-17 lineage for protection against pathogens 
in the postnatal period.  
 
In response to BCG stimulation, neonates born in Papua New Guinea had a significantly 
higher production of IFN-γ, TNF-α and IL-6 at birth compared to neonates born in Western 
Australia (van den Biggelaar et al., 2009). This suggests a bias towards the early 
development of TH-1 responses in neonates born in the low-income settings with high disease 
burden. The increased IL-10 production suggests the development of regulatory T-
lymphocytes and immunosuppression in Papua New Guinea neonates (van den Biggelaar et 
al., 2009). Therefore, the production of IL-10 and proinflammatory cytokines to BCG and 
other antigens provides a balance between microbial defence and prevention of systemic 
inflammation in neonates exposed to an environment with increased microbial pathogen 
exposure.  
 
A significantly heightened proinflammatory cytokine response was observed in our study in 
monocytes and mDCs of six-month-old infants, compared to two weeks, 6 weeks and 12 
months as well as adult group. Our findings were in contrast to a Belgian infant study, which 
observed higher levels of TNF-α at six months compared to birth but similar to adult levels at 
this age. The IL-6 responses in this cohort were higher at birth but became comparable to 
adults at 3 months and remained stable at 6 months (Nguyen et al., 2010). In the Gambian 
infant study, the TNF-α and IL-6 levels peaked at one month of age and remained stable up to 
12 months of age (Burl et al., 2011). Data from the single-, double- and triple cytokine 
expressing monocytes and mDCs followed the same trend with a significant increase in the 
expression of TNF-α+ and IL-12+ single cytokine producing cells  as well as the TNF-α+IL-
6+, TNF-α+IL-12+ and TNF-α+IL-6+IL-12+ polyfunctional cytokine producing cells. This is 
the first study to report on the polyfunctional expression of cytokines at six months. 
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Interestingly, the elevated LPS response in our study population coincided with the age of 
weaning and introduction of mixed feeding into the infants’ diet as well as increased 
infectious morbidity observed at this time point.  
 
In early life, infants receive passive immunity by breastfeeding through the transfer of 
immunomodulatory factors, including IgG, IgM and soluble IgA, cytokines (M’Rabet et al., 
2008), as well as soluble TNF-α receptors and IL-1 receptor antagonists that suppress 
inflammatory activity in neonates (Buescher et al., 2001; M’Rabet et al., 2008). Apart from 
protective factors, human breast milk has the capacity to influence microbial recognition by 
modulation of the TLR-mediated response. Soluble TLR2 and CD14 receptors present in 
human milk augment the immune response (Labeta et al., 2000; M’Rabet et al., 2008). This 
has an enhancing effect on the binding and recognition of bacteria and could sensitise the 
neonatal gut to gram-negative bacteria. In addition, an 80-kDa protein identified in colostrum 
is associated with the enhanced TLR4 and TLR5 response observed in neonatal gut 
(LeBouder et al., 2006) aiding in the recognition of gram-negative and flagellated bacteria, 
which are common infectious agents in neonates and young infants (Zaidi et al., 2009). 
  
Exclusive or predominant breastfeeding is associated with decreased risk of gastrointestinal 
and acute respiratory infections in infants, especially within low-income settings (Arifeen et 
al., 2001). The infants in our study were exclusively breastfed for up to a minimum of 12 
weeks of age, with the gradual introduction of complementary foods and mixed feeding 
thereafter. This finding was in line with a WHO data bank survey performed in 2003-2004 
where 11.8% of South African mothers exclusively breastfed their infants less than 4 months 
of age and 8.3% of mothers continued up to <6 months of age before mixed feeding or 
complementary food introduction (WHO Global Data Bank, South Africa). In contrast, a 
2005-2006 survey revealed that 52.5% of Gambian mothers were found to breastfeed 
exclusively to <4 months of age and 40.8% of Gambian mothers exclusively breastfed to <6 
months of age, after which complementary foods were introduced (WHO Global Data Bank, 
Gambia). Thus, South African infants are likely to exhibit lower levels of protective passive 
immunity acquired from breastmilk. 
 
The incidence of diarrhoeal disease is shown to peak between 6-11 months of age, when 
infants are introduced to complementary foods and begin to explore their environment, 
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resulting in exposure to several infectious microbial pathogens (Dewey & Mayer 2011). 
However, subclinical infections can occur in infants due to the frequent exposure to 
pathogens. In developing countries, there is a high prevalence of a subclinical condition 
known as environmental enteropathy or tropical enteropathy. Environmental enteropathy is 
speculated to be caused by the chronic ingestion of pathogenic microorganisms, which leads 
to a high concentration of pathogens in the gastrointestinal tract, and consequently a 
continuous production of inflammatory cytokines in response to infection (Dewey & Mayer 
2011).  
 
The heightened inflammatory response to TLR4 stimulation at six months of age differed 
substantially from the Gambian infant cohort. This difference could be attributed to the 
different trends in breastfeeding of the mothers in the respective countries, with Gambian 
infants having better immunological protection through breastmilk. Consequently, with the 
increase in microbial load through mixed feeding as well as the environmental exposure at six 
months, infants within our setting demonstrated the development of an amplified 
inflammatory response and immune activation at this age as a result of exposure and/or 
infection. This phenomenon has adverse effects as during infection and immune activation 
nutrients are diverted away from growth, resulting in inadequate availability of nutrients to 
support growth and subsequent stunting during the infectious period (Dewey & Mayer 2011).  
 
The LPS-induced TNF-α and IL-12/23p40 response in monocytes and mDCs  reached 
maturation at 12  months of age, but the percentage of IL-6-producing cells remained 
distinctly higher than adults at 12 months of age. Our findings were in agreement with a 
Canadian infant cohort at one year of age with regards to IL-12/23p40 and IL-6 responses. 
The TNF-α response in their study differed from our findings as they observed significantly 
higher responses compared to the adults at one year of age (Corbett et al., 2010). Similar to 
our results, Nguyen et al (2010) described the maturation of the TNF-α production in 
response to TLR4 at one year of age. The IL-6 response in our study was in disaccord with 
the abovementioned study, which reported maturation of IL-6 production at 3 months of age 
(Nguyen et al., 2010). Burl et al (2011) describes continually high IL-6 production from birth 
to 12 months of age. 
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The single cytokine producing cells (TNF-α+, IL-6+, IL-12+) reached adult-like levels at 12 
months of age in both monocytes and mDCs. This in contrast to what was observed by 
Corbett et al (2010), that reported diminished single cytokine production at one year 
compared to the adult group. Concerning the double-expressing polyfunctional cells, we 
observed maturation of TNF-α+IL-12+ but the expression of TNF-α+IL-6+ remained high 
compared to the adult group. In addition, the triple cytokine-expressing monocytes and mDCs 
remained higher than the adult group, but this was not significant. Corbett et al found that the 
double cytokine expressing cells were higher than the adults at one year of age for both cell 
types as well as a diminished ability to produce triple cytokine producing cells in response to 
LPS. This is in contrast with our data. 
 
The early inflammatory responses and maturation of LPS-induced cytokine responses in 
South African infants demonstrates an enhanced ability to produce TH-1 type cytokines. This 
observation may suggest that the early inflammatory maturation may be due to vaccination, 
increased microbial exposure and hence the necessity to develop protective immunity earlier 
in life compared to infants in a setting with lower disease burden. Also, these responses may 
support the hygiene hypothesis as infants with a background of increased microbial exposure 
have a decreased risk of developing allergies and atopic disease (Belderbos et al., 2009a). 
Furthermore, the robust responses to LPS in infancy suggests the suitability of TLR4 
agonists, such as monophosphoryl lipid A (MPL-A), as vaccine adjuvants in infancy. MPL-A 
is derived from the lipopolysaccharide portion of Salmonella minnesota, is recognised by 
TLR4, and has been accepted as a low toxicity and efficient effective vaccine adjuvant able to 
elicit an immune response through TLR4 stimulation (Casella & Mitchell 2008). 
 
In the Gambian study, high IL-6 and IL-1β production was observed from birth to 12 months 
of age (Burl et al., 2011). Apart from inducing TH-17 lineage differentiation, IL-6 is a key 
inducer of acute phase proteins and a potent inflammatory inducer (with IL-1β) (Borish & 
Steinke 2003). Therefore, the infants may remain, in part, skewed towards the acute phase 
and TH-17 differentiation responses.  
 
5.2.3.  Differential maturation in infants response to R-848 (TLR7/8) 
R-848 is a potent immunostimulant known to activate host cells via TLR7/8 ligation. In 
monocytes and mDCs, R-848 stimulation induced strong cytokine responses in both the 
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infants and adults for all cytokines evaluated. This was similar to previous studies employing 
this or other TLR7/8 agonists (Levy et al., 2004; Kollmann et al., 2009; Corbett et al., 2010; 
Burl et al., 2011). 
 
As with the LPS responses, a heightened TNF-α, IL-6 and IL-12/23p40 cytokine response to 
R-848 was observed in monocytes and mDCs of infants at two and six weeks of age 
compared to adults. This amplified response was higher compared to observations from 
previous studies, which observed lower percentages of TNF-α-, IL-6- and IL-12/23p40-
producing cord blood monocytes and mDCs compared to adults to TLR7/8 (Kollmann et al., 
2009; Corbett et al., 2010). However, one study observed impaired TNF-α production from 
cord blood monocytes for all TLRs evaluated, with the exception of TLR7/8. The variation in 
response to R-848 and TLRs activated by bacterial lipoproteins suggests different 
mechanisms of p38 MAP kinase phosphorylation upstream in the TLR activation pathway 
(Levy et al., 2004). 
 
In infants at two and six weeks of age,  we observed an increased ability in the single 
cytokine expression in monocytes, with TNF-α expression being the most prominent, as well 
as decreased single cytokine expression of TNF-α+ and IL-12+ mDCs compared to the 
adults. In comparison with a Canadian cohort, the monocyte responses were in contrast to 
their findings as they observed lower single cytokine expression in cord blood. However, the 
single cytokine expression in mDCs was similar to their findings in cord blood (Corbett et al., 
2010). The expression of TNF-α+IL-6+ is significantly lower in infants at two and six weeks 
of age, while the expression of TNF-α+IL-12+, remains significantly higher at both two and 
six-week old infants compared to the adults. In a Canadian infant cohort, neonates 
demonstrated higher levels of double cytokine polyfunctionality in cord blood monocytes but 
lower levels of double cytokine polyfunctionality in cord blood mDCs in response to TLR7/8 
stimulation (Corbett et al., 2010). The expression of triple cytokines TNF-α+IL-6+IL-12+ 
were higher in both cell types at two and six weeks of age, which was in agreement with 
Corbett et al, which observed similar results from neonatal monocytes and mDCs in cord 
blood (Corbett et al., 2010). 
 
The significantly higher TLR7/8 response observed in our infant cohort at two and six weeks 
of age can be attributed to the scheduled EPI vaccines administered at birth. As part of the 
Stellenbosch University  http://scholar.sun.ac.za
108 
 
EPI programme in South Africa, oral polio vaccine (OPV) and BCG is administered to 
neonates after birth. BCG is speculated to elicit protective responses by engagement of 
TLR8. Polymorphisms in the TLR8 gene have been associated with increased susceptibility to 
pulmonary tuberculosis and decreased ability to induce TLR8 expression by macrophages 
after BCG exposure (Davila et al., 2008). OPV is also able to initiate an innate immune 
response by the stimulation of TLR7 and TLR8 on endosomal membranes. OPV, a live 
attenuated trivalent vaccine, is composed of three serotypes of poliovirus (Mueller et al., 
2005; Nathanson & Kew 2010). The virus itself is an enterovirus with a genome composed of 
positive sense ssRNA (Mueller et al., 2005; Nathanson & Kew 2010) which is recognised by 
and innate immune response by activation through TLR7 and TLR8.  
 
TLR8 is abundantly expressed in monocytes and mDCs (Gorden et al., 2005), and neonatal 
monocytes and mDCs preferentially generate robust TNF-α and IL-12p40/70 production via 
TLR8 stimulation. Therefore, the comparable inflammatory cytokine responses in between 
two and six week old infants and adults are attributable to two factors. Firstly, the efficacy of 
TLR8 agonist to elicit a response is through the mechanism of phosphorylating p38 MAP 
kinases and the prolonged degradation of IκB-α in the NF-κB activation pathway (Levy et al., 
2006b). Secondly, due to the exposure of infant monocytes and mDCs to BCG and OPV at 
birth, infants have an amplified inflammatory cytokine response at two and six weeks of age 
with subsequent stimulation of TLR7/8.  
 
At six months of age, divergent responses were observed in the infant monocyte and mDC 
populations. The TNF-α response in infant monocytes remained significantly higher at six 
months compared to the adults, whereas the TNF-α response in infant mDCs reached at state 
of maturity at this time point. The IL-6 response also remained noticeably higher in both cell 
types compared to the infant group. The IL-12/23p40 responses were considerably lower than 
early infancy (two and six weeks of age) and were comparable to the adults at six months for 
both monocyte and mDC populations. As this is the first study, to our knowledge, to evaluate 
cell-specific cytokine responses in infants at six months, we are unable to compare our 
findings to previous literature.  
 
With the polyfunctional cytokine evaluation, differing responses were also observed between 
monocytes and mDCs at six months. The expression of TNF-α single cytokine in monocytes 
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reached maturation, though the TNF-α+ expression in mDCs remained lower than the adults 
at this time point. The IL-12+ single cytokine expression in monocytes at six months 
remained lower than adult  levels but reached maturation in the infant mDC population at this 
age. The TNF-α+IL-6+ monocytes in infants at six months remained higher than the adult 
monocytes, however, the TNF-α+IL-6+ mDCs in infants at six months found to be 
comparable to the adult mDCs. The TNF-α+IL-12+ monocytes and mDCs were both 
significantly lower than the adult group at this age. TNF-α+IL-6+IL-12+ triple cytokine 
producing monocytes and mDCs at six months were significantly higher in infants compared 
to the adult monocytes and mDCs. Again, as this is the first study to evaluate cell-specific 
polyfunctional cytokine responses in infants at six months, we are unable to compare our 
findings to previous literature.  
 
Interestingly, TNF-α response to R-848 in infant monocytes reached maturation at 12 months 
of age. This finding was different when compared to a previous Canadian cohort study where 
diminished TNF-α response showed at one year of life (Corbett et al., 2010). Moreover, the 
percentage of TNF-α-producing mDCs, as well as the percentage of IL-12/23p40-producing 
monocytes and mDCs showed a significant decline at 12 months when compared to the six-
month time point. This observation was also in disaccord with Corbett et al (2010), which 
observed significantly lower percentages of TNF-α-producing monocytes, and significantly 
higher percentages of TNF-α-producing mDCs and IL-12/23p40-producing monocytes 
compared to adults. This study also observed maturation of IL-12/23p40 response in mDCs at 
one year of age (Corbett et al., 2010). In our study, the IL-6 responses in infant monocytes 
and mDCs remained consistently higher than adult monocytes and mDCs until the age of 12 
months. This was only consistent with Corbett et al (2010) concerning the monocyte 
responses. Findings by Yerkovich et al (2007) also did not agree with our data, as they 
observed similar IL-6 production in cord blood and adult monocytes, which wanes by one 
year and two years of age. 
 
The cytokine responses to TLR7/8 stimulation in infant monocytes and mDCs show 
fluctuation in maturation from six to 12 months of age. The TNF-α response in mDCs and IL-
12/23p40 response in both monocytes and mDCs reached maturity at six months, whereas the 
TNF-α response in monocytes matured at 12 months of age. The decline in the adult-like 
proinflammatory cytokine responses from 6 months to 12 months of age suggests a trend 
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towards lower inflammatory profile in South African infants and may be an indication of 
early immune senescence due to the high inflammatory responses caused by the chronic 
exposure to pathogens. The IL-6 response in infant monocytes and mDCs did not reach 
maturity at 12 months. Corbett et al (2010) have observed increased IL-6 responses in infant 
monocytes and mDCs up to two years of age, thus possibly indicating maturation of IL-6 
responses in later in childhood. 
 
In the monocytes and mDCs, lower responses single cytokine-expressing TNF-α+ mDCs as 
well as IL-12+ monocytes and mDCs were observed in infants at 12 months, with the 
exception of TNF-α+ monocytes where maturation was reached at this time point. This is 
largely in agreement with the Corbett et al (2010) that observed lower single cytokine 
expression. The TNF-α+IL-6+ monocytes and mDCs at 12 months remained significantly 
higher than adults, while the TNF-α+IL-12+ monocytes and mDCs remained lower than the 
adults at 12 months. This was in contrast to the Canadian infant cohort as they observed 
similar double cytokine expression in monocytes and mDCs in infants at one year and adults 
(Corbett et al., 2010). Maturation of the TNF-α+IL-6+IL-12+ triple expressing monocytes 
and mDCs was observed at 12 months, which in monocytes were similar to the responses in 
the Canadian infant cohort at one year. However, this was in disagreement with the mDCs in 
this cohort as they observed higher triple cytokine responses at one year of age in response to 
TLR7/8 stimulation (Corbett et al., 2010). 
 
Overall, infant monocytes and mDCs show early inflammatory cytokine responses and 
skewing towards TH-1 cytokine maturation in response to R-848 stimulation.  The early 
inflammatory response is possibly due to BCG and OPV immunisation, with early maturation 
of cytokine responses indicating development of adequate response by six months of age. 
However, the decline observed at 12 months suggests a trend to decreased inflammatory 
responses, which are as a result of regulatory mechanisms to prevention of systemic 
inflammation. 
 
5.3. Maturation of the cytokine in infant pDCs  
5.3.1. Cytokine-specific responses at basal level 
Plasmacytoid DCs are the most potent cell type involved in antiviral defence and are the 
dominant producers of type I IFNs. In our study, we found that pDCs were the dominant 
source of IFN-α, as this was not produced by monocytes and mDCs in either adult or infant 
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groups. This was in agreement with Kollmann et al (2009) and Corbett et al (2010). The 
cytokine responses in pDCs at basal level showed an overall low cell-specific TNF-α, an 
IFN-α response in comparison to TLR7/8 stimulation.  
 
Infant pDCs showed similar TNF-α  and IFN-α  cytokine responses at two and six weeks 
compared to the adult response. No robust expression TNF-α was observed in cells were 
observed at basal level. This finding was in agreement with in Danis et al (2008), which 
found no robust production TNF-α and IFN-α in purified cord blood pDCs at basal level.  
 
At six months, however, a significantly higher TNF-α response was observed in infant pDCs, 
whereas the IFN-α response remained similar to the adult group. At 12 months of age, the 
TNF-α and IFN-α responses were similar to the adults group. For both the six months and 
twelve month time points, still no robust production was seen. Though this is an expected 
finding. No literature was found to enable us to compare our results to previously published 
data.  
 
5.3.2. Maturation of the TLR7/8 response 
Through activation of TLR7 and TLR9, pDCs secrete large amounts of type I IFNs during 
viral infection (Barchet et al., 2005; Cao & Liu 2007; Koyama et al., 2008). Neonatal and 
young infant pDCs, similar to monocytes and mDCs, show increased responsiveness to 
TLR7/8 agonist (R-848), though only produce TNF-α and IFN-α in response to stimulation. 
This finding was in agreement with Kollmann et al (2009) and Corbett et al (2010).The 
percentage of neonatal pDCs producing TNF-α and IFN-α at two weeks was similar to the 
adults. This was in contrast to previous studies performed on cord blood, where reduced 
production of TNF-α and IFN-α to TLR7 and TLR7/8 agonists was observed (Danis et al., 
2008; Kollmann et al., 2009; Corbett et al., 2010). This trend continued in infant pDCs at six 
weeks.  
 
The same trend was observed when comparing single cytokine TNF-α and IFN-α pDC 
responses. Comparable single cytokine responses were observed between the infants at two 
and six weeks of age and the adult group. This was in contrast to the findings from the 
Canadian infant cohort, which observed higher single cytokine expression in neonatal cord 
blood pDCs (Corbett et al., 2010). The double cytokine expression showed lower but 
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comparable TNF-α+IFN-α+ pDCs at two and six weeks in infants, which was also in contrast 
to the Canadian infant cohort, which found lower double cytokine expressing pDCs in 
neonatal cord, blood in response to R-848 (Corbett et al., 2010). 
 
A previous study has associated defective IRF-7 translocation in neonatal pDCs with 
diminished IFN-α/β production, both during exposure to TLR7/8 agonist (R-848) and viral 
exposure (Danis et al., 2008). IRF-7 is expressed in large quantities in the cytosol of resting 
pDCs and translocates to the nucleus upon activation of TLR7 and TLR9, resulting in 
activation of IFN gene transcription and expression (Cao & Liu 2007; Danis et al., 2008). 
IRF-5 translocation and NF-κB activation is crucial for the production of inflammatory 
cytokines and upregulation of co-stimulatory molecules in pDCs (Cao & Liu 2007). The 
decreased inflammatory cytokine production described in previous literature indicates a 
maturational defect in IRF-5 pathway that is responsible for reduced TNF-α production in 
pDCs (Danis et al., 2008). 
 
In our study, the heightened responsiveness in infant pDCs at two and six weeks of age is 
presumably due to administration of OPV at birth as part of the EPI programme in South 
Africa. OPV is able to elicit an inflammatory cytokine response in neonatal pDCs through 
activation of TLR7 on the endosomal membrane. Thus, subsequent stimulation of TLR7 by 
the TLR agonist, R-848, at the abovementioned time points results in the production of robust 
TNF-α and IFN-α responses observed in our cohort. This hyper-responsiveness of pDCs 
observed in early infancy in our cohort is an indication of the ability of neonates and young 
infants to mount robust antiviral responses to vaccination and possibly viral infection. 
 
The TNF-α and IFN-α cytokine responses in infant pDCs reached maturation by the age of 
six months. At this time point, no significant difference was observed in the percentage of 
pDCs producing TNF-α and IFN-α between infants and adults. Although the TNF-α response 
showed a significant decline at 12 months, the IFN-α response in pDCs remained stable 
throughout the first 12 months of life. The maturation of the infant pDCs in our cohort 
reached maturity at an earlier time point. In comparison to the observations by Corbett et al 
(2010), the infant pDCs in our cohort reached maturity at an earlier time point compared to a 
Canadian infant cohort (Corbett et al., 2010). In comparison to adults, in this study they 
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observed equivalent TNF-α response and greater IFN-α+ response at one year of age (Corbett 
et al., 2010). 
 
Maturation of the single and double-expressing pDCs were observed at 6 months of age, with 
little change observed at 12 months of age in infants. In the Canadian infant cohort, they 
observed adult-like responses at one year of age in infant pDCs, which is similar to our 
findings (Corbett et al., 2010). 
 
5.4. The use of LPS and R-848 as vaccine adjuvants 
The marked TH-2 polarisation in neonatal immune responses presents a distinct problem 
concerning the vaccination. The innate immune response is crucial in vaccine efficacy as this 
is responsible for the antigen presentation and instruction of the adaptive immune function 
(Philbin& Levy, 2009).  The use of vaccine adjuvants is to stimulate the immune system in 
order to enhance the efficacy of vaccines and is a crucial component in vaccine development 
(Casella & Mitchell, 2008). 
 
5.4.1. LPS response 
Within our study, we observed robust proinflammatory cytokine production in response to 
LPS stimulation, with similar or higher TH-1 cytokine responses in infants. Infants showed 
early maturation of these LPS-induced responses within the first six months of life compared 
to the European and Canadian cohorts. This finding may suggest the efficacy and use of 
TLR4 agonists as vaccine adjuvants in infancy.  
 
LPS is known to be potent immunostimulant due to its lipid-A component (Akira et al., 
2006). An attenuated production of LPS derived from Salmonella Minnesota, MPL-A has 
been recognised as a clinical adjuvant (Casella & Mitchell, 2008). Studies have revealed that 
MPL-A has a 0.08% lethality of LPS, while maintaining the immunogenicity of its parent 
(Casella & Mitchell, 2008).  A previous study has found that MPL-A demonstrates 
dramatically less toxicity whilst still enhancing CD4+ clonal expansion, and reducing the 
levels of inflammatory cytokine (IL-1β, IL-6 and TNF-α) production (Thompson et al., 
2008), thereby reducing the risk of systemic inflammation. Although TLR4 activation is 
observed with administration of certain vaccines, including BCG and Haemophilus influenza 
type B, further investigation is required to ascertain the efficacy of the MPL-A adjuvant for 
neonatal and infant adjuvant use.  
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5.4.2. R-848 response 
Both the infant and adult group showed robust cytokine production upon R-848 exposure.  At 
each time points, substantially higher TNF-α, IL-6 and IL-12/23p40 responses were observed 
with this specific TLR7/8 agonist. As with the LPS response, early maturation of 
proinflammatory responses were observed in the infants, which were in contrast to infant 
cohort studies in Europe and Canada, indicating the sensititvity of infants cells to the agonist 
and its efficacy in eliciting an immune response.   
 
The robust TH-1-polarisation in infant and neonatal pDCs to R-848 indicates a potential of 
this agonist as a candidate for vaccine adjuvant in neonatal and infant vaccines. The exposure 
of pDCs to imidazoquinolines, such as imiquimod (TLR7 agonist) and R-848 is shown to 
boost maturation of this cell type by the induction of robust proinflammatory cytokine and 
type I IFN production, upregulation of co-stimulatory marker expression as well as  B-
lymphocyte activation (Gibson et al., 2002). The efficacy of R-848 as a vaccine adjuvant has 
been established either alone or in combination with another TLR agonist. R-848 was 
successful as an adjuvant when covalently linked to HIV Gag protein in a Rhesus macaque 
model in vivo, with enhanced TH-1 cellular and antibody responses (Wille-Reece et al., 
2005). The combination of R-848 and TLR9 agonist CpG ODN forms a potent adjuvant for 
hepatitis B antigen (HBsAg) vaccination in mice. The TLR7/8/9 adjuvant consequently 
resulted in the T-lymphocyte differentiation into HBsAg-specific effector memory T-
lymphocyte phenotype and IFN-γ-producing T-lymphocytes, as well as in higher HBsAg-
specific antibody production (Ma et al., 2007). Thus, the success of this agonist in producing 
strong TH-1 immune responses provides strong motivation for use in neonatal vaccination.  
However, the safety of this adjuvant in infancy requires further investigation. 
 
5.5. Novel aspects and limitations of the study 
To the best of our knowledge, this is the first study to characterise the longitudinal cell-
specific TLR-mediated cytokine response of infants in a resource-limited setting. Here, we 
describe the progression of the TLR4- and TLR7/8-mediated responses in three major APCs 
(monocytes, mDCs and pDCs) at a single-cell level, using the ICS method described in 
previous studies (Jansen et al., 2008; Kollmann et al., 2009; Corbett et al., 2010). Preceeding 
studies have evaluated the ontogeny of the TLR-mediated cytokine response in supernatant 
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(Corbett et al., 2010; Nguyen et al., 2010), including resource-limited settings (Burl et al., 
2011; Teran et al., 2011). The evaluation of cytokine production in supernatant provides a 
global comparison of cytokine levels, but does not allow for measurement of cell-specific 
cytokine production. In our study, we were able to provide information on precise, single-
cell-specific cytokine production in response to TLR stimulation by using ICS.  
 
Our study described the evolution of these responses within the first year of life as compared 
to the adults in a similar environment. This is of considerable value as previous studies have 
concluded that infants from countries with a higher disease burden may exhibit noticeably 
different innate immune profiles, including TLR-mediated responses influenced by BCG 
vaccination (van den Biggelaar et al., 2009). Thus, characterising the ontogeny of TLR 
responses in an African cohort is essential for the development and selection of appropriate 
vaccine adjuvants for neonates and infants in this setting. 
 
Presently, this is the second study describing the maturation of the TLR-mediated responses 
within an African infant cohort. Several differences exist between our study and the Gambian 
infant cohort (Burl et al., 2011). The previously mentioned cross-sectional study evaluated 
the cytokine production to TLRs 1-9 in whole blood culture.  The Gambian study recruited 
120 infants into eight different age groups: birth and 1-, 2-, 3-, 4-, 6-, 9- or 12- months of age 
with 15 infants per age group. The main limitation of the Gambian study was that it only 
focused on the measurement of total cytokine secreted in cell-free supernatants, and did not 
evaluate the cell-specific cytokine production in response to TLR ligation. The total secreted 
cytokine measurements do not provide any insight into the various cell populations as per our 
current study.  
 
Though limited to TLR4 and TLR7/8 responses, our study was able to delineate cell-specific 
cytokine responses in response to TLR ligation in the primary APCs. This allows the 
evaluation of cell-specific TLR responses, as several other leukocytes express TLRs and 
respond to ligation. For example, neutrophils (Hayashi et al., 2003; Iwasaki & Medzhitov, 
2004) and NK cells (Hornung et al., 2002; Iwasaki & Medzhitov, 2004) are able to respond 
to TLR stimulation and therefore looking at cytokine production in supernatant may not 
provide an accurate representation of the APC function in response to TLRs. Furthermore, we 
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specifically focused on TLR4 and TLR7/8 responses due to the high incidence of infections 
caused by gram-negative and viral pathogens in infants in resource-limited settings.  
 
Unfortunately, as a limitation, we were unable to assess the maturation of the anti-
inflammatory cytokine responses or cytokine production in supernatant. Several other studies 
have reported higher production of IL-10 in the first few months of life (Belderbos et al., 
2003; Nguyen et al., 2010; Burl et al., 2011), which remained elevated at 12 months of age 
(Nguyen et al., 2010). The bias towards high IL-10 production, especially to BCG, may aid in 
dampening the exuberant inflammatory responses to antigenic exposure in early life (Madura 
Larsen et al., 2007). This aspect was not evaluated in the current study. Therefore, in our 
study we speculate that the innate responses are skewed to TH-1, due to the 
hyperresponsiveness in the infants. Our speculation that the innate responses of neonates are 
skewed towards a TH-1 bias could neither be confirmed nor refuted.   
 
Another disparity between our study and the Gambian cohort is the longitudinal follow up 
our infant cohort from 2 weeks to 12 months of age, evaluating their TLR-mediated cytokine 
response at each time point. This allowed us to document the development of these responses 
in the same infant cohort over time, thereby eliminating inter-patient variability that arises 
with recruitment of several infants within each age group. The only limitation in our follow-
up was that we were unable to obtain cord blood from the infants to evaluate the TLR4 and 
TLR7/8 responses at birth. In addition, by inclusion of a comparative adult group, we were 
able to establish a baseline TLR-mediated response for South African infants as well as 
determine when these infants’ responses reached a state of maturity within the first year of 
life. A summary of the findings in our study is presented is hereunder in Table 5.1. 
 
5.6. Future work 
Our study revealed different TLR-mediated inflammatory responses in our cohort compared 
to industrialised countries. This study was the first study to evaluate the TLR4 and TLR7/8 
responses in APCs (monocytes, mDCs and pDCs) in an African cohort. However, in order to 
address the limitations in our study, further investigation is required. An important aspect for 
future research is evaluation of TLR2/1, TLR3, TLR5, TLR2/6, and TLR9 responses within 
this cohort. This will provide a more comprehensive evaluation of the infant’s innate 
response to infectious agents and for the selection of appropriate adjuvants in settings with 
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higher incidence of disease. Furthermore, as this was a small cohort, a larger cohort study is 
necessary to validate our findings.  
 
Table 5.12 Summary of the main results 
Parameter measured Response at 2 weeks 
compared to adult 
Response reaches 
adult level at 
LPS response   
Monocytes   
   TNF-α  ▲   12 months 
   IL-6 ▲ >12 months 
   IL-12/23p40 ▲   12 months 
mDCs   
   TNF-α ▲ >12 months 
   IL-6 ▲ >12 months 
   IL-12/23p40 ▲   12 months 
R-848 response   
Monocytes   
   TNF-α ▲   12 months 
   IL-6 ▲ >12 months 
   IL-12/23p40 ▲     6 months 
mDCs   
   TNF-α ▲     6 months 
   IL-6 ▲ >12 months 
   IL-12/23p40 ▲    6 months 
pDCs   
   TNF-α ▲    6 months 
   IFN-α ▲    6 months 
 
In addition, the comparison of our findings to other cohorts globally will provide us with a 
better understanding of the disparate cytokine responses in our cohort to other countries and 
impact of environmental and social factors on these responses.  
 
An area of future interest is the parallel measurement of both TH-1 and TH-2 cytokines. This 
will enable the differentiation and quantification cell-specific proinflammatory and anti-
inflammatory cytokine production in APCs. Jansen et al (2008) has previously described the 
ICS method employed in our innate immune analysis, which is adaptable to include several 
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markers of interest, specifically TH-2 type cytokines such as IL-10 and IL-4. By employment 
of this modified multiparameter flow cytometric platform, it would provide a basis to 
determine the maturation of both proinflammatory and anti-inflammatory responses within 
the first year of life.  
 
A much broader assessment of both cell-specific and secreted cytokines is the coupling of the 
multiparameter flow cytometric ICS method with multiplexed cytokine bead array. This 
platform was employed in the Canadian infant cohort studies (Kollmann et al., 2009; Corbett 
et al.,2010) to allow simultaneous analysis of cytokine production by extracellular secretion 
(via multiplexed bead array) and cell-specific production by multiparameter flow cytometry 
(via ICS) to assess both TH-1 and TH-2 mediated cytokine production. This robust platform 
would provide a more comprehensive comparison of the maturation of infant’s innate 
response to TLR stimulation over time and provide a better understanding of the innate 
immune response in infants and adults alike.  
 
In the evaluation of adaptive immunity, further investigation is required to assess the 
vaccination responses in this setting. According to the literature, vaccinated infants had a low 
capacity to mount TH-1 cytokine responses to diphtheria, tetanus (Upham et al., 2006) and 
polio antigens (Vekemans et al., 2002) even with adequate IgG production (Upham et al., 
2006). However, Upham et al concluded that this reduced response was primarily due to the 
diminished antigen presentation in infants up to 12 months. With the increased inflammatory 
responses in infants within our setting, evaluation of the vaccine-specific T-lymphocyte 
responses would be beneficial to delineate the vaccine-specific response in this inflamed 
background. 
  
Taken as a whole, the further characterisation of the innate or adaptive immune responses in 
South Africa will provide a comprehensive description of the infant’s innate response to 
infectious agents as well as aiding in the selection of appropriate vaccine adjuvants in settings 
with higher incidence of disease.   
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Chapter Six 
Conclusion 
 
In recent years, a substantial amount of evidence has accumulated of significant differences 
between adult and neonatal innate immune responses and the possible mechanisms that could 
explain these observations. To the best of our knowledge, this study represents the first 
longitudinal, cell-specific study describing the TLR-mediated innate immune profile of infants 
within the first year of life in a resource-poor setting. The findings in our present study differ 
significantly from most published literature in resource-rich countries. Instead, South African 
infants appear to have increased or adult-like inflammatory cytokine profile within the first six 
weeks of life to both TLR4 and TLR7/8 stimulation. These robust TLR4- and TLR7/8-mediated 
innate responses in infants may be related to BCG and OPV vaccinations administered at birth, 
suggesting an adequate TH-1 responsiveness to neonatal vaccination in South African neonates.  
 
A novel finding in our study when compared to the Gambian, Canadian and European cohorts is 
that infants in our setting tend to have an increased inflammatory response at six months of age. 
This may be caused by the subsequent exposure to and infection with pathogenic microorganisms 
at the time of breastmilk weaning in this high disease burden setting. Maturation of most cytokine 
responses was reached within the first year of life. We speculate that infants in our setting display 
an early TH-1 polarisation and maturation of proinflammatory responses in this cohort reflects the 
impact of environmental exposure to pathogens, thereby priming the infants to develop adequate 
TH-1 responses for protective immunity to infection. This needs to be ascertained withTH-2 
cytokine investigation Furthermore, as with the Gambian infant study, the efficacy of TLR4 and 
TLR7/8 agonists to produce robust responses in infants advocates the use of these agonists as 
adjuvants for childhood vaccine.    
 
Therefore, in our study with the currently acquired knowledge, on the developmental changes in 
TLR4 and TLR7/8-mediated responses in South African infants, we conclude that infants in this 
high disease burden setting show increased capacity to develop TH-1 responses from birth, due to 
vaccination and environmental exposure, with maturation seen earlier in life. This response 
suggests a mechanism to conferring protection through TH-1 and/or TH-17 pathway and possibly 
adequate adaptive immunity. These observations should be taken into consideration during the 
development of age-specific interventions for vaccination or selection of vaccine adjuvants for 
this group of highly susceptible infants in early life.   
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Addendum B 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
AMENDMENT AND STUDY EXTENSION, SEPTEMBER 2009 
 
 
REFERENCE NUMBER: N08/10/289 
 
PRINCIPAL INVESTIGATOR: Dr M. Esser 
CONTACT NUMBER:              021 938 4032  
 
ADDRESS: Department of Pathology, Immunology Unit, 9th Floor, 
Core Laboratory, Tygerberg Hospital 
STUDY NURSE PHONE: 0765623119    
 
You are being invited to take part in this research project with extension to 2, 6,12 weeks, 6, 
12 and 18 months visits which will also include questions relating to the food that your baby 
drinks and eats.  Please take some time to read the information presented here, which will 
explain the details of this project.  Please ask the study staff or doctor any questions about 
any part of this project that you do not fully understand.  It is very important that you are fully 
satisfied that you clearly understand what this research entails and how you could be 
involved.  Also, your participation is entirely voluntary and you are free to decline to 
participate.  If you say no, this will not affect you negatively in any way whatsoever.  You are 
also free to withdraw from the study at any point, even if you do agree to take part. Your 
child will still be given best treatment. 
 
This study has been approved by the Committee for Human Research at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
 
What is this research study all about? 
 The study will be conducted at Tygerberg Hospital.  We are looking at new blood tests to 
explain why some babies whose parents are HIV positive have severe infections even 
though they are not infected with the virus. 
 5ml blood – about one teaspoon full, will be taken from your child’s vein at each of the 
visits in the KID CRU research ward by a person experienced in drawing blood from 
babies.  Soothing and pain relief will be provided with a local anaesthetic cream (which 
makes pain less felt). 
 Nothing will be injected into your baby.  
 Different laboratory tests will be done on different parts of your baby’s blood (whole blood, 
serum, plasma) to evaluate the general health and functioning of the immune system of 
your baby. 
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 You may withdraw your baby from the study at any time without any negative impact on 
the future treatment of your baby at this or any other medical facility.  Please inform the 
study nurse if you wish to do so. 
 
What about future investigations on current or new samples? 
 If you give additional consent, any unused blood will be stored for future analysis to test 
for new markers in the immune system that may help us predict the chance of 
getting infections more easily, after obtaining extended approval from the Committee 
for Human Research.  These tests will not increase the volume of blood collected from 
your child. 
 This consent is not linked to the primary participation in the study and you may refuse the 
storage of your baby’s samples without withdrawing from the primary study. 
 You may also be recalled for additional samples if the volume collected at the routine visit 
seems to be insufficient or if blood clots appear in the routine sample. 
 The unused samples will be stored for a period up to 10 years and all unused samples 
will be destroyed after this time.  All samples will be stored at the Immunology and/or 
Virology laboratory, Tygerberg Hospital. 
 Only the investigators will have access to your child’s information. Your child will receive 
a unique code number when enrolling in the study.  Any reference to your child will only 
be via the code number. 
 
Why have you been invited to participate? 
You have been asked to participate, because your baby may have been in contact with HIV 
during your pregnancy or you may have been selected for the control study group if your 
baby was not exposed to HIV in pregnancy.  Some children who have been born to HIV 
positive mothers suffer from severe infections in the early years of life even though the tests 
for HIV are negative.  We aim to look at blood tests which may predict the onset of such 
infections earlier so that babies can be treated and protected better from infections. 
It may be that your child may not yet be able to fight infections normally and our tests may 
help to show what this abnormality is by testing the immune system very early in life.  We 
hope that children may benefit in future from the findings of this study through guidelines for 
improved care, even if your child may not benefit directly now. 
  
What will your responsibilities be? 
 You are not required to do anything when you give consent. 
 
Will you benefit from taking part in this research? 
Your child will be examined carefully and we may be able to advise you on additional 
medication and healthy feeding practices which may help your child.  
 
Are there in risks involved in your taking part in this research? 
 There may be a bit of bleeding or bruising where the blood has been drawn. 
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If you do not agree to take part, what alternatives do you have? 
 You do not have to partake in this study and your child will receive the best available 
treatment.  You may also withdraw your child from one or both parts of the study at any 
stage without impacting on your child’s future treatment at this or any other medical 
facility. 
 
Who will have access to your medical records? 
 The medical records of your child will at all times be kept with the doctors looking after 
your child.  Any part of the study that may be communicated to other doctors, meetings or 
medical journals will be confidential and the name of the patient remains unknown.  
 
What will happen in the unlikely event of some form injury occurring as a direct result 
of your taking part in this research study? 
 Other than a small amount of blood oozing from the vein there should be harm to your 
child.  
 
Will you be paid to take part in this study and are there any costs involved? 
 A compensation of R70.00 will be given for each visit for partaking in the research project.  
There will be no costs involved for you, if you do take part.  Your transport costs will be 
covered and your child will receive a free medical examination by a qualified child care 
trained doctor at each visit.  Also free HIV counselling is provided at each visit if you 
would like to make use of this.  
 
Is there any thing else that you should know or do? 
 You can contact Dr M Esser at Tel 021-938 4032 or 082 883 4216 if you have any further 
queries or encounter any problems.  
 You can contact the Committee for Human Research at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor.  
 You will receive a copy of this information and consent form for your own records.  
 
Declaration by participant 
1. By signing below, I ……………………………..……..…………. agree to take part in a 
research study entitled “PILOT STUDY OF INNATE IMMUNE ABNORMALITIES IN HIV 
EXPOSED UNINFECTED INFANTS”.  
 
And / or 
2. By signing below, I ……………………………..……..…………. agree that my child’s blood 
samples may be stored and analysed further at a later stage as set out in the informed 
consent above. 
 
I declare that: 
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 I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately 
answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised to 
take part. 
 I may choose to leave the study at any time and will not be penalised or prejudiced in any 
way. 
 I may be asked to leave the study before it has finished, if the study doctor or researcher 
feels it is in my best interests, or if I do not follow the study plan, as agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....………..  
 
 ………………………………………. ………………………………………….. 
 Signature of participant Signature of witness 
 
Declaration by investigator / person obtaining consent 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
 I did/did not use an interpreter.  (If a interpreter is used then the interpreter must sign the 
declaration below) 
 
Signed at (place) ......................…........…………….. on (date) …………....………..  
 
 ………………………………………. ………………………………………….. 
Signature of person obtaining consent Signature of witness 
 
 ……………………………………….  
 Signature of investigator 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
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 I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) …………………………….. using the 
language medium of Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
 
Signed at (place) ......................…........…………….. on (date) ……………......………... 
 
……………………………………. ………………………………………….. 
 Signature of interpreter Signature of witness 
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Addendum C 
Innate Immune Abnormalities in HIV Exposed Uninfected 
Infants 
PILOT STUDY 
(MATERNAL) 
 
Study Number: _____   
Hospital folder number:  _______________     Ward:  
_____     
Maternal visit        Date:  _____/_____/2009  
          
1. Date of birth  _____/_____/_____ 
2. Age at delivery ___________ years 
3. Highest schooling level achieved:  
Primary school (grade 1 - 7)  
 Some high school (grade 8 - 11) 
  Grade 12 
Tertiary education, specify:  _______________ 
4. House currently living in:  
Formal     
Informal 
5. How many people live in the mother’s household (including the mother)?   
 ______ 
6.         How many people share the bedroom with the baby and the mother?   
 ______    
7.         Is there access to running water (tap) inside or outside the house?   
 ______  
Inside     
Outside 
8. If no, what is the source of water?
 _________________________________________   
9. What is the main source of income for the mother’s household? 
Salary /  
Any government grant / Other, specify:   ___________________________  
10. Current marital status? 
Single / unmarried  
Married / living as married 
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11. Did the mother smoke during pregnancy? 
Yes, if yes, how many per day:  _____ 
No 
12. Did the mother use alcohol during this pregnancy? 
Yes, _____ drinks per day / week / month (circle indicator)   
No 
 
Medical and Obstetric History  
13. Gravida: Para: Miscarriage: Ectopic    ____:____:____:____ 
14. Gestational age (GA) at booking:    _____weeks 
15. Obstetric history 
a. 
 Year 
b.  
Gestation 
c.  
Delivery 
Method 
d.  
Weight 
e.  
Sex 
f.  
Outcome 
g.  
Complications 
       
       
       
       
       
 
16. Last Normal Period    ___/___/20__ 
17. Ultrasound (date & gestation)  ___/___/20__   ___w___d
  
18. Medication during pregnancy   (1 = yes; 2 = no)  ________ 
If yes, specify:  
______________________________________________________ 
19. Chronic illness        ________ 
(No = 0; Hpt = 1; DM = 2; Anaemia = 3; Heart disease = 4; Psychiatric = 5; TB = 6; Other = 7) 
20. Pregnancy complications       ________ 
(No = 0; PE = 1; Hpt = 2; DM = 3; Anaemia = 4; APH = 5; PROM = 6; PPROM = 7; PTL = 8; Placenta 
praevia = 9; Other = 10) 
21. Total antenatal visits        ________ 
22. HIV diagnosis          
 a. Positive = 1; Negative = 2 (if 2, go to Q23)    _________ 
 b. Diagnosed during current pregnancy = 1; prior to pregnancy = 2) __________ 
 a. If 22b = 1, what was the GA at diagnosis?    _____weeks 
23. CD4 count         _________ 
24. Was mother on dual therapy (1) or HAART (2)     _________
  
25. Date therapy started       
 ___/___/20__ 
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26. GA when therapy started      
 _____weeks 
27. Diagnosed with genital infections during pregnancy? 
Yes, specify:  _______________   
No 
28. Has the mother been treated for any of the following conditions prior to delivery? 
a. Tuberculosis, treated for > 2/12  Yes  No (if treated for <2/12, baby not 
eligible)  
b. Syphilis, on treatment  >4 weeks  Yes  No (if treated for <4/52, baby not 
eligible) 
29. Has the mother been hospitalized during this pregnancy? 
Yes, _____ time(s)   
No    
Give primary reason and dates for admissions: 
a. ______________________________________________________________
___ 
b. ______________________________________________________________
___ 
c. ______________________________________________________________
___ 
d. ______________________________________________________________
___ 
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Addendum D 
INNATE IMMUNE ABNORMALITIES IN HIV EXPOSED UNINFECTED INFANTS 
PILOT STUDY 
(INFANT) 
 
Study number: _____ 
Hospital folder number:  _______________     Ward:  _____     
Visit 1 (BIRTH)     Date: _____/______/2009 
 
1. Date of birth        
 _____/_____/2009 
2. GA at birth:         ________ 
weeks  
2a. Determined by:   obstetric history /  LMP /  ultrasound  
3. Mode of delivery        ________
  
(NVD = 1; Breech = 2; Forceps = 3; Vacuum extraction = 4; C/S = 5) 
If 3, 4 or 5, specify reason:  
___________________________________________________ 
4. Duration of ROM:          _____ 
h_____ min 
5. Birth weight        
 ____________ 
5a.   Large for GA (>90%), 
  Appropriate for GA 
   SGA (<10%)                          
  Not evaluated 
6. APGAR        
 ___:___:___  
7. Birth Length:         
 ___________cm 
8. Head Circumference:       
 ___________cm  
9. Was there a break/cut in the skin? 
  Yes             No 
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10. Gender:        
  Male   Female 
11. Racial group 
 African (specify, _______________) / Coloured / White / Asian     
12. Any minor congenital anomalies / birth defects identified at birth? 
   Yes      No (e.g. extra digits – no functional impairment)  
If yes, specify:  
______________________________________________________________ 
13. PHYSICAL EXAMINATION OF INFANT 
Examination Normal Abnormal                       Comment 
HEENT 
[head,eyes,ears,nose,throat] 
   
Cardiovascular 
 
   
Chest lungs 
 
   
Abdominal 
 
   
Liver 
 
   
Spleen 
 
   
Musculoskeletal 
 
   
Genitourinary / rectal 
 
   
Skin 
 
   
Lymph nodes 
 
   
Extremities 
 
   
Neurological function 
 
   
Other    
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14. Did infant receive any medication? 
  Yes (complete table below)     No 
 
Medication name Start date Stop date / ongoing Indication 
    
    
    
 
15. Feeding method 
a. Formula 
b. Breast 
c. Mixed feeding (including solids) 
 
Signature:  ____________________              Date:  _____/_____/2009 
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Addendum E 
INNATE IMMUNE ABNORMALITIES IN HIV EXPOSED UNINFECTED INFANTS 
PILOT STUDY 
(INFANT) 
Visit __     Date:  _____/_____/2009   
 
1. Weight:    _____ grams or □ not done 
2. Length:  _____ cm or □ not done 
3. Head circumference: _____ cm or □ not done     
4. Temperature:   _____ °C or □ not done   
Method:  □ Axillary;  □ Oral;  □ Rectal;  □ Tympanic;  □ Other: _________ 
5. Heart Rate:    _____ pm or □ not done    
6. Respirations:    _____ pm or □ not done 
7. PHYSICAL EXAMINATION OF INFANT 
Examination Normal Abnormal                       Comment 
HEENT[head,eyes,ears,nose,throat]    
Cardiovascular 
 
   
Chest lungs 
 
   
Abdominal 
 
   
Liver 
 
   
Spleen 
 
   
Musculoskeletal 
 
   
Genitourinary / rectal 
 
   
Skin 
 
   
Lymph nodes 
 
   
Extremities    
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Neurological function 
 
   
Other    
 
8. Did infant receive any medication? 
  Yes (complete table below)     No 
 
Medication name Start date Stop date / ongoing Indication 
    
    
    
 
9. Feeding method 
  Formula 
  Breast 
  Mixed feeding (including solids) 
 
10. Blood obtained for PCR? 
   Yes      No, give reason:  
_______________________________________________ 
 
11. PCR result 
a.   Positive      Negative 
b. Mother informed on _____/_____/20__ 
c. If baby positive, where was he / she referred to?  
______________________________ 
 
 
Signature:  ____________________  Date:  _____/_____/2009 
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Addendum F 
MIFlowCyt standard compliant information for submitted flow cytometric data.  
1. Experiment overview.  
1.1. Purpose: The purpose of this experiment was to track the changing responses of 
monocytes, B cells (by negative gating), plasmacytoid dendritic cells, and myeloid 
dendritic cells to TLR stimulation from 2 weeks to 12 months of life in South African 
infants born to non-HIV infected mothers (HIV unexposed; UE).  Comparison to adult 
peripheral blood was performed to give an idea as to the relationship between adult and 
changing early life TLR responses. This was done in whole blood to reduce the any 
possible processing artifact. We hypothesized that–given the changes in environment and 
ontogeny–that TLR responses would vary over time in the very young, and that this 
knowledge could form the basis of future work in rational vaccine design. 
  
1.2. Keywords:  
1.3. Organization:  
1.3.1.  Kollmann Lab, University of British Columbia 
1.3.2.  950 W28th Ave. Vancouver, British Columbia, V5Z4H4, Room: A5-1147 
1.4. Primary Contact:  
1.4.1.  P.I. Dr. Tobias Kollmann tkollmann@cw.bc.ca  
 1.4.2. Graduate Student. Ms Rozanne Adams 14914085@sun.ac.za 
1.5. Date: Experiments were set up from June 2009 to June 2010 and stained from 
August 2010 to December 2010.  
1.7. Quality Control Measures:  
Unstipulated controls were set up for each condition tested. Single stain controls were set 
up by staining 3 ul of Anti-Mouse Ig CompBeads (BD #552843) and 3 ul of anti-FBS 
negative control beads (included with BD #552843) with 3ul of each antibody used.  
2. Flow Sample/Specimen Description  
2.1. Sample/Specimen Material  
2.1.1.  Biological Samples:  
2.1.1.1. Biological Sample Name 
 Whole blood obtained by peripheral blood venipuncture.  
2.1.1.2.Biological Sample Source:  Healthy human peripheral blood; obtained and 
processed within < 4h from. 
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2.1.1.2.1. Biological Sample Source Organism:  
2.1.1.2.1.1. Taxonomy:  
Kingdom Animalia Subkingdom Metazoa Phylum Chordata 
Subphylum Vertebrata Superclass Tetrapoda Class Mammalia 
Subclass Theria Infraclass Eutheria Order Primates Suborder 
Anthropoidea Family Hominidae Subfamily Homininae Tribe 
Hominini Genus Homo Subspecies sapiens  
2.1.1.2.1.2. Age:  
2 weeks to 12 months of age 
2.1.1.2.1.3. Gender:  
Male and Female  
2.1.1.2.1.4. Phenotype:  
healthy (none); UE for infant group only. All adults were UE.  
2.1.1.2.1.5. Genotype:  
not applicable  
2.1.1.2.1.6. Treatment:  
Whole blood diluted 1:1 in RPMI. 
2.1.2. Environmental Samples: not applicable  
2.1.3. Control Sample Description:  
Single stain controls were set up by staining 3 ul of Anti-Mouse Ig CompBeads 
(BD #552843) and 3 ul of anti-FBS negative control beads (included with BD 
#552843) with 3ul of each antibody used.  
2.1.4 Sample Treatment Description  
Cells were plated in a 96 well plate and cultured for a total of 6 hrs.  Cells were 
stimulated with either nothing, 0111:B4 LPS (TLR4, InVivogen) and R848 (TLR7/8, 
InVivogen) in the presence of Brefeldin A (Sigma) at 2mg/ml. After culture, cells were 
treated with a final concentration of 2mM EDTA for 15 min at 37
o
C, then centrifuged 
@400g for 5min @22˚C and resuspended in 100ul of 1x BD FACS Lysing solution (BD 
349202) for 10 minutes at room temperature before being frozen at  -80
 o
C.  
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3. Fluorescence Reagent Description: 
Table 13. 
 Characteristic Being 
Measured  
Antibody Name Clone Name  Vendor cat# dilution used  
VIOLET     
Pacific Blue  Intracellular Protein  IL12p40/70 (eBio: C8.6)  eBio#577129 1:100  
RED    
 APC  Cell Surface Protein  CD11c (5HCL3)  BD#340714 1:50  
APC-Cy7  Intracellular Protein  IL6 (AS12)  BD #custom 1:100 
 Alexa 700  Intracellular Protein  TNFa (Mab11)  BD#557996 1:100  
BLUE    
 FITC/OG  Intracellular Protein  IFNa (A11)  Antigenix#MC100133 1:100  
PerCPCy5.5  Cell Surface Protein  MHCII TU36  BD#custom 1:100  
PE-Cy7  Cell Surface Protein  CD14 (M5E2)  BD #557742 1:50 
PE Cell Surface Protein CD123 (6H6) eBio #121239 
 
Instrument Details: 
3.1. Manufacturer: 
BD Biosciences 
3.2. Model: 
BD FACSAria Flow 3 Laser, Blue/Red/Violet serial # P22300055 
3.3. Instrument Configuration and Settings: 
All lasers, filters and mirrors were manufactured by BD Biosciences. The machine 
has not been altered. 
3.3.1. Light Sources: 
The light path, filters and detectors are described below in Table 2. The 
lasers are listed in the order the cells pass through them. The detectors and 
filters are listed in the order the light hits them, with the exception of FSC 
which is measured from light that passes through the cell/bead while all the 
other 488 detectors detect light that has been scattered 90 o, in the order 
listed. For example, for blue laser detector A light passes through or is 
reflected off of filter 1, 735 LP, then the light passes through filter 2, 780/60 
BP, then it hits the PMT detector. Light that is reflected off the long pass 
goes to detector B and so on. For parameters used in this experiment, it is 
indicated whether Area (-A), Height (-H) or Width (-W) was used. 
Abbreviations: 
PMT = photomultiplier tube 
PD = photodiode, 
BP = band pass filter, first number is center of interval, second number is the 
width of the interval. 
LP = long pass filter, lets light waves through that have a longer wavelength 
than the number specified. All LP filters are dichroic and reflect at an angle 
of incidence at 11.25o. 
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Table 14. 
Laser  
Detector 
Name 
(Type)  
Filter 1 
(LP)  
Filter 2 (BP)  Parameter 
detected  
Detector 
voltage  
Amplificati
on Type  
Blue Laser (488 nm)  SSC (PD)  na  488/10 BP  SSC-A  440 LINEAR  
 488 A 
(PMT)  735 LP  780/60 BP  PE-Cy7-A  605 LOG  
488 B 
(PMT)  655 LP  695/40 BP  PerCP-Cy5.5-A  585 LOG  
488 C 
(PMT)  595 LP  610/20 BP  PE-TexRed  na  
  
488 D 
(PMT)  556 LP  575/26 BP  PE 498 
LOG  
488 E 
(PMT)  502 LP  530/30 BP  FITC 480 
    LOG 
Violet Laser (407 nm)  
407 A 
(PMT)  502 LP  530/30 BP  Alexa-430-A  na   
 407 B 
(PMT)  blank  450/40 BP  Pacific Blue-A  530 LOG  
Red Laser (633 nm)  
633 A 
(PMT)  755 LP  780/60 BP  APC-Cy7-A  605 LOG  
 633 B 
(PMT)  685 LP  720/40 BP  Alexa700-A  515 LOG  
633 C 
(PMT)  blank  660/20 BP   APC-A  492 LOG  
 
4. Data Analysis 
4.1. FCS Data File: 
To request raw data please contact Dr. Tobias Kollmann tkollmann@cw.bc.ca 
4.1.1. Total Count of Events: 
Recorded within individual FCS files, as keyword $TOT, 200,000. 
4.2. Compensation Description: 
Compensation was done in FlowJo using BDCompBeads as single stain 
controls. 
A representative compensation matrix for one of the samples is shown 
below. 
 
 
 FITC PE PerCP-Cy5-5 PE-Cy7 APC APC-Cy7 Pacific Blue Alex 700 
FITC-A  29.11 1.847 0.2719 0 -0.1527 0.6106 -0.4128 
PE-A 0.6607  6.615 1.07 -0.249 -0.3758 0.3544 -0.6247 
PerCP-Cy5-5-
A 0.1683 0.2436  33.73 2.026 11.66 1.175 30.06 
PE-Cy7-A 0.1653 1.982 0.3268  0 15.32 0.1029 0.5033 
APC-A 0.1415 0.1788 1.576 0.4223  20.5 0.9705 65.71 
APC-Cy7-A 0.08945 0.119 0.3078 2.183 12.56  0.3553 13.26 
Pacific Blue-
A 0.1281 0.1833 0 0 0.05744 -0.172  -0.2704 
Alex 700-A 0.1859 0.208 1.44 0.9827 0.2883 29.7 0.662  
 
4.3. Gating (Data Filtering) Description:  
4.3.1. Gate Summary Information:  
4.3.1.1. -4.3.1.3 Gate Descriptions/subpopulations/statistics:  
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4.4. Data Transformation Description: 
Data was transformed using FlowJo’s “Define BiExponential Transformation” 
function using the above mentioned compensation matrix, with an additional 
negative display size set at 0.5 and Positive Decades of “log” Display set at 5. 
 
 
  Gate Statistics (% Parent Gate)  
Gate Description:  
Qualitative Description of the 
Subpopulation  
Unstim (red)  R848 stim 
(blue)  
Live Cells  
High cell density excluding lower left 
corner population  
61.0 62.9  
Monocytes  CD14 high, MCHII high  8.63 4.61 
Other MHCII+ cells  MHCII high, CD14 mid to low  6.24 7.02  
Myeloid Dendritic Cells (mDCs)  MHCII high, CD11c high, CD123 low  41.8  30.7  
Plasmacytoid Dendritic Cells (pDCs)  MHCII high, CD11c low, CD123 high  2.76  2.62  
Monocyte TNF+ IL-6  "Monocyte" TNFa high, IL-6 low   0.145 27.5  
Monocyte TNF+ IL-6+  "Monocyte" TNFa high, IL-6 high  0.0104 65.6  
Monocyte TNF- IL-6+  "Monocyte" TNFa low, IL-6 high  0.28  0.306  
Monocyte TNF- IL-6 "Monocyte" TNFa low, IL-6 low  99.5 6.65 
Monocyte TNF+ IL-12 "Monocyte" TNFa high, IL-12 low  0.149 64.3  
Monocyte TNF+ IL-12+  "Monocyte" TNFa high, IL-12 high  0.00346  28.7  
Monocyte TNF- IL-12+  "Monocyte" TNFa low, IL-12 high  0.0588 0.174  
Monocyte TNF- IL-12 "Monocyte" TNFa low, IL-12 low  99.8 6.78 
Monocyte TNF+ IFNa  "Monocyte" TNFa high, IFNa low  0.0934  92.1  
Monocyte TNF+ IFNa+  "Monocyte" TNFa high, IFNa high  0.0554  0.917  
Monocyte TNF- IFNa+  "Monocyte" TNFa low, IFNa high  0.166 0.535  
Monocyte TNF- IFNa "Monocyte" TNFa low, IFNa low  99.7 6.38 
mDC TNF+ IL-6  "mDC" TNFa high, IL-6 low  0.194 40.1  
mDC TNF+ IL-6+  "mDC" TNFa high, IL-6 high  0  52.7  
mDC TNF- IL-6+  "mDC" TNFa low, IL-6 high  0.343  0.446  
mDC TNF- IL-6 "mDC" TNFa low, IL-6 low  99.5 6.79 
mDC TNF+ IL-12 "mDC" TNFa high, IL-12 low  0.194  43.0  
mDC TNF+ IL-12+  "mDC" TNFa high, IL-12 high  0  49.8  
mDC TNF- IL-12+  "mDC" TNFa low, IL-12 high  0.0915  2.9 
mDC TNF- IL-12 "mDC" TNFa low, IL-12 low  99.7 4.34  
mDC TNF+ IFNa  "mDC" TNFa high, IFNa low  0.194 92.7 
mDC TNF+ IFNa+  "mDC" TNFa high, IFNa high  0  0.0297  
mDC TNF- IFNa+  "mDC" TNFa low, IFNa high  0 0.0149 
mDC TNF- IFNa "mDC" TNFa low, IFNa low  99.8  7.19 
pDC TNF+ IL-6  "pDC" TNFa high, IL-6 low  0  70.0  
pDC TNF+ IL-6+  "pDC" TNFa high, IL-6 high  0 5.23  
pDC TNF- IL-6+  "pDC" TNFa low, IL-6 high  0 0  
pDC TNF- IL-6 "pDC" TNFa low, IL-6 low  100 25.1  
pDC TNF+ IL-12 "pDC" TNFa high, IL-12 low  0  73.7 
pDC TNF+ IL-12+  "pDC" TNFa high, IL-12 high  0  1.57 
pDC TNF- IL-12+  "pDC" TNFa low, IL-12 high  0  0.174 
pDC TNF- IL-12 "pDC" TNFa low, IL-12 low  100  24.9 
pDC TNF+ IFNa  "pDC" TNFa high, IFNa low  0  5.92  
pDC TNF+ IFNa+  "pDC" TNFa high, IFNa high  0  69.2  
pDC TNF- IFNa+  "pDC" TNFa low, IFNa high  0  15.0  
pDC TNF- IFNa "pDC" TNFa low, IFNa low  100  10.1  
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Addendum G 
Flow cytometric comparison of percentage of single-, double- and triple cytokine expressing cells expressing cytokines for longitudinal infant and 
adult responses to LPS and R-848 stimulation and basal stimulation. Analysis of the mean percentage of monocytes, mDC, or pDC expressing a particular 
cytokine. Statistically significant differences between age groups are indicated in bold. 
   LPS (TLR4)  R-848 (TLR7/8)  
 Cytokine  Mean ± SD p-value  Mean ± SD p-value  
Monocytes                
 TNF-α+ 2 wk  4.46 ± 3.45     2 wk  13.07 ± 7.09     2 wk 
 % positive 6 wk  3.47 ± 2.77    6 wk 0.4324  10.70 ± 6.97    6 wk 0.2154 
  6 mo  8.43 ± 6.44   6 mo 0.0002 0.0029  8.83 ± 5.06   6 mo 0.3380 0.0329 
  12 mo 4.24 ±5.63  12 mo 0.0029 0.5636 0.8720  10.78 ± 8.75  12 mo 0.3500 0.9691 0.2630 
  Adult 2.79 ± 1.06 Adult 0.4063 0.0013 0.6850 0.3232  10.99 ± 3.41 Adult 0.9335 0.4010 0.9063 0.4164 
 IL-6+ 2 wk  0.39 ± 0.40     2 wk  0.00 ± 0.28     2 wk 
 % positive 6 wk  0.27 ± 0.36    6 wk 0.3209  0.00 ±0.45    6 wk 0.8763 
  6 mo  0.21 ± 0.41   6 mo 0.5652 0.1270  0.00 ± 0.16   6 mo 0.8756 0.9966 
  12 mo 0.44 ± 0.52  12 mo 0.0585 0.1610 0.6403  0.96 ± 2.50  12 mo 0.0064 0.0032 0.0054 
  Adult 0.02 ± 0.04 Adult 0.0075 0.2172 0.0907 0.0162  0.00 ± 0.04 Adult 0.0247 0.9325 0.9726 0.9343 
 IL-12/23p40+ 2 wk  0.15 ± 1.45     2 wk  -4.63 ± 14.00     2 wk 
 % positive 6 wk  0.38 ± 0.44    6 wk 0.5580  0.62 ± 1.00    6 wk 0.0091 
  6 mo  1.33 ± 1.59   6 mo 0.0182 0.0040  0.64 ± 0.90   6 mo 0.9933 0.0111 
  12 mo 0.71 ± 1.08  12 mo 0.1454 0.4247 0.1822  1.78 ± 2.58  12 mo 0.5986 0.5830 0.0031 
  Adult 1.37 ± 0.92 Adult 0.2205 0.9394 0.0572 0.0205  7.20 ± 2.51 Adult 0.0500 0.0159 0.0139 0.0000 
mDCs                
 TNF-α+ 2 wk  8.92 ± 7.02     2 wk  15.35 ± 6.34     2 wk 
 % positive 6 wk  7.71 ± 6.75    6 wk 0.5449  13.18 ± 7.59    6 wk 0.2537 
  6 mo  12.11 ± 8.50   6 mo 0.0325 0.1219  14.11 ± 6.09   6 mo 0.6342 0.5236 
  12 mo 6.11± 7.35  12 mo 0.0075 0.4747 0.2979  13.31 ± 8.05  12 mo 0.7011 0.9494 0.3155 
  Adult 4.95 ± 1.93 Adult 0.6506 0.0089 0.2979 0.1380  21.57 ± 3.04 Adult 0.0021 0.0044 0.0012 0.0159 
 IL-6+ 2 wk  0.23 ± 0.22     2 wk  0.16 ± 0.22     2 wk 
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 % positive 6 wk  1.36 ± 0.22    6 wk 0.1925  0.32 ± 0.44    6 wk 0.3124 
  6 mo  0.06 ± 0.19   6 mo 0.3489 0.0298  0.32 ± 0.41   6 mo 0.9881 0.3202 
  12 mo 0.35 ± 0.36  12 mo 0.0002 0.0039 0.0917  1.30 ± 1.00  12 mo 0.0000 0.0000 0.0000 
  Adult 0.16 ± 0.18 Adult 0.0484 0.3259 0.7793 0.4838  0.22 ± 0.32 Adult 0.0000 0.6244 0.6263 0.7844 
 IL-12/23p40+ 2 wk  0.00 ± 2.27     2 wk  1.16 ± 9.29     2 wk 
 % positive 6 wk  0.30 ± 0.41    6 wk 0.0564  3.60 ± 2.56    6 wk 0.1194 
  6 mo  0.78 ± 0.77   6 mo 0.2059 0.0023  7.23 ± 2.76   6 mo 0.0243 0.0002 
  12 mo 0.18 ± 1.21  12 mo 0.1386 0.7577 0.1379  5.34 ± 5.70  12 mo 0.2665 0.2952 0.0137 
  Adult 0.12 ± 0.14 Adult 0.9157 0.1920 0.7213 0.2786  9.84 ± 1.37 Adult 0.0385 0.2170 0.0031 0.0000 
pDCs                
 TNF-α+ 2 wk  Undetectable        10.24 ± 8.27     2 wk 
 % positive 6 wk  Undetectable       10.30 ± 7.58    6 wk 0.9674 
  6 mo  Undetectable         5.06 ± 3.46   6 mo 0.0032 0.0039 
  12 mo Undetectable         5.36 ± 3.93  12 mo 0.8722 0.0072 0.0086 
  Adult Undetectable         7.27 ± 0.66 Adult 0.4185 0.3390 0.1815 0.1941 
 IFN-α+ 2 wk  Undetectable         7.26 ± 8.05     2 wk 
 % positive 6 wk  Undetectable       11.42 ± 8.37    6 wk 0.0370 
  6 mo  Undetectable       10.36 ± 5.71   6 mo 0.5970 0.1306 
  12 mo Undetectable       14.61 ± 6.44  12 mo 0.0500 0.1309 0.0074 
  Adult Undetectable         7.62 ± 2.93 Adult 0.0117 0.3062 0.1488 0.8923 
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   Basal Stimulation  
 Cytokine  Mean ± SD p-value 
Monocytes         
 TNF-α+ 2 wk  0.32 ± 0.40     2 wk 
 % positive 6 wk  0.47 ± 0.32    6 wk 0.3988 
  6 mo  0.59 ± 0.55   6 mo 0.5076 0.1441 
  12 mo 0.74 ± 1.22  12 mo 0.4668 0.1656 0.0325 
  Adult 0.61 ± 0.17 Adult 0.6233 0.9317 0.5515 0.2254 
 IL-6+ 2 wk  0.21 ± 0.20     2 wk 
 % positive 6 wk  0.34 ± 0.41    6 wk 0.083 
  6 mo  0.25 ± 0.25   6 mo 0.2532 0.5894 
  12 mo 0.11 ± 0.30  12 mo 0.1190 0.0074 0.2762 
  Adult 0.17 ± 0.07 Adult 0.5869 0.4784 0.1107 0.7588 
 IL-12/23p40+ 2 wk  6.53 ± 16.22     2 wk 
 % positive 6 wk  0.40 ± 0.62    6 wk 0.0070 
  6 mo  0.52 ± 0.51   6 mo 0.9582 0.0110 
  12 mo 0.92 ± 1.22  12 mo 0.8727 0.8287 0.0219 
  Adult 1.76 ± 1.03 Adult 0.7904 0.6885 0.6525 0.1166 
mDCs         
 TNF-α+ 2 wk  0.28 ± 0.15     2 wk 
 % positive 6 wk  0.49 ± 0.33    6 wk 0.1353 
  6 mo  0.79 ± 0.77   6 mo 0.0406 0.0007 
  12 mo 0.54 ± 0.67  12 mo 0.1173 0.7214 0.0839 
  Adult 1.38 ± 0.41 Adult 0.0000 0.0031 0.0000 0.0000 
 IL-6+ 2 wk  0.30 ± 0.22     2 wk 
 % positive 6 wk  0.38 ± 0.41    6 wk 0.5412 
  6 mo  0.35 ± 0.45   6 mo 0.2963 0.1064 
  12 mo 0.21 ± 0.22  12 mo 0.0646 0.3565 0.7252 
  Adult 0.38 ± 0.35 Adult 0.1537 0.9697 0.4456 0.2274 
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 IL-12/23p40+ 2 wk  4.25 ± 10.29     2 wk 
 % positive 6 wk  0.65 ± 0.67    6 wk 0.0138 
  6 mo  0.50 ± 0.55   6 mo 0.9169 0.0137 
  12 mo 1.30 ± 1.98  12 mo 0.6187 0.6776 0.0601 
  Adult 1.60 ± 0.80 Adult 0.8815 0.5796 0.6262 0.1754 
pDCs         
 TNF-α+ 2 wk  0.22 ± 0.44     2 wk 
 % positive 6 wk  0.40 ± 0.59    6 wk 0.3847 
  6 mo  0.78 ± 1.33   6 mo 0.0667 0.0097 
  12 mo 0.17 ± 0.35  12 mo 0.0074 0.2852 0.8048 
  Adult 0.00 ± 0.00 Adult 0.05605 0.0060 0.1453 0.4238 
 IFN-α+ 2 wk  2.05 ± 5.32     2 wk 
 % positive 6 wk  1.25 ± 2.01    6 wk 0.3435 
  6 mo  1.87 ± 1.60   6 mo 0.4734 0.8375 
  12 mo 1.38 ± 1.92  12 mo 0.5954 0.8926 0.4605 
  Adult 2.00 ± 0.90 Adult 0.5930 0.9062 0.5036 0.9688 
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   LPS (TLR4)  R-848 (TLR7/8)  
 Cytokine  Mean ± SD p-value  Mean ± SD p-value  
Monocytes                
 TNF-α+IL-6+ 2 wk  1.31 ± 1.32     2 wk  18.41 ± 10.85     2 wk 
 % positive 6 wk  0.90 ± 0.59    6 wk 0.5646  19.75 ± 11.00    6 wk 0.6729 
  6 mo  3.00 ± 3.87   6 mo 0.0045 0.0226  14.57 ± 10.43   6 mo 0.1116 0.2408 
  12 mo 2.50 ± 3.64  12 mo 0.5209 0.0354 0.1185  19.72 ± 15.10  12 mo 0.1385 0.9921 0.7007 
  Adult 0.09 ± 0.07 Adult 0.0155 0.0030 0.3978 0.2013    2.52 ± 2.09 Adult 0.0001 0.0058 0.0001 0.0003 
 TNF-α+IL-12+ 2 wk  0.88 ± 1.01     2 wk  20.59 ± 9.02     2 wk 
 % positive 6 wk  0.62 ± 0.59    6 wk 0.6445  15.39 ±7.53    6 wk 0.05531 
  6 mo  3.59 ± 3.67   6 mo 0.0000 0.0000  19.06 ± 11.49   6 mo 0.1837 0.5815 
  12 mo 1.18 ± 1.57  12 mo 0.0001 0.3481 0.6164  11.06 ± 8.62  12 mo 0.0074 0.1312 0.0013 
  Adult 2.60 ± 1.47 Adult 0.070 0.1899 0.0092 0.0024  44.33 ± 12.39 Adult 0.0000 0.0000 0.0000 0.0000 
 IL-6+IL-12+ 2 wk  0.02 ± 0.03     2 wk  0.04 ± 0.07     2 wk 
 % positive 6 wk  0.02 ± 0.02    6 wk 0.6107  0.05± 0.10    6 wk 0.5981 
  6 mo  0.02 ± 0.06   6 mo 0.7069 0.9305  0.01 ± 0.04   6 mo 0.1956 0.4383 
  12 mo 0.07 ± 0.10  12 mo 0.0025 0.0027 0.0114  0.16 ± 0.19  12 mo 0.0002 0.0010 0.0002 
  Adult 0.01 ± 0.01 Adult 0.0064 0.4768 0.6631 0.4160  -0.01 ± 6.54 Adult 0.0001 0.6560 0.1482 0.2948 
mDCs                
 TNF-α+IL-6+ 2 wk  2.42 ± 2.54     2 wk  8.18 ± 4.19     2 wk 
 % positive 6 wk  2.15 ± 2.26    6 wk 0.8124  9.19 ± 4.70    6 wk 0.4524 
  6 mo  4.24 ± 7.13   6 mo 0.0744 0.1229  6.20 ± 4.24   6 mo 0.0304 0.1519 
  12 mo 4.77 ± 7.13  12 mo 0.6651 0.0315 0.0551  10.26 ± 6.68  12 mo 0.0063 0.4528 0.1497 
  Adult 0.54 ± 0.24 Adult 0.0803 0.0175 0.2862 0.2163  3.59 ± 1.91 Adult 0.0005 0.1530 0.0022 0.0115 
 TNF-α+IL-12+ 2 wk  1.89 ± 1.82     2 wk  31.78 ± 6.84     2 wk 
 % positive 6 wk  1.52 ± 1.71    6 wk 0.5511  26.45 ± 7.63    6 wk 0.0137 
  6 mo  3.95 ± 3.88   6 mo 0.0003 0.0023  23.76 ± 9.61   6 mo 0.2181 0.0004 
  12 mo 0.70 ± 1.12  12 mo 0.0000 0.2342 0.0841  10.76 ± 6.76  12 mo 0.0000 0.0000 0.0000 
  Adult 1.01 ± 0.52 Adult 0.7276 0.0009 0.5544 0.3020  31.93 ± 4.86 Adult 0.0000 0.0054 0.0552 0.9589 
 IL-6+IL-12+ 2 wk  0.01 ± 0.03     2 wk  0.34 ± 0.19     2 wk 
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 % positive 6 wk  0.01 ± 0.02    6 wk 0.7405  0.52 ± 0.58    6 wk 0.1787 
  6 mo  0.03 ± 0.04   6 mo 0.2312 0.1328  0.43 ± 0.34   6 mo 0.5078 0.5142 
  12 mo 0.06 ± 0.11  12 mo 0.0942 0.0047 0.0019  1.02 ± 0.72  12 mo 0.0000 0.0005 0.0000 
  Adult 0.05 ± 0.02 Adult 0.6447 0.3601 0.0655 0.0382  0.27 ± 0.14 Adult 0.0000 0.3747 0.1590 0.6921 
pDCs                
 TNF-α+ IFN-α+ 2 wk  Undetectable       44.49 ± 19.05     2 wk 
 % positive 6 wk  Undetectable       49.47 ± 11.08    6 wk 0.2127 
  6 mo  Undetectable       59.99 ± 11.92   6 mo 0.0108 0.0002 
  12 mo Undetectable       48.12 ± 16.81  12 mo 0.0072 0.7492 0.3955 
  Adult Undetectable       54.53 ±   3.03 Adult 0.2450 0.3115 0.0611 0.3955 
 TNF-α+IL-6+ 2 wk  Undetectable         0.57 ± 0.77     2 wk 
 % positive 6 wk  Undetectable         0.69 ± 0.73    6 wk 0.4611 
  6 mo  Undetectable         0.12 ± 0.13   6 mo 0.0004 0.0051 
  12 mo Undetectable         0.18 ± 0.21  12 mo 0.7306 0.0023 0.0178 
  Adult Undetectable         0.18 ± 0.12 Adult 0.0258 0.0109 0.8857 0.6822 
 IFN-α+IL-6+ 2 wk  Undetectable         0.06 ± 0.13     2 wk 
 % positive 6 wk  Undetectable         0.07 ± 0.19    6 wk 0.8636 
  6 mo  Undetectable         0.02 ± 0.07   6 mo 0.2642 0.3467 
  12 mo Undetectable         0.12 ± 0.17  12 mo 0.0313 0.2469 0.1914 
  Adult Undetectable         0.00 ± 0.00 Adult 0.0314 0.6401 0.1829 0.2311 
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   Basal Stimulation  
 Cytokine  Mean ± SD p-value 
Monocytes         
 TNF-α+IL-6+ 2 wk  0.04 ± 0.09     2 wk 
 % positive 6 wk  0.03 ± 0.02    6 wk 0.9314 
  6 mo  0.11 ± 0.17   6 mo 0.0379 0.0479 
  12 mo 0.07 ± 0.22  12 mo 0.2512 0.4101 0.4606 
  Adult 0.14 ± 0.07 Adult 0.1732 0.6386 0.0387 0.0460 
 TNF-α+IL-12+ 2 wk  0.05 ± 0.07     2 wk 
 % positive 6 wk  0.05 ± 0.07    6 wk 0.9633 
  6 mo  0.13 ± 0.10   6 mo 0.0672 0.0764 
  12 mo 0.17 ± 0.32  12 mo 0.5036 0.0149 0.0176 
  Adult 0.26 ± 0.07 Adult 0.1458 0.0439 0.0006 0.0008 
 IL-6+IL-12+ 2 wk  0.02 ± 0.02     2 wk 
 % positive 6 wk  0.01 ± 0.01    6 wk 0.7064 
  6 mo  0.05 ± 0.06   6 mo 0.0007 0.0024 
  12 mo 0.02 ± 0.05  12 mo 0.0045 0.7211 0.9951 
  Adult 0.07 ± 0.02 Adult 0.0006 0.2027 0.0003 0.0003 
mDCs         
 TNF-α+IL-6+ 2 wk  0.03 ± 0.04     2 wk 
 % positive 6 wk  0.06 ± 0.05    6 wk 0.6305 
  6 mo  0.16 ± 0.33   6 mo 0.6608 0.0232 
  12 mo 0.07 ± 0.18  12 mo 0.1377 0.8136 0.4979 
  Adult 0.17 ± 0.20 Adult 0.1795 0.8620 0.1122 0.0539 
 TNF-α+IL-12+ 2 wk  0.03 ± 0.04     2 wk 
 % positive 6 wk  0.06 ± 0.05    6 wk 0.6088 
  6 mo  0.16 ± 0.29   6 mo 0.0194 0.0053 
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  12 mo 0.08 ± 0.15  12 mo 0.1016 0.5685 0.3000 
  Adult 0.24± 0.09 Adult 0.0127 0.2099 0.0024 0.0007 
 IL-6+IL-12+ 2 wk  0.02 ± 0.03     2 wk 
 % positive 6 wk  0.03 ± 0.04    6 wk 0.9246 
  6 mo  0.09 ± 0.0.23   6 mo 0.0457 0.0386 
  12 mo 0.01 ± 0.03  12 mo 0.0197 0.6102 0.6757 
  Adult 0.07 ± 0.07 Adult 0.2019 0.5498 0.3514 0.3190 
pDCs         
 TNF-α+ IFN-α+ 2 wk  0.00 ± 0.01     2 wk 
 % positive 6 wk  0.04 ± 0.09    6 wk 0.7849 
  6 mo  0.45 ± 0.99   6 mo 0.0019 0.0011 
  12 mo 0.00 ± 0.00  12 mo 0.0019 0.7852 0.9875 
  Adult 0.00 ± 0.00 Adult 1.0000 0.0116 0.8285 0.9899 
 TNF-α+IL-6+ 2 wk  0.01 ± 0.02     2 wk 
 % positive 6 wk  0.01 ± 0.04    6 wk 0.7751 
  6 mo  0.08 ± 0.14   6 mo 0.0008 0.0004 
  12 mo 0.00 ± 0.02  12 mo 0.0007 0.7248 0.9349 
  Adult 0.00 ± 0.00 Adult 0.8694 0.0034 0.6509 0.8137 
 IFN-α+IL-6+ 2 wk  0.01 ± 0.05     2 wk 
 % positive 6 wk  0.06 ± 0.15    6 wk 0.1862 
  6 mo  0.12 ± 0.15   6 mo 0.0628 0.0025 
  12 mo 0.00 ± 0.00  12 mo 0.0012 0.0988 0.6864 
  Adult 0.04 ± 0.13 Adult 0.3612 0.0836 0.7199 0.5335 
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   LPS (TLR4)  R-848 (TLR7/8)  
 Cytokine  Mean ± SD p-value  Mean ± SD p-value  
Monocytes                
TNF-α+IL-6+IL-12+ 2 wk  0.65 ± 0.74     2 wk  41.03 ± 14.74     2 wk 
 % positive 6 wk  0.53 ± 0.48    6 wk 0.8512  47.06 ± 14.95    6 wk 0.1746 
  6 mo  3.64 ± 4.01   6 mo 0.0000 0.0000  49.90 ± 14.41   6 mo 0.5308 0.0541 
  12 mo 2.09 ± 2.91  12 mo 0.0314 0.0265 0.0423  36.06 ± 19.82  12 mo 0.0049 0.0208 0.2952 
  Adult 0.46 ± 0.23 Adult 0.0749 0.0005 0.9414 0.8309  24.31 ± 13.80 Adult 0.0570 0.0004 0.0001 0.0055 
mDCs                
TNF-α+IL-6+IL-12+ 2 wk  1.32 ± 1.58     2 wk  30.48 ± 9.66     2 wk 
 % positive 6 wk  1.14 ± 1.28    6 wk 0.8014  33.95 ±10.22    6 wk 0.2575 
  6 mo  4.21 ± 4.15   6 mo 0.0000 0.0001  27.00 ± 11.06   6 mo 0.0279 0.2715 
  12 mo 1.69 ± 0.04  12 mo 0.0013 0.4596 0.6178  22.54 ± 13.89  12 mo 0.1837 0.0006 0.0169 
  Adult 0.28 ± 0.15 Adult 0.1456 0.0000 0.3530 0.2668  15.90 ± 7.65 Adult 0.1187 0.0084 0.0000 0.0005 
pDCs                
TNF-α+IFN-α+IL-6+ 2 wk  Undetectable       8.12 ± 5.93     2 wk 
 % positive 6 wk  Undetectable       8.28 ± 4.79    6 wk 0.9086 
  6 mo  Undetectable       6.64 ± 3.55   6 mo 0.2473 0.3002 
  12 mo Undetectable       5.73 ± 4.96  12 mo 0.5473 0.0848 0.1087 
  Adult Undetectable       5.84 ± 5.10 Adult 0.9534 0.6698 0.1864 0.2189 
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   Basal Stimulation  
 Cytokine  Mean ± SD p-value 
Monocytes         
 TNF-α+IL-6+IL-12+ 2 wk  0.01 ± 0.02     2 wk 
 % positive 6 wk  0.01 ± 0.01    6 wk 0.9666 
  6 mo  0.04 ± 0.06   6 mo 0.0004 0.0046 
  12 mo 0.02 ± 0.05  12 mo 0.0339 0.5867 0.5634 
  Adult 0.07 ± 0.02 Adult 0.0003 0.0398 0.0000 0.0000 
mDCs         
 TNF-α+IL-6+IL-12+ 2 wk  0.01 ± 0.02     2 wk 
 % positive 6 wk  0.02 ± 0.04    6 wk 0.6872 
  6 mo  0.08 ± 0.21   6 mo 0.0348 0.0137 
  12 mo 0.01 ± 0.02  12 mo 0.0172 0.6514 0.9391 
  Adult 0.07± 0.07 Adult 0.1621 0.6075 0.2686 0.1632 
pDCs         
 TNF-α+IFN-α+IL-6+ 2 wk  2.06 ± 5.32     2 wk 
 % positive 6 wk  1.36 ± 2.17    6 wk 0.8184 
  6 mo  2.51 ± 2.66   6 mo 0.0039 0.0026 
  12 mo 1.38 ± 1.92  12 mo 0.0041 0.8159 0.9867 
  Adult 2.04 ± 1.03 Adult 1.0000 0.0197 0.8532 0.9894 
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